{"PMC7232592": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel member of the betacoronavirus genus which has caused the ongoing pandemic of coronavirus disease 2019 (COVID-19).", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 161, 180], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["coronavirus", "ORGANISM", 161, 172], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["the betacoronavirus genus", "PROBLEM", 94, 119], ["coronavirus disease", "PROBLEM", 161, 180], ["COVID", "TEST", 187, 192], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 161, 180]]], ["Fever and respiratory symptoms, including cough and shortness of breath have been reported to be the most common manifestations of the disease [1].", [["respiratory", "ANATOMY", 10, 21], ["Fever", "DISEASE", 0, 5], ["respiratory symptoms", "DISEASE", 10, 30], ["cough", "DISEASE", 42, 47], ["shortness of breath", "DISEASE", 52, 71], ["Fever", "PROBLEM", 0, 5], ["respiratory symptoms", "PROBLEM", 10, 30], ["cough", "PROBLEM", 42, 47], ["shortness of breath", "PROBLEM", 52, 71], ["the disease", "PROBLEM", 131, 142], ["respiratory", "ANATOMY", 10, 21], ["symptoms", "OBSERVATION", 22, 30]]], ["The signs and symptoms often manifest within 2 to 14 days following primary exposure [1].", [["The signs and symptoms", "PROBLEM", 0, 22]]], ["SARS-CoV-2 is highly contagious and can be transmitted through respiratory droplets and contact with infected persons or fomites.", [["respiratory droplets", "ANATOMY", 63, 83], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["persons", "ORGANISM", 110, 117], ["persons", "SPECIES", 110, 117], ["highly", "OBSERVATION_MODIFIER", 14, 20], ["contagious", "OBSERVATION", 21, 31]]], ["Aerosol transmission has not been confiremd [2].IntroductionSome clinicians have expressed concerns about the transmission of SARS-CoV-2 via tears and conjunctival secretions of infected patients [3].", [["conjunctival secretions", "ANATOMY", 151, 174], ["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 126, 136], ["tears", "TISSUE", 141, 146], ["conjunctival secretions", "ORGANISM_SUBSTANCE", 151, 174], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 126, 134], ["Aerosol transmission", "TREATMENT", 0, 20], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["tears", "PROBLEM", 141, 146], ["conjunctival secretions", "PROBLEM", 151, 174], ["conjunctival", "ANATOMY", 151, 163]]], ["A genetic similarity of greater than 80% have been reported between SARS-CoV and SARS-CoV-2 [4].", [["SARS-CoV", "ORGANISM", 68, 76], ["SARS-CoV-2", "ORGANISM", 81, 91], ["SARS-CoV", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 81, 89], ["A genetic similarity", "TEST", 0, 20], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["greater", "OBSERVATION_MODIFIER", 24, 31]]], ["During the SARS outbreak in 2004, some studies reported the presence of SARS-CoV in the tears of the patients [5].", [["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 72, 76], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["tears", "PATHOLOGICAL_FORMATION", 88, 93], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 72, 80], ["some studies", "TEST", 34, 46], ["SARS", "PROBLEM", 72, 76]]], ["Additionally, during the recent outbreak of the coronavirus 2019, a large number of ophthalmologists have been reported to be infected [2].", [["coronavirus", "DISEASE", 48, 59], ["the coronavirus", "PROBLEM", 44, 59], ["large", "OBSERVATION_MODIFIER", 68, 73], ["infected", "OBSERVATION", 126, 134]]], ["Some recent studies have evaluated the infectivity of tears of COVID-19 patients [3].", [["tears", "ANATOMY", 54, 59], ["tears", "PATHOLOGICAL_FORMATION", 54, 59], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Some recent studies", "TEST", 0, 19], ["COVID", "TEST", 63, 68]]], ["In the present study we evaluated the presence of SARS-CoV-2 in tears of patients diagnosed with clinically confirmed COVID-19.Materials and methodsIn this prospective interventional case series, we included patients with clinically confirmed COVID-19 patients who were admitted to our hospital between March 28, 2020 and April 5, 2020.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 50, 60], ["tears", "PATHOLOGICAL_FORMATION", 64, 69], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 208, 216], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 252, 260], ["SARS-CoV", "SPECIES", 50, 58], ["the present study", "TEST", 3, 20], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["tears", "PROBLEM", 64, 69], ["COVID", "TEST", 118, 123]]], ["The study protocol was approved by institutional ethics committee and followed the Declaration of Helsinki.", [["The study protocol", "TEST", 0, 18]]], ["A written informed consent was provided from each patient or patient\u2019s family.Materials and methodsThe criteria for clinical diagnosis and admission of COVID-19 patients (severe COVID-19) followed the Iran National Guideline on Prevention and Control of COVID-19: (1) highly suspicious radiological findings related to COVID-19 (unilateral or bilateral multi-lobar infiltration of the lungs especially the peripheral zones and/or ground glass appearance) as confirmed by a radiologist; (2) pneumonia with a poor response to appropriate treatment and an unpredicted progression; (3) respiratory rate \u226524 cycles/minute, oxygen saturation \u226490%, or heart rate >125 beats/min.Materials and methodsQuantitative reverse transcription polymerase chain reaction (RT-PCR) tests were performed on the first day of admission for each patient.", [["multi-lobar", "ANATOMY", 353, 364], ["lungs", "ANATOMY", 385, 390], ["peripheral zones", "ANATOMY", 406, 422], ["respiratory", "ANATOMY", 582, 593], ["heart", "ANATOMY", 645, 650], ["pneumonia", "DISEASE", 490, 499], ["oxygen", "CHEMICAL", 618, 624], ["oxygen", "CHEMICAL", 618, 624], ["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 61, 68], ["patients", "ORGANISM", 161, 169], ["lungs", "ORGAN", 385, 390], ["peripheral zones", "TISSUE", 406, 422], ["oxygen", "SIMPLE_CHEMICAL", 618, 624], ["heart", "ORGAN", 645, 650], ["patient", "ORGANISM", 822, 829], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 61, 68], ["patients", "SPECIES", 161, 169], ["patient", "SPECIES", 822, 829], ["COVID", "TEST", 152, 157], ["severe COVID", "PROBLEM", 171, 183], ["COVID", "TEST", 254, 259], ["highly suspicious radiological findings", "PROBLEM", 268, 307], ["COVID", "TEST", 319, 324], ["bilateral multi-lobar infiltration of the lungs", "PROBLEM", 343, 390], ["pneumonia", "PROBLEM", 490, 499], ["appropriate treatment", "TREATMENT", 524, 545], ["an unpredicted progression", "PROBLEM", 550, 576], ["respiratory rate", "TEST", 582, 598], ["oxygen saturation", "TEST", 618, 635], ["heart rate", "TEST", 645, 655], ["Quantitative reverse transcription polymerase chain reaction", "PROBLEM", 692, 752], ["RT-PCR) tests", "TEST", 754, 767], ["bilateral", "ANATOMY_MODIFIER", 343, 352], ["multi-lobar", "ANATOMY_MODIFIER", 353, 364], ["infiltration", "OBSERVATION", 365, 377], ["lungs", "ANATOMY", 385, 390], ["peripheral", "ANATOMY_MODIFIER", 406, 416], ["zones", "ANATOMY_MODIFIER", 417, 422], ["ground glass", "OBSERVATION", 430, 442], ["pneumonia", "OBSERVATION", 490, 499], ["progression", "OBSERVATION_MODIFIER", 565, 576], ["heart", "ANATOMY", 645, 650]]], ["Sampling of both nasopharyngeal and conjunctival secretions was performed at the same time for each patient with caution to avoid any cross contamination.", [["nasopharyngeal", "ANATOMY", 17, 31], ["conjunctival secretions", "ANATOMY", 36, 59], ["nasopharyngeal", "CANCER", 17, 31], ["conjunctival secretions", "ORGANISM_SUBSTANCE", 36, 59], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["both nasopharyngeal and conjunctival secretions", "PROBLEM", 12, 59], ["caution", "TREATMENT", 113, 120], ["any cross contamination", "PROBLEM", 130, 153], ["both", "ANATOMY_MODIFIER", 12, 16], ["nasopharyngeal", "ANATOMY", 17, 31], ["conjunctival", "ANATOMY", 36, 48], ["secretions", "OBSERVATION", 49, 59]]], ["RT-PCR assay sampling of nasopharyngeal secretions was performed according to the protocol established by the World Health Organization (WHO).", [["nasopharyngeal secretions", "ANATOMY", 25, 50], ["nasopharyngeal secretions", "ORGAN", 25, 50], ["RT-PCR assay", "TEST", 0, 12], ["nasopharyngeal secretions", "PROBLEM", 25, 50], ["nasopharyngeal", "ANATOMY", 25, 39], ["secretions", "OBSERVATION", 40, 50]]], ["To collect tear samples, we used disposable swabs.", [["tear samples", "ANATOMY", 11, 23], ["tear samples", "CANCER", 11, 23], ["tear samples", "TEST", 11, 23], ["disposable swabs", "TREATMENT", 33, 49], ["tear", "OBSERVATION", 11, 15]]], ["After opening the eyelids, the swab was placed in the lower fornix for at least 10 s in each eye.", [["eyelids", "ANATOMY", 18, 25], ["swab", "ANATOMY", 31, 35], ["lower fornix", "ANATOMY", 54, 66], ["eye", "ANATOMY", 93, 96], ["eyelids", "PATHOLOGICAL_FORMATION", 18, 25], ["lower fornix", "ORGANISM_SUBDIVISION", 54, 66], ["eye", "ORGAN", 93, 96], ["opening the eyelids", "PROBLEM", 6, 25], ["the swab", "TREATMENT", 27, 35], ["eyelids", "ANATOMY", 18, 25], ["lower fornix", "ANATOMY", 54, 66], ["eye", "ANATOMY", 93, 96]]], ["No anesthesia was used during the procedure.", [["anesthesia", "TREATMENT", 3, 13], ["the procedure", "TREATMENT", 30, 43], ["anesthesia", "OBSERVATION", 3, 13]]], ["All tear samples were collected by a single ophthalmologist (AA).", [["tear samples", "ANATOMY", 4, 16], ["tear samples", "CANCER", 4, 16], ["All tear samples", "TEST", 0, 16], ["tear", "OBSERVATION", 4, 8]]], ["All nasopharyngeal and tear specimens were stored at 4 \u00b0C and were immediately sent to the same laboratory for processing.ResultsA total of 43 patients (14 female and 29 male) were enrolled.", [["nasopharyngeal", "ANATOMY", 4, 18], ["tear specimens", "ANATOMY", 23, 37], ["nasopharyngeal", "CANCER", 4, 18], ["tear specimens", "CANCER", 23, 37], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["All nasopharyngeal and tear specimens", "TEST", 0, 37], ["nasopharyngeal", "ANATOMY", 4, 18], ["tear", "OBSERVATION", 23, 27]]], ["The mean age of the patients was 56 \u00b1 13 years.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["At the time of sampling, the average disease time from the initiation of symptoms was 3.27 days, range 1\u20137 days.", [["sampling", "TEST", 15, 23], ["the average disease time", "PROBLEM", 25, 49], ["symptoms", "PROBLEM", 73, 81], ["average", "OBSERVATION_MODIFIER", 29, 36], ["disease", "OBSERVATION", 37, 44]]], ["The mean of body temperature was 38.33 \u00b0C. At the time of sampling, 41 (95.3%), 38 (88.3%), and 30 (69.8%) patients had fever, shortness of breath, and cough, respectively.", [["body", "ANATOMY", 12, 16], ["fever", "DISEASE", 120, 125], ["shortness of breath", "DISEASE", 127, 146], ["cough", "DISEASE", 152, 157], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["The mean of body temperature", "TEST", 0, 28], ["sampling", "TEST", 58, 66], ["fever", "PROBLEM", 120, 125], ["shortness of breath", "PROBLEM", 127, 146], ["cough", "PROBLEM", 152, 157], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["cough", "OBSERVATION", 152, 157]]], ["Other symptoms were myalgia, fatigue, and chills.", [["myalgia", "DISEASE", 20, 27], ["fatigue", "DISEASE", 29, 36], ["chills", "DISEASE", 42, 48], ["Other symptoms", "PROBLEM", 0, 14], ["myalgia", "PROBLEM", 20, 27], ["fatigue", "PROBLEM", 29, 36], ["chills", "PROBLEM", 42, 48], ["myalgia", "OBSERVATION", 20, 27], ["chills", "OBSERVATION", 42, 48]]], ["Nine patients (20.9%) were admitted to ICU because of respiratory failure needing ventilators.", [["respiratory", "ANATOMY", 54, 65], ["respiratory failure", "DISEASE", 54, 73], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["respiratory failure", "PROBLEM", 54, 73], ["ventilators", "TREATMENT", 82, 93], ["respiratory", "ANATOMY", 54, 65], ["failure", "OBSERVATION", 66, 73]]], ["One patient had bilateral conjunctivitis that was manifested by conjunctival congestion and mucus discharge.", [["conjunctival", "ANATOMY", 64, 76], ["mucus", "ANATOMY", 92, 97], ["conjunctivitis", "DISEASE", 26, 40], ["patient", "ORGANISM", 4, 11], ["conjunctival", "TISSUE", 64, 76], ["mucus", "ORGANISM_SUBSTANCE", 92, 97], ["patient", "SPECIES", 4, 11], ["bilateral conjunctivitis", "PROBLEM", 16, 40], ["conjunctival congestion", "PROBLEM", 64, 87], ["mucus discharge", "PROBLEM", 92, 107], ["bilateral", "ANATOMY_MODIFIER", 16, 25], ["conjunctivitis", "OBSERVATION", 26, 40], ["conjunctival", "ANATOMY", 64, 76], ["congestion", "OBSERVATION", 77, 87], ["mucus discharge", "OBSERVATION", 92, 107]]], ["In addition, one patient reported bilateral foreign body sensation since 3 days before the onset of systemic manifestations.", [["body", "ANATOMY", 52, 56], ["patient", "ORGANISM", 17, 24], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["patient", "SPECIES", 17, 24], ["bilateral foreign body sensation", "PROBLEM", 34, 66], ["systemic manifestations", "PROBLEM", 100, 123], ["bilateral", "ANATOMY_MODIFIER", 34, 43], ["foreign body", "OBSERVATION", 44, 56], ["systemic", "OBSERVATION_MODIFIER", 100, 108], ["manifestations", "OBSERVATION", 109, 123]]], ["Demographic and clinical characteristics of the study patients are summarized in Table 1.ResultsNasopharyngeal RT-PCR yielded positive results in 30 patients (69.8%).", [["Nasopharyngeal", "ANATOMY", 96, 110], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 149, 157], ["the study", "TEST", 44, 53], ["Nasopharyngeal RT-PCR", "TEST", 96, 117], ["Nasopharyngeal", "ANATOMY", 96, 110]]], ["Both tear RT-PCR and nasopharyngeal RT-PCR were positive for SARS-CoV-2 in 3 (7%) patients.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 61, 69], ["Both tear RT-PCR", "TEST", 0, 16], ["nasopharyngeal RT-PCR", "TEST", 21, 42], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["tear", "OBSERVATION", 5, 9], ["nasopharyngeal RT", "ANATOMY", 21, 38]]], ["None of these three patients were admitted to ICU.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Tear RT-PCR was positive in the patient with conjunctivitis but negative for the patient with ocular foreign body sensation.", [["ocular", "ANATOMY", 94, 100], ["body", "ANATOMY", 109, 113], ["conjunctivitis", "DISEASE", 45, 59], ["ocular foreign body sensation", "DISEASE", 94, 123], ["patient", "ORGANISM", 32, 39], ["patient", "ORGANISM", 81, 88], ["body", "ORGANISM_SUBDIVISION", 109, 113], ["patient", "SPECIES", 32, 39], ["patient", "SPECIES", 81, 88], ["Tear RT-PCR", "TEST", 0, 11], ["conjunctivitis", "PROBLEM", 45, 59], ["ocular foreign body sensation", "PROBLEM", 94, 123], ["positive", "OBSERVATION", 16, 24], ["conjunctivitis", "OBSERVATION", 45, 59]]], ["Both tear RT-PCR and nasopharyngeal RT-PCR were negative in 13 patients (30%).", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Both tear RT-PCR", "TEST", 0, 16], ["nasopharyngeal RT-PCR", "TEST", 21, 42], ["tear", "OBSERVATION", 5, 9], ["nasopharyngeal RT", "ANATOMY", 21, 38]]], ["The results of RT-PCR tests are summarized in Table 2.What was known before ::: Summary ::: Discussion", [["RT-PCR tests", "TEST", 15, 27]]]], "35d689040adaed0f1ffde727416dff2daccab813": [["INTRODUCTIONRapidly emerging knowledge in breast cancer control has put pressure on the health system for the adoption of new technologies and policies.", [["breast cancer", "ANATOMY", 42, 55], ["breast cancer", "DISEASE", 42, 55], ["breast cancer", "CANCER", 42, 55], ["breast cancer control", "TREATMENT", 42, 63], ["breast", "ANATOMY", 42, 48], ["cancer", "OBSERVATION", 49, 55]]], ["Randomized trials are the gold standard of evidence to introduce new interventions in clinical practice and public health; however, such evidence is not always relevant for informing policy decisions because the context of the interventions evolves quickly compared to the time that elapses between the design of a trial and the availability of its results.", [["Randomized trials", "TREATMENT", 0, 17], ["new interventions", "TREATMENT", 65, 82], ["the interventions", "TREATMENT", 223, 240]]], ["For example, most breast cancer screening randomized trials were from the era before breast cancer adjuvant treatment was available and used film-screen mammography1,2; breast cancer survival has since vastly improved3 and digital mammography has superseded film-screen mammography.", [["breast cancer", "ANATOMY", 18, 31], ["breast cancer", "ANATOMY", 85, 98], ["breast cancer", "ANATOMY", 169, 182], ["breast cancer", "DISEASE", 18, 31], ["breast cancer", "DISEASE", 85, 98], ["breast cancer", "DISEASE", 169, 182], ["breast cancer", "CANCER", 18, 31], ["breast cancer", "CANCER", 85, 98], ["breast cancer", "CANCER", 169, 182], ["most breast cancer", "PROBLEM", 13, 31], ["breast cancer adjuvant treatment", "TREATMENT", 85, 117], ["film", "TEST", 141, 145], ["breast cancer survival", "PROBLEM", 169, 191], ["digital mammography", "TEST", 223, 242], ["film", "TEST", 258, 262], ["mammography", "TEST", 270, 281], ["breast", "ANATOMY", 18, 24], ["cancer", "OBSERVATION", 25, 31], ["breast", "ANATOMY", 85, 91], ["cancer", "OBSERVATION", 92, 98], ["breast", "ANATOMY", 169, 175], ["cancer", "OBSERVATION", 176, 182]]], ["A cancer simulation model can help integrate evidence from multiple sources and make them more relevant to inform contemporary clinical and policy decisions.", [["cancer", "ANATOMY", 2, 8], ["cancer", "DISEASE", 2, 8], ["cancer", "CANCER", 2, 8], ["A cancer simulation model", "PROBLEM", 0, 25], ["cancer", "OBSERVATION", 2, 8]]], ["Several groups have developed sophisticated cancer-specific models based on the natural history of cancer that can be revised for additional analyses and incorporate knowledge from experts in different areas4.INTRODUCTIONOncoSim is an example of a cancer simulation model.", [["cancer", "ANATOMY", 44, 50], ["cancer", "ANATOMY", 99, 105], ["cancer", "ANATOMY", 248, 254], ["cancer", "DISEASE", 44, 50], ["cancer", "DISEASE", 99, 105], ["cancer", "DISEASE", 248, 254], ["cancer", "CANCER", 44, 50], ["cancer", "CANCER", 99, 105], ["cancer", "CANCER", 248, 254], ["areas4", "CELL_LINE", 202, 208], ["sophisticated cancer", "PROBLEM", 30, 50], ["cancer", "PROBLEM", 99, 105], ["a cancer simulation model", "PROBLEM", 246, 271], ["cancer", "OBSERVATION", 44, 50], ["cancer", "OBSERVATION", 99, 105], ["cancer", "OBSERVATION", 248, 254]]], ["The validation and applications of OncoSim colorectal, cervical, and lung cancers have been described previously5-19.", [["OncoSim colorectal", "ANATOMY", 35, 53], ["cervical", "ANATOMY", 55, 63], ["lung cancers", "ANATOMY", 69, 81], ["OncoSim colorectal, cervical, and lung cancers", "DISEASE", 35, 81], ["OncoSim colorectal", "CANCER", 35, 53], ["cervical", "CANCER", 55, 63], ["lung cancers", "CANCER", 69, 81], ["The validation", "TREATMENT", 0, 14], ["OncoSim colorectal", "TREATMENT", 35, 53], ["cervical, and lung cancers", "PROBLEM", 55, 81], ["cervical", "ANATOMY", 55, 63], ["lung", "ANATOMY", 69, 73], ["cancers", "OBSERVATION", 74, 81]]], ["Breast cancer is the latest addition to OncoSim's suite of cancer models.", [["Breast cancer", "ANATOMY", 0, 13], ["cancer", "ANATOMY", 59, 65], ["Breast cancer", "DISEASE", 0, 13], ["cancer", "DISEASE", 59, 65], ["Breast cancer", "CANCER", 0, 13], ["cancer", "CANCER", 59, 65], ["Breast cancer", "PROBLEM", 0, 13], ["cancer models", "PROBLEM", 59, 72], ["cancer", "OBSERVATION", 7, 13], ["cancer", "OBSERVATION", 59, 65]]], ["The primary objective of OncoSim-Breast is to investigate emerging issues related to breast cancer control in Canada.INTRODUCTIONThis work builds on a strong foundation of analyses performed over a decade ago to estimate the impact of diagnostic and therapeutic approaches to non-metastatic breast cancer in Canada, using the Statistics Canada POHEM mathematical model20.", [["Breast", "ANATOMY", 33, 39], ["breast cancer", "ANATOMY", 85, 98], ["non-metastatic breast cancer", "ANATOMY", 276, 304], ["breast cancer", "DISEASE", 85, 98], ["breast cancer", "DISEASE", 291, 304], ["breast cancer", "CANCER", 85, 98], ["non-metastatic breast cancer", "CANCER", 276, 304], ["emerging issues", "PROBLEM", 58, 73], ["breast cancer control", "PROBLEM", 85, 106], ["non-metastatic breast cancer", "PROBLEM", 276, 304], ["Breast", "ANATOMY", 33, 39], ["breast", "ANATOMY", 85, 91], ["cancer", "OBSERVATION", 92, 98], ["non-metastatic", "OBSERVATION_MODIFIER", 276, 290], ["breast", "ANATOMY", 291, 297], ["cancer", "OBSERVATION", 298, 304]]], ["First, it aims to describe the key assumptions in OncoSim-Breast.", [["Breast", "ANATOMY", 58, 64], ["Breast", "ANATOMY", 58, 64]]], ["Secondly, it compares OncoSim-Breast's projections with observed data in the Canadian Cancer Registry, projected breast cancer mortality estimates in the Canadian Vital Statistics, and the observed screening effects in a randomized trial.INTRODUCTION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)INTRODUCTIONThe copyright holder for this preprint this version posted May 24, 2020.OncoSim-BreastThe model inputs have several components:OncoSim-Breast\u2022 Demography is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)OncoSim-BreastThe copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.", [["breast cancer", "ANATOMY", 113, 126], ["Breast", "ANATOMY", 546, 552], ["Cancer", "DISEASE", 86, 92], ["breast cancer", "DISEASE", 113, 126], ["CC", "CHEMICAL", 252, 254], ["Cancer", "CANCER", 86, 92], ["breast cancer", "CANCER", 113, 126], ["projected breast cancer mortality", "PROBLEM", 103, 136], ["a randomized trial", "TREATMENT", 219, 237], ["CC", "TEST", 252, 254], ["ND", "PROBLEM", 261, 263], ["The copyright holder", "TREATMENT", 466, 486], ["Breast", "ANATOMY", 30, 36], ["Cancer", "OBSERVATION", 86, 92], ["breast", "ANATOMY", 113, 119], ["cancer", "OBSERVATION", 120, 126], ["NC", "ANATOMY", 258, 260], ["med", "ANATOMY", 357, 360], ["Breast", "ANATOMY", 546, 552], ["several", "OBSERVATION_MODIFIER", 574, 581], ["components", "OBSERVATION_MODIFIER", 582, 592], ["med", "ANATOMY", 658, 661], ["Breast", "ANATOMY", 763, 769]]], ["22.20110569 doi: medRxiv preprint The model combines these inputs to project outcomes, such as breast cancer incidence and mortality, screening outcomes, stage and age at diagnosis, life-years, quality-adjusted lifeyears, lifetime breast cancer costs, and screening or follow-up procedure costs ( Figure 1 ).DemographyOncoSim simulates one individual at a time, replicating the age and sex distributions, and allcause mortality of the population in each province and territory in Canada (Supplemental Appendix 1).", [["breast cancer", "ANATOMY", 95, 108], ["breast cancer", "ANATOMY", 231, 244], ["breast cancer", "DISEASE", 95, 108], ["breast cancer", "DISEASE", 231, 244], ["breast cancer", "CANCER", 95, 108], ["breast cancer", "CANCER", 231, 244], ["breast cancer incidence", "PROBLEM", 95, 118], ["breast cancer costs", "PROBLEM", 231, 250], ["screening", "TEST", 256, 265], ["breast", "ANATOMY", 95, 101], ["cancer", "OBSERVATION", 102, 108], ["breast", "ANATOMY", 231, 237], ["cancer", "OBSERVATION", 238, 244]]], ["Each simulated individual has attributes, such as demography (sex, province/territory), and breast cancer-related risk factors (BRCA1/2 gene mutation, family history, exposure to hormone replacement therapy, Supplemental Table 1 ).Natural historyOncoSim-Breast simulates the onset, growth and spread of tumours, both invasive cancer and Tumour onset: In OncoSim-Breast, tumours start from 2mm, based on the probable minimum size detectable by mammography screening and similar to the Wisconsin Breast model.Natural historyProbability of tumour onset varies by age and years (Supplemental Figure 1 ).", [["breast cancer", "ANATOMY", 92, 105], ["tumours", "ANATOMY", 303, 310], ["invasive cancer", "ANATOMY", 317, 332], ["Tumour", "ANATOMY", 337, 343], ["Breast", "ANATOMY", 362, 368], ["tumours", "ANATOMY", 370, 377], ["Breast", "ANATOMY", 494, 500], ["tumour", "ANATOMY", 537, 543], ["breast cancer", "DISEASE", 92, 105], ["tumours", "DISEASE", 303, 310], ["cancer", "DISEASE", 326, 332], ["Tumour", "DISEASE", 337, 343], ["tumour", "DISEASE", 537, 543], ["breast cancer", "CANCER", 92, 105], ["BRCA1/2", "GENE_OR_GENE_PRODUCT", 128, 135], ["tumours", "CANCER", 303, 310], ["cancer", "CANCER", 326, 332], ["Tumour", "CANCER", 337, 343], ["OncoSim-Breast", "CANCER", 354, 368], ["tumours", "CANCER", 370, 377], ["tumour", "CANCER", 537, 543], ["BRCA1/2 gene", "DNA", 128, 140], ["breast cancer", "PROBLEM", 92, 105], ["risk factors", "PROBLEM", 114, 126], ["BRCA1/2 gene mutation", "PROBLEM", 128, 149], ["hormone replacement therapy", "TREATMENT", 179, 206], ["spread of tumours", "PROBLEM", 293, 310], ["both invasive cancer", "PROBLEM", 312, 332], ["mammography screening", "TEST", 443, 464], ["tumour onset", "PROBLEM", 537, 549], ["breast", "ANATOMY", 92, 98], ["cancer", "OBSERVATION", 99, 105], ["growth", "OBSERVATION_MODIFIER", 282, 288], ["spread", "OBSERVATION_MODIFIER", 293, 299], ["invasive", "OBSERVATION_MODIFIER", 317, 325], ["cancer", "OBSERVATION", 326, 332], ["Tumour", "OBSERVATION", 337, 343], ["Breast", "ANATOMY", 362, 368], ["tumours", "OBSERVATION", 370, 377], ["probable", "UNCERTAINTY", 407, 415], ["minimum size", "OBSERVATION_MODIFIER", 416, 428], ["Breast", "ANATOMY", 494, 500], ["tumour", "OBSERVATION", 537, 543]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint risk increases if a woman has any of the breast cancer-related risk factors (BRCA1/2 mutation, family history of breast cancer or exposure to hormone replacement therapy, Supplemental Tables 3-4) ; if a woman has previously had a DCIS tumour, she is also more likely to have an invasive cancer.Cancer detection, staging and tumour biologyLarger tumours are more likely to get detected clinically than smaller tumours (Supplementary Table 7ScreeningFor evaluating screening strategies or related performance, the model allows users to create different screening strategies and scenarios by modifying the following input parameters (Supplemental Appendix 4):Screening.", [["breast cancer", "ANATOMY", 383, 396], ["breast cancer", "ANATOMY", 455, 468], ["DCIS tumour", "ANATOMY", 572, 583], ["invasive cancer", "ANATOMY", 620, 635], ["Cancer", "ANATOMY", 636, 642], ["tumour", "ANATOMY", 666, 672], ["tumours", "ANATOMY", 687, 694], ["tumours", "ANATOMY", 751, 758], ["CC", "CHEMICAL", 0, 2], ["breast cancer", "DISEASE", 383, 396], ["breast cancer", "DISEASE", 455, 468], ["DCIS tumour", "DISEASE", 572, 583], ["cancer", "DISEASE", 629, 635], ["Cancer", "DISEASE", 636, 642], ["tumour", "DISEASE", 666, 672], ["woman", "ORGANISM", 362, 367], ["breast cancer", "CANCER", 383, 396], ["BRCA1/2", "GENE_OR_GENE_PRODUCT", 419, 426], ["breast cancer", "CANCER", 455, 468], ["woman", "ORGANISM", 545, 550], ["DCIS tumour", "CANCER", 572, 583], ["cancer", "CANCER", 629, 635], ["Cancer", "CANCER", 636, 642], ["tumour", "CANCER", 666, 672], ["tumours", "CANCER", 687, 694], ["tumours", "CANCER", 751, 758], ["BRCA1", "DNA", 419, 424], ["woman", "SPECIES", 362, 367], ["woman", "SPECIES", 545, 550], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the breast cancer", "PROBLEM", 379, 396], ["risk factors", "PROBLEM", 405, 417], ["BRCA1/2 mutation", "PROBLEM", 419, 435], ["breast cancer", "PROBLEM", 455, 468], ["hormone replacement therapy", "TREATMENT", 484, 511], ["Supplemental Tables", "TREATMENT", 513, 532], ["a DCIS tumour", "PROBLEM", 570, 583], ["an invasive cancer", "PROBLEM", 617, 635], ["Cancer detection", "TEST", 636, 652], ["staging", "TEST", 654, 661], ["Larger tumours", "PROBLEM", 680, 694], ["smaller tumours", "PROBLEM", 743, 758], ["screening strategies", "TREATMENT", 805, 825], ["different screening strategies", "TREATMENT", 883, 913], ["scenarios", "TREATMENT", 918, 927], ["Screening", "TEST", 998, 1007], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["breast", "ANATOMY", 383, 389], ["cancer", "OBSERVATION", 390, 396], ["breast", "ANATOMY", 455, 461], ["cancer", "OBSERVATION", 462, 468], ["tumour", "OBSERVATION", 577, 583], ["invasive", "OBSERVATION_MODIFIER", 620, 628], ["cancer", "OBSERVATION", 629, 635]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint \u2022 Screening program recruitment strategy (e.g. start/end age and years)(which was not certified by peer review)\u2022 Screening participation and retention(which was not certified by peer review)\u2022 Screening frequency \u2022 Screening modality (e.g. digital mammography)(which was not certified by peer review)\u2022 Sensitivity and specificity of screening Table 9 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Screening modality", "TEST", 556, 574], ["digital mammography", "TEST", 581, 600], ["Sensitivity", "TEST", 643, 654], ["screening Table", "TEST", 674, 689], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Oncosim-Breast captures the benefits of screening on breast cancer survival using lead time calibrated from observed survival data (Supplemental Figure 3 ).Disease progressionUpon cancer detection, the model estimates the survival outcomes based on stage, tumour biology, age at diagnosis, and detection method; in the case of disease progression, it draws time to recurrence and possible breast cancer death (Supplemental Appendix 5).", [["Breast", "ANATOMY", 8, 14], ["breast cancer", "ANATOMY", 53, 66], ["cancer", "ANATOMY", 180, 186], ["tumour", "ANATOMY", 256, 262], ["breast cancer", "ANATOMY", 389, 402], ["breast cancer", "DISEASE", 53, 66], ["Disease progressionUpon cancer", "DISEASE", 156, 186], ["tumour", "DISEASE", 256, 262], ["breast cancer death", "DISEASE", 389, 408], ["breast cancer", "CANCER", 53, 66], ["cancer", "CANCER", 180, 186], ["tumour", "CANCER", 256, 262], ["breast cancer", "CANCER", 389, 402], ["screening on breast cancer survival", "TREATMENT", 40, 75], ["Disease progressionUpon cancer detection", "PROBLEM", 156, 196], ["detection method", "TEST", 294, 310], ["disease progression", "PROBLEM", 327, 346], ["recurrence", "PROBLEM", 365, 375], ["breast cancer death", "PROBLEM", 389, 408], ["Breast", "ANATOMY", 8, 14], ["breast", "ANATOMY", 53, 59], ["cancer", "OBSERVATION", 60, 66], ["cancer", "OBSERVATION", 180, 186], ["disease", "OBSERVATION", 327, 334], ["possible", "UNCERTAINTY", 380, 388], ["breast", "ANATOMY", 389, 395], ["cancer", "OBSERVATION", 396, 402]]], ["Stage-specific recurrence risks and breast cancer survival outcomes were estimated using data from the British Columbia Cancer Agency because comprehensive staging data only became available recently in the Canadian Cancer Registry.", [["breast cancer", "ANATOMY", 36, 49], ["breast cancer", "DISEASE", 36, 49], ["Cancer", "DISEASE", 120, 126], ["Cancer", "DISEASE", 216, 222], ["breast cancer", "CANCER", 36, 49], ["Cancer", "CANCER", 216, 222], ["Stage-specific recurrence risks", "PROBLEM", 0, 31], ["breast cancer", "PROBLEM", 36, 49], ["comprehensive staging data", "TEST", 142, 168], ["specific", "OBSERVATION_MODIFIER", 6, 14], ["recurrence", "OBSERVATION", 15, 25], ["breast", "ANATOMY", 36, 42], ["cancer", "OBSERVATION", 43, 49], ["Cancer", "OBSERVATION", 216, 222]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint survival, the model applies province-specific relative risks, estimated from more recent data in the Canadian Cancer Registry, to the British Columbia survival curves.Breast cancer costsThe model included healthcare costs associated with breast cancer from the perspective of a public healthcare payer, such as the Ministry of Health (Supplemental Appendix 6).", [["Breast cancer", "ANATOMY", 509, 522], ["breast cancer", "ANATOMY", 580, 593], ["CC", "CHEMICAL", 0, 2], ["Cancer", "DISEASE", 452, 458], ["Breast cancer", "DISEASE", 509, 522], ["breast cancer", "DISEASE", 580, 593], ["Breast cancer", "CANCER", 509, 522], ["breast cancer", "CANCER", 580, 593], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint survival", "TREATMENT", 325, 350], ["Breast cancer", "PROBLEM", 509, 522], ["breast cancer", "PROBLEM", 580, 593], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Cancer", "OBSERVATION", 452, 458], ["cancer", "OBSERVATION", 516, 522], ["breast", "ANATOMY", 580, 586], ["cancer", "OBSERVATION", 587, 593]]], ["The costs included breast cancer surgery, radiation treatment, chemotherapy, imaging tests and oncology physician fees, acute hospitalizations, emergency department visits, home care, long-term care, complex continuing care, and others.", [["breast cancer", "ANATOMY", 19, 32], ["breast cancer", "DISEASE", 19, 32], ["breast cancer", "CANCER", 19, 32], ["breast cancer surgery", "TREATMENT", 19, 40], ["radiation treatment", "TREATMENT", 42, 61], ["chemotherapy", "TREATMENT", 63, 75], ["imaging tests", "TEST", 77, 90], ["home care", "TREATMENT", 173, 182], ["long-term care", "TREATMENT", 184, 198], ["complex continuing care", "TREATMENT", 200, 223], ["breast", "ANATOMY", 19, 25], ["cancer", "OBSERVATION", 26, 32]]], ["The model captures lifetime costs of breast cancer across three phases of care (first 18 months after diagnosis, continuing care and terminal care), a similar approach used in other established breast cancer simulation models.3Health-related quality of lifeTo calculate quality-adjusted life-years, the model multiplies the duration of each health state with age and sex-specific preference scores for the Canadian population27 and breast cancerspecific health state utilities28 (upon cancer diagnosis) (Supplemental Appendix 7).", [["breast cancer", "ANATOMY", 37, 50], ["breast cancer", "ANATOMY", 194, 207], ["breast", "ANATOMY", 432, 438], ["cancer", "ANATOMY", 485, 491], ["breast cancer", "DISEASE", 37, 50], ["breast cancer", "DISEASE", 194, 207], ["cancer", "DISEASE", 485, 491], ["breast cancer", "CANCER", 37, 50], ["breast cancer", "CANCER", 194, 207], ["breast", "ORGANISM_SUBDIVISION", 432, 438], ["cancer", "CANCER", 485, 491], ["breast cancer", "PROBLEM", 37, 50], ["continuing care and terminal care", "TREATMENT", 113, 146], ["a similar approach", "TREATMENT", 149, 167], ["breast", "ANATOMY", 37, 43], ["cancer", "OBSERVATION", 44, 50], ["breast", "ANATOMY", 194, 200], ["cancer", "OBSERVATION", 201, 207], ["breast", "ANATOMY", 432, 438]]], ["First, we compared the projected incidence and stage distribution of breast cancer in Canada with the observed data in the Canadian Cancer Registry is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.", [["breast cancer", "ANATOMY", 69, 82], ["breast cancer", "DISEASE", 69, 82], ["Cancer", "DISEASE", 132, 138], ["breast cancer", "CANCER", 69, 82], ["Cancer", "CANCER", 132, 138], ["breast cancer", "PROBLEM", 69, 82], ["The copyright holder", "TREATMENT", 282, 302], ["stage", "OBSERVATION_MODIFIER", 47, 52], ["distribution", "OBSERVATION_MODIFIER", 53, 65], ["breast", "ANATOMY", 69, 75], ["cancer", "OBSERVATION", 76, 82], ["Cancer", "OBSERVATION", 132, 138], ["med", "ANATOMY", 186, 189]]], ["22.20110569 doi: medRxiv preprint The UK Age trial is a randomized trial that compared annual screening in women aged 40-49 years with usual care in the UK in the 1990s31.", [["women", "ORGANISM", 107, 112], ["women", "SPECIES", 107, 112], ["annual screening", "TEST", 87, 103]]], ["Other established breast cancer simulation models have validated their predictions against the UK trial results34.", [["breast cancer", "ANATOMY", 18, 31], ["breast cancer", "DISEASE", 18, 31], ["breast cancer", "CANCER", 18, 31], ["Other established breast cancer", "PROBLEM", 0, 31], ["breast", "ANATOMY", 18, 24], ["cancer", "OBSERVATION", 25, 31]]], ["We simulated a cohort of women born in 1950-1957 to match the birth cohort in the UK Age trial in two scenarios: (i) no screening; and (ii) annual screening for women age 40-49.", [["women", "ORGANISM", 25, 30], ["women", "ORGANISM", 161, 166], ["women", "SPECIES", 25, 30], ["women", "SPECIES", 161, 166], ["annual screening", "TEST", 140, 156]]], ["In the screening scenario, we calibrated the rescreening rate to the average number of mammograms per woman in the Age trial (4.8)33.", [["woman", "SPECIES", 102, 107], ["mammograms", "TEST", 87, 97]]], ["For each scenario, we estimated the incidence of breast cancer and breast cancer deaths in women aged 40-49 years.", [["breast cancer", "ANATOMY", 49, 62], ["breast cancer", "ANATOMY", 67, 80], ["breast cancer", "DISEASE", 49, 62], ["breast cancer deaths", "DISEASE", 67, 87], ["breast cancer", "CANCER", 49, 62], ["breast cancer", "CANCER", 67, 80], ["women", "ORGANISM", 91, 96], ["women", "SPECIES", 91, 96], ["breast cancer", "PROBLEM", 49, 62], ["breast cancer", "PROBLEM", 67, 80], ["breast", "ANATOMY", 49, 55], ["cancer", "OBSERVATION", 56, 62], ["breast", "ANATOMY", 67, 73], ["cancer", "OBSERVATION", 74, 80]]], ["We then compared OncoSim Breast's projected incidence of breast cancer (DCIS and invasive cancers) with the trial's mean estimate and its 95% confidence interval.", [["Breast", "ANATOMY", 25, 31], ["breast cancer", "ANATOMY", 57, 70], ["DCIS", "ANATOMY", 72, 76], ["invasive cancers", "ANATOMY", 81, 97], ["breast cancer", "DISEASE", 57, 70], ["DCIS", "DISEASE", 72, 76], ["invasive cancers", "DISEASE", 81, 97], ["breast cancer", "CANCER", 57, 70], ["DCIS", "CANCER", 72, 76], ["cancers", "CANCER", 90, 97], ["breast cancer", "PROBLEM", 57, 70], ["DCIS", "PROBLEM", 72, 76], ["invasive cancers", "PROBLEM", 81, 97], ["Breast", "ANATOMY", 25, 31], ["breast", "ANATOMY", 57, 63], ["cancer", "OBSERVATION", 64, 70], ["DCIS", "OBSERVATION", 72, 76], ["invasive", "OBSERVATION_MODIFIER", 81, 89], ["cancers", "OBSERVATION", 90, 97]]], ["For breast cancer mortality, we compared the mortality reduction ratio from OncoSim Breast with the trial's mean estimate and 95% confidence interval over a 17 years follow-up period.", [["breast cancer", "ANATOMY", 4, 17], ["Breast", "ANATOMY", 84, 90], ["breast cancer", "DISEASE", 4, 17], ["breast cancer", "CANCER", 4, 17], ["breast cancer mortality", "PROBLEM", 4, 27], ["the mortality reduction ratio", "TREATMENT", 41, 70], ["breast", "ANATOMY", 4, 10], ["cancer", "OBSERVATION", 11, 17], ["Breast", "ANATOMY", 84, 90]]], ["We chose to compare rate ratios rather than rates because the populations were different: volunteers in the UK Age trial vs. Canadian population.RESULTSOncoSim's projected incidence, stage distribution and mortality of breast cancer were close to the observed data in the Canadian Cancer Registry and the Vital Statistics32.", [["breast cancer", "ANATOMY", 219, 232], ["breast cancer", "DISEASE", 219, 232], ["Cancer", "DISEASE", 281, 287], ["volunteers", "ORGANISM", 90, 100], ["breast cancer", "CANCER", 219, 232], ["Cancer", "CANCER", 281, 287], ["rate ratios", "TEST", 20, 31], ["stage distribution", "PROBLEM", 183, 201], ["breast cancer", "PROBLEM", 219, 232], ["stage distribution", "OBSERVATION_MODIFIER", 183, 201], ["mortality", "OBSERVATION_MODIFIER", 206, 215], ["breast", "ANATOMY", 219, 225], ["cancer", "OBSERVATION", 226, 232], ["Cancer", "OBSERVATION", 281, 287]]], ["Figures 2A and 2B compare OncoSim's projected incidence rates of breast cancer (invasive cancer and DCIS) by age group in 1992-2013 with the observed data in the Canadian Cancer Registry. .", [["breast cancer", "ANATOMY", 65, 78], ["invasive cancer", "ANATOMY", 80, 95], ["DCIS", "ANATOMY", 100, 104], ["breast cancer", "DISEASE", 65, 78], ["invasive cancer", "DISEASE", 80, 95], ["DCIS", "DISEASE", 100, 104], ["Cancer", "DISEASE", 171, 177], ["breast cancer", "CANCER", 65, 78], ["invasive cancer", "CANCER", 80, 95], ["DCIS", "CANCER", 100, 104], ["Cancer", "CANCER", 171, 177], ["breast cancer", "PROBLEM", 65, 78], ["invasive cancer", "PROBLEM", 80, 95], ["breast", "ANATOMY", 65, 71], ["cancer", "OBSERVATION", 72, 78], ["Cancer", "OBSERVATION", 171, 177]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["22.20110569 doi: medRxiv preprint In our external validation exercise simulating the UK Age trial, OncoSim projected that annual breast cancer screening in women age 40-49 years would detect 16% more invasive breast cancers vs. 10% (95% CI: 0.95-1.21) observed in the UK Age trial34.", [["breast cancer", "ANATOMY", 129, 142], ["invasive breast cancers", "ANATOMY", 200, 223], ["breast cancer", "DISEASE", 129, 142], ["breast cancers", "DISEASE", 209, 223], ["breast cancer", "CANCER", 129, 142], ["women", "ORGANISM", 156, 161], ["breast cancers", "CANCER", 209, 223], ["women", "SPECIES", 156, 161], ["annual breast cancer", "PROBLEM", 122, 142], ["16% more invasive breast cancers", "PROBLEM", 191, 223], ["CI", "TEST", 237, 239], ["breast", "ANATOMY", 129, 135], ["cancer", "OBSERVATION", 136, 142], ["invasive", "OBSERVATION_MODIFIER", 200, 208], ["breast", "ANATOMY", 209, 215], ["cancers", "OBSERVATION", 216, 223]]], ["When estimating the impact of screening on breast cancer deaths, OncoSim's projection was also within the confidence interval of the observed trial estimate.", [["breast cancer", "ANATOMY", 43, 56], ["breast cancer deaths", "DISEASE", 43, 63], ["breast cancer", "CANCER", 43, 56], ["breast cancer deaths", "PROBLEM", 43, 63], ["OncoSim's projection", "TREATMENT", 65, 85], ["breast", "ANATOMY", 43, 49], ["cancer", "OBSERVATION", 50, 56]]], ["Over a 17 years follow-up period, OncoSim estimated that annual breast cancer screening in women age 40-49 years had an 85% relative risk of breast cancer death (i.e. 15% reduction), as compared with 88% (95% CI: 74%-104%)LimitationsThis paper has several limitations.", [["breast cancer", "ANATOMY", 64, 77], ["breast cancer", "ANATOMY", 141, 154], ["breast cancer", "DISEASE", 64, 77], ["breast cancer death", "DISEASE", 141, 160], ["breast cancer", "CANCER", 64, 77], ["women", "ORGANISM", 91, 96], ["breast cancer", "CANCER", 141, 154], ["women", "SPECIES", 91, 96], ["annual breast cancer", "PROBLEM", 57, 77], ["breast cancer death", "PROBLEM", 141, 160], ["CI", "TEST", 209, 211], ["breast", "ANATOMY", 64, 70], ["cancer", "OBSERVATION", 71, 77], ["breast", "ANATOMY", 141, 147], ["cancer", "OBSERVATION", 148, 154]]], ["First, OncoSim is a simulation model built using the best available data; the accuracy of projections depends on the quality of data input and the validity of assumptions.", [["OncoSim", "PROTEIN", 7, 14]]], ["To address the issue of rapidly emerging evidence, OncoSim-Breast allows users to modify the inputs and assumptions.", [["Breast", "ANATOMY", 59, 65], ["Breast", "ANATOMY", 59, 65]]], ["Second, our validation exercise comparing OncoSim-Breast's projections with more recent Canadian Cancer Registry data was limited by the availability and quality of data in the Registry.", [["Cancer", "DISEASE", 97, 103], ["our validation exercise", "TEST", 8, 31], ["Breast", "ANATOMY", 50, 56], ["Cancer", "OBSERVATION", 97, 103]]], ["Third, our simulation of the UK Age trial was an exploratory external validation exercise; we did not calibrate the model to match historically poorer breast cancer outcomes at that time.", [["breast cancer", "ANATOMY", 151, 164], ["breast cancer", "DISEASE", 151, 164], ["breast cancer", "CANCER", 151, 164], ["an exploratory external validation exercise", "TEST", 46, 89], ["poorer breast cancer outcomes", "PROBLEM", 144, 173], ["breast", "ANATOMY", 151, 157], ["cancer", "OBSERVATION", 158, 164]]], ["Fourth, OncoSim-Breast was built to be a multipurpose breast cancer simulation tool and could simulate many scenarios; therefore, it would not be feasible to validate all its possible projections against observed data.", [["Breast", "ANATOMY", 16, 22], ["breast cancer", "ANATOMY", 54, 67], ["breast cancer", "DISEASE", 54, 67], ["breast cancer", "CANCER", 54, 67], ["a multipurpose breast cancer simulation tool", "PROBLEM", 39, 83], ["Breast", "ANATOMY", 16, 22], ["breast", "ANATOMY", 54, 60], ["cancer", "OBSERVATION", 61, 67]]], ["To ensure OncoSim-Breast's relevance for supporting policy decisions, the team compares OncoSim-Breast's projections with emerging real-world data and refines the model based on new evidence, on an ongoing basis.", [["Breast", "ANATOMY", 18, 24], ["Breast", "ANATOMY", 96, 102]]], ["In the upcoming releases, examples of further enhancements will include adding emerging data on new screening modalities, costs of new treatments, and .", [["new screening modalities", "TEST", 96, 120], ["new treatments", "TREATMENT", 131, 145], ["new", "OBSERVATION_MODIFIER", 131, 134]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint other factors that might affect screening performance, such as breast density and polygenic risk scores.ConclusionOncoSim-Breast is a natural history-based simulation model developed using Canadian cancer incidence, mortality, screening program and cost data.", [["breast", "ANATOMY", 405, 411], ["cancer", "ANATOMY", 540, 546], ["CC", "CHEMICAL", 0, 2], ["cancer", "DISEASE", 540, 546], ["breast", "ORGANISM_SUBDIVISION", 405, 411], ["cancer", "CANCER", 540, 546], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["screening performance", "TEST", 374, 395], ["polygenic risk scores", "PROBLEM", 424, 445], ["cost data", "TEST", 591, 600], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["breast", "ANATOMY", 405, 411], ["density", "OBSERVATION", 412, 419], ["Breast", "ANATOMY", 464, 470]]], ["It reproduces breast cancer trends in the Canadian Cancer Registry, breast cancer mortality in the Vital Statistics, and the breast cancer screening effects observed in a randomized screening trial.ACKNOWLEDGMENTSOncoSim is led and supported by the Canadian Partnership Against Cancer, with model development by Statistics Canada, and is made possible through funding provided by Health Canada.", [["breast cancer", "ANATOMY", 14, 27], ["breast cancer", "ANATOMY", 68, 81], ["breast cancer", "ANATOMY", 125, 138], ["Cancer", "ANATOMY", 278, 284], ["breast cancer", "DISEASE", 14, 27], ["Cancer", "DISEASE", 51, 57], ["breast cancer", "DISEASE", 68, 81], ["breast cancer", "DISEASE", 125, 138], ["Cancer", "DISEASE", 278, 284], ["breast cancer", "CANCER", 14, 27], ["Cancer", "CANCER", 51, 57], ["breast cancer", "CANCER", 68, 81], ["breast cancer", "CANCER", 125, 138], ["Cancer", "CANCER", 278, 284], ["breast cancer", "PROBLEM", 14, 27], ["breast cancer mortality", "PROBLEM", 68, 91], ["the breast cancer", "PROBLEM", 121, 138], ["a randomized screening trial", "TREATMENT", 169, 197], ["Cancer", "PROBLEM", 278, 284], ["breast", "ANATOMY", 14, 20], ["cancer", "OBSERVATION", 21, 27], ["Cancer", "OBSERVATION", 51, 57], ["breast", "ANATOMY", 68, 74], ["cancer", "OBSERVATION", 75, 81], ["breast", "ANATOMY", 125, 131], ["cancer", "OBSERVATION", 132, 138], ["Cancer", "OBSERVATION", 278, 284]]], ["In particular, we would like to acknowledge the substantial contribution from other members of the OncoSim-Breast technical working group (full list is in Supplemental Appendix 8).", [["Breast", "ANATOMY", 107, 113]]], ["Also, we would like to thank Dr. James Mainprize for his contribution in the Age trial validation exercise.ACKNOWLEDGMENTS. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)ACKNOWLEDGMENTSThe copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint .", [["CC", "CHEMICAL", 124, 126], ["ND", "PROBLEM", 133, 135], ["medRxiv preprint", "TREATMENT", 465, 481], ["med", "ANATOMY", 229, 232]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)ACKNOWLEDGMENTSThe copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.22.20110569 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 341, 348], ["med", "ANATOMY", 105, 108]]]], "PMC7101672": [["MethodsIn response to an outbreak of H1N1-2009 infection in Mexico, members of the Canadian Critical Care Trials Group (CCCTG) developed a case report form and designed a multicentre observational study of critically ill patients who were infected with this virus.", [["H1N1-2009 infection", "DISEASE", 37, 56], ["critically ill", "DISEASE", 206, 220], ["H1N1-2009", "ORGANISM", 37, 46], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["H1N1-2009", "SPECIES", 37, 46], ["H1N1", "PROBLEM", 37, 41], ["a multicentre observational study", "TEST", 169, 202], ["this virus", "PROBLEM", 253, 263], ["H1N1", "OBSERVATION", 37, 41]]], ["Data were collected retrospectively or prospectively on all patients who had H1N1-2009-related critical illness from April 2009 to August 2009.", [["critical illness", "DISEASE", 95, 111], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["H1N1", "PROBLEM", 77, 81]]], ["The need for a priori informed consent was waived due to the non-interventional study design.", [["the non-interventional study", "TEST", 57, 85]]], ["The results of the entire cohort were recently published.10 An additional form was developed and disseminated to allow collection of ECLS-specific data.", [["ECLS", "TEST", 133, 137], ["specific data", "TEST", 138, 151], ["disseminated", "OBSERVATION", 97, 109]]], ["Herein we present a detailed examination of patients who were supported with ECLS.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["a detailed examination", "TEST", 18, 40], ["ECLS", "TREATMENT", 77, 81]]], ["The use and indications for ECLS were left to the treating physician.", [["ECLS", "TREATMENT", 28, 32]]], ["For study purposes, indications for ECLS were grouped into broad categories, i.e., hypoxemia, hypercarbia, impossible to ventilate, other, and the worst physiologic data preceding initiation of ECLS were recorded.MethodsEligible patients included all adult and pediatric critically ill patients, as previously defined,10 who were admitted to participating ICUs in Canada and had suspected, probable, or confirmed H1N1-2009 infection.14,15 Eligibility criteria were confirmed and data were recorded by research coordinators or site investigators at each centre.", [["hypoxemia", "DISEASE", 83, 92], ["hypercarbia", "DISEASE", 94, 105], ["critically ill", "DISEASE", 271, 285], ["H1N1-2009 infection", "DISEASE", 413, 432], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 286, 294], ["study purposes", "TEST", 4, 18], ["ECLS", "TREATMENT", 36, 40], ["hypoxemia", "PROBLEM", 83, 92], ["hypercarbia", "PROBLEM", 94, 105], ["the worst physiologic data", "PROBLEM", 143, 169], ["ECLS", "TREATMENT", 194, 198], ["H1N1", "PROBLEM", 413, 417], ["infection", "PROBLEM", 423, 432], ["Eligibility criteria", "TEST", 439, 459], ["hypoxemia", "OBSERVATION", 83, 92], ["hypercarbia", "OBSERVATION", 94, 105], ["H1N1", "OBSERVATION", 413, 417], ["infection", "OBSERVATION", 423, 432]]], ["Severity of illness was assessed in adults and children using the Acute Physiology and Chronic Health Evaluation (APACHE) II and the Pediatric Risk of Mortality (PRISM) III score,16,17 respectively.", [["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["illness", "PROBLEM", 12, 19], ["Chronic Health Evaluation", "TEST", 87, 112], ["III score", "TEST", 169, 178], ["illness", "OBSERVATION", 12, 19]]], ["We recorded co-morbidities and a priori defined major co-morbidities as the presence of one or more of the following chronic medical conditions: congestive heart failure; cerebrovascular, neoplastic, chronic liver, or renal diseases; and use of immunosuppressant medications.18 Data were submitted to the coordinating centre and checked for errors by manual inspection and electronic range limits.", [["heart", "ANATOMY", 156, 161], ["cerebrovascular", "ANATOMY", 171, 186], ["neoplastic", "ANATOMY", 188, 198], ["liver", "ANATOMY", 208, 213], ["renal", "ANATOMY", 218, 223], ["congestive heart failure", "DISEASE", 145, 169], ["chronic liver, or renal diseases", "DISEASE", 200, 232], ["heart", "ORGAN", 156, 161], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 171, 186], ["liver", "ORGAN", 208, 213], ["renal", "ORGAN", 218, 223], ["congestive heart failure", "PROBLEM", 145, 169], ["cerebrovascular, neoplastic", "PROBLEM", 171, 198], ["chronic liver", "PROBLEM", 200, 213], ["renal diseases", "PROBLEM", 218, 232], ["immunosuppressant medications", "TREATMENT", 245, 274], ["manual inspection", "TEST", 351, 368], ["congestive", "OBSERVATION_MODIFIER", 145, 155], ["heart", "ANATOMY", 156, 161], ["failure", "OBSERVATION", 162, 169], ["cerebrovascular", "ANATOMY", 171, 186], ["neoplastic", "OBSERVATION", 188, 198], ["chronic", "OBSERVATION_MODIFIER", 200, 207], ["liver", "ANATOMY", 208, 213], ["renal", "ANATOMY", 218, 223], ["diseases", "OBSERVATION", 224, 232]]], ["Descriptive statistics included frequency analysis (percentages) for categorical variables and means (standard deviation [SD]) or medians (interquartile range [IQR]) for continuous variables.", [["frequency analysis", "TEST", 32, 50], ["categorical variables", "PROBLEM", 69, 90]]], ["Analyses were conducted using SAS\u00ae version 9.1 (SAS Institute, Cary, NC, USA).Characteristics of study patients ::: ResultsAs previously reported,10 from April 2009 to August 2009, 168 critically ill patients were admitted to 34 study ICUs in Canada due to confirmed H1N1-2009 infection.", [["critically ill", "DISEASE", 185, 199], ["H1N1-2009 infection", "DISEASE", 267, 286], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 200, 208], ["H1N1-2009", "SPECIES", 267, 276], ["Analyses", "TEST", 0, 8], ["SAS\u00ae version", "TEST", 30, 42], ["H1N1", "PROBLEM", 267, 271], ["infection", "PROBLEM", 277, 286], ["H1N1", "OBSERVATION", 267, 271], ["infection", "OBSERVATION", 277, 286]]], ["Six of these patients were unresponsive to conventional therapy and were treated with ECLS.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["conventional therapy", "TREATMENT", 43, 63], ["ECLS", "TREATMENT", 86, 90]]], ["Although there were no standard inclusion/exclusion criteria, all ECLS programs were heavily influenced by the criteria outlined in the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial,19 with hypoxemia (P/F ratio < 100 on FiO2 = 1.0) being the primary indication for ECLS in our series.", [["Respiratory Failure", "DISEASE", 186, 205], ["hypoxemia", "DISEASE", 228, 237], ["all ECLS programs", "TREATMENT", 62, 79], ["the Conventional Ventilation", "TREATMENT", 132, 160], ["ECMO", "TREATMENT", 164, 168], ["Severe Adult Respiratory Failure", "PROBLEM", 173, 205], ["hypoxemia", "PROBLEM", 228, 237], ["P/F ratio", "TEST", 239, 248], ["FiO2", "TEST", 258, 262], ["ECLS", "TREATMENT", 303, 307], ["no", "UNCERTAINTY", 20, 22], ["Severe", "OBSERVATION_MODIFIER", 173, 179], ["Respiratory Failure", "OBSERVATION", 186, 205]]], ["These patients were profoundly hypoxemic (mean PaO2/FiO2 61 mmHg) and hypercapneic (mean PaCO2 70 mmHg) one hour before the start of ECLS.", [["hypoxemic", "DISEASE", 31, 40], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["profoundly hypoxemic", "PROBLEM", 20, 40], ["mean PaO2", "TEST", 42, 51], ["FiO2", "TEST", 52, 56], ["hypercapneic", "PROBLEM", 70, 82], ["mean PaCO2", "TEST", 84, 94], ["ECLS", "TREATMENT", 133, 137], ["hypoxemic", "OBSERVATION", 31, 40]]], ["Three patients were treated with high frequency oscillation ventilation (HFOV); all received inhaled nitric oxide during their ICU stay, and two had hemodynamic instability requiring intravenous inotropic medication.", [["intravenous", "ANATOMY", 183, 194], ["nitric oxide", "CHEMICAL", 101, 113], ["hemodynamic instability", "DISEASE", 149, 172], ["nitric oxide", "CHEMICAL", 101, 113], ["patients", "ORGANISM", 6, 14], ["nitric oxide", "SIMPLE_CHEMICAL", 101, 113], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 194], ["patients", "SPECIES", 6, 14], ["high frequency oscillation ventilation", "TREATMENT", 33, 71], ["HFOV)", "TREATMENT", 73, 78], ["inhaled nitric oxide", "TREATMENT", 93, 113], ["hemodynamic instability", "PROBLEM", 149, 172], ["intravenous inotropic medication", "TREATMENT", 183, 215]]], ["Two patients had a cardiac arrest before initiation of ECLS.", [["cardiac", "ANATOMY", 19, 26], ["cardiac arrest", "DISEASE", 19, 33], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a cardiac arrest", "PROBLEM", 17, 33], ["ECLS", "TREATMENT", 55, 59], ["cardiac", "ANATOMY", 19, 26], ["arrest", "OBSERVATION", 27, 33]]], ["Table 2 outlines the ECLS patient characteristics.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]]], "c8310c515a4749d9625398b92c56a18a06418158": [["(VLDL), low-density lipoprotein (LDL)) along with reduced high-density lipoprotein levels (HDL), has been postulated as a possible exacerbating factor indicating poor outcomes by dysregulating protective immunity and promoting exaggerated pulmonary and systemic inflammatory responses.", [["pulmonary", "ANATOMY", 239, 248], ["VLDL", "SIMPLE_CHEMICAL", 1, 5], ["low-density lipoprotein", "SIMPLE_CHEMICAL", 8, 31], ["LDL", "SIMPLE_CHEMICAL", 33, 36], ["high-density lipoprotein", "GENE_OR_GENE_PRODUCT", 58, 82], ["HDL", "SIMPLE_CHEMICAL", 91, 94], ["pulmonary", "ORGAN", 239, 248], ["VLDL", "PROTEIN", 1, 5], ["low-density lipoprotein", "PROTEIN", 8, 31], ["LDL", "PROTEIN", 33, 36], ["VLDL", "TEST", 1, 5], ["low-density lipoprotein (LDL)", "PROBLEM", 8, 37], ["reduced high-density lipoprotein levels", "PROBLEM", 50, 89], ["exacerbating factor", "PROBLEM", 131, 150], ["dysregulating protective immunity", "TREATMENT", 179, 212], ["exaggerated pulmonary and systemic inflammatory responses", "PROBLEM", 227, 284], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["high-density", "OBSERVATION_MODIFIER", 58, 70], ["lipoprotein levels", "OBSERVATION", 71, 89], ["possible", "UNCERTAINTY", 122, 130], ["exaggerated", "OBSERVATION_MODIFIER", 227, 238], ["pulmonary", "ANATOMY", 239, 248], ["systemic", "OBSERVATION_MODIFIER", 253, 261], ["inflammatory", "OBSERVATION", 262, 274]]], ["[1] COVID-19 is an RNA virus having a lipid envelope.", [["COVID", "TEST", 4, 9], ["an RNA virus", "PROBLEM", 16, 28], ["a lipid envelope", "TREATMENT", 36, 52]]], ["Hence, cholesterol biosynthesis pathways play an important role in the assembly, replication and infectivity of these viral particles.", [["cholesterol", "CHEMICAL", 7, 18], ["cholesterol", "CHEMICAL", 7, 18], ["cholesterol", "SIMPLE_CHEMICAL", 7, 18], ["cholesterol biosynthesis pathways", "TREATMENT", 7, 40], ["these viral particles", "PROBLEM", 112, 133], ["viral particles", "OBSERVATION", 118, 133]]], ["[2] Cholesterol-modifying drugs, mainly statins, have been hypothesized to have antiviral effects.", [["Cholesterol", "CHEMICAL", 4, 15], ["statins", "CHEMICAL", 40, 47], ["[2] Cholesterol", "CHEMICAL", 0, 15], ["statins", "CHEMICAL", 40, 47], ["[2] Cholesterol-modifying drugs", "SIMPLE_CHEMICAL", 0, 31], ["statins", "SIMPLE_CHEMICAL", 40, 47], ["Cholesterol-modifying drugs", "TREATMENT", 4, 31], ["statins", "TREATMENT", 40, 47], ["antiviral effects", "TREATMENT", 80, 97]]], ["These drugs decrease the synthesis, systemic absorption of cholesterol or exhibit direct antiviral activity altering the target cell membrane cholesterol.", [["cell membrane", "ANATOMY", 128, 141], ["cholesterol", "CHEMICAL", 59, 70], ["cholesterol", "CHEMICAL", 142, 153], ["cholesterol", "CHEMICAL", 59, 70], ["cholesterol", "CHEMICAL", 142, 153], ["cholesterol", "SIMPLE_CHEMICAL", 59, 70], ["cell membrane", "CELLULAR_COMPONENT", 128, 141], ["cholesterol", "SIMPLE_CHEMICAL", 142, 153], ["These drugs", "TREATMENT", 0, 11], ["the synthesis", "TREATMENT", 21, 34], ["systemic absorption of cholesterol", "TREATMENT", 36, 70], ["direct antiviral activity", "TREATMENT", 82, 107], ["antiviral activity", "OBSERVATION", 89, 107], ["target cell membrane cholesterol", "OBSERVATION", 121, 153]]], ["Statins also have additional non-lipid-related pleiotropic effects.", [["Statins", "CHEMICAL", 0, 7], ["Statins", "CHEMICAL", 0, 7], ["Statins", "TREATMENT", 0, 7], ["pleiotropic effects", "PROBLEM", 47, 66], ["pleiotropic effects", "OBSERVATION", 47, 66]]], ["This includes improved endothelial function, atherosclerotic plaques stabilization, anti-inflammatory, immunomodulatory and antithrombotic effects.", [["endothelial", "ANATOMY", 23, 34], ["atherosclerotic plaques", "ANATOMY", 45, 68], ["atherosclerotic plaques", "DISEASE", 45, 68], ["endothelial", "CELL", 23, 34], ["atherosclerotic plaques stabilization", "PROBLEM", 45, 82], ["anti-inflammatory", "TREATMENT", 84, 101], ["immunomodulatory", "TREATMENT", 103, 119], ["antithrombotic effects", "TREATMENT", 124, 146], ["improved", "OBSERVATION_MODIFIER", 14, 22], ["endothelial function", "OBSERVATION", 23, 43], ["atherosclerotic", "OBSERVATION_MODIFIER", 45, 60], ["plaques", "OBSERVATION", 61, 68], ["anti-inflammatory", "OBSERVATION_MODIFIER", 84, 101]]], ["[3, 4] These additional properties of statins might confer a possible benefit in patients infected with COVID-19.", [["statins", "CHEMICAL", 38, 45], ["statins", "CHEMICAL", 38, 45], ["COVID-19", "CHEMICAL", 104, 112], ["statins", "SIMPLE_CHEMICAL", 38, 45], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["statins", "TREATMENT", 38, 45], ["COVID", "TEST", 104, 109]]]], "45b2c2a129723a1caed0d61d5970524d41192105": [["IntroductionThe novel coronavirus SARS-CoV-2 (COVID-19), has spread to many countries.", [["coronavirus SARS-CoV-2", "ORGANISM", 22, 44], ["COVID-19", "ORGANISM", 46, 54], ["coronavirus", "SPECIES", 22, 33], ["The novel coronavirus SARS", "TEST", 12, 38], ["CoV", "TEST", 39, 42], ["COVID", "TEST", 46, 51]]], ["Given the fragile health systems in most countries, and especially in war zones, we studied the data available in Palestine as well as their possible evolution.", [["the fragile health systems", "PROBLEM", 6, 32], ["fragile", "OBSERVATION_MODIFIER", 10, 17]]], ["How will the number of unreported cases influence the severity of the epidemic?IntroductionMost of the Palestinian territories live under a blockade and apartheid.", [["a blockade", "TREATMENT", 138, 148]]], ["What is the effect of these oppressive policies on the epidemic?", [["these oppressive policies", "TREATMENT", 22, 47]]], ["To answer these questions, we developed mathematical models that recover from data of reported cases and the number of unreported cases for the COVID-19 epidemic in Palestine.", [["mathematical models", "PROBLEM", 40, 59], ["the COVID", "TEST", 140, 149]]], ["It represents the epidemic transmission in Palestine.", [["epidemic", "OBSERVATION_MODIFIER", 18, 26], ["Palestine", "OBSERVATION_MODIFIER", 43, 52]]], ["Four deaths are reported on 22 April 2020 with more than 466 total number of infected cases.", [["deaths", "DISEASE", 5, 11], ["infected", "OBSERVATION", 77, 85]]], ["The three phases of COVID-19 epidemics can be decomposed as a linear phase, an exponential growth, and a decreasing stage.", [["COVID", "TEST", 20, 25], ["an exponential growth", "PROBLEM", 76, 97], ["a decreasing stage", "PROBLEM", 103, 121], ["exponential", "OBSERVATION_MODIFIER", 79, 90], ["growth", "OBSERVATION_MODIFIER", 91, 97], ["decreasing", "OBSERVATION_MODIFIER", 105, 115]]], ["The linear growth in the number of reported cases (from 5 March to 31 March) is where the number of daily reported cases is almost constant day after day.", [["The linear growth", "PROBLEM", 0, 17], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["growth", "OBSERVATION_MODIFIER", 11, 17]]], ["The second phase of the epidemic corresponds to an exponential increasing phase, it starts on April 1st, 2020.", [["exponential", "OBSERVATION_MODIFIER", 51, 62], ["increasing", "OBSERVATION_MODIFIER", 63, 73], ["phase", "OBSERVATION_MODIFIER", 74, 79]]], ["The third phase of the epidemic corresponds to a time-dependent exponentially decreasing transmission rate, due to major public interventions and social distancing measures [5] .IntroductionOur analysis identifies the epidemics in Palestine as in the exponential phase.", [["social distancing measures", "TREATMENT", 146, 172], ["Our analysis", "TEST", 190, 202], ["third", "OBSERVATION_MODIFIER", 4, 9], ["phase", "OBSERVATION_MODIFIER", 10, 15]]], ["The main objective of this study is the estimation of the average number of infections one case can generate throughout the infectious period.", [["infections", "DISEASE", 76, 86], ["this study", "TEST", 22, 32], ["infections", "PROBLEM", 76, 86], ["main", "OBSERVATION_MODIFIER", 4, 8], ["average", "OBSERVATION_MODIFIER", 58, 65], ["number", "OBSERVATION_MODIFIER", 66, 72], ["infections", "OBSERVATION", 76, 86], ["infectious", "OBSERVATION", 124, 134]]], ["It is the basic reproduction number of an infectious agent.", [["an infectious agent", "TREATMENT", 39, 58], ["infectious", "OBSERVATION", 42, 52]]], ["Section 2 presents the data set and an estimation of an actual number of infected cases in Palestine based on the 18-day effect from infection to death. introduces two deterministic compartmental model based on the clinical progression of the disease and the epidemiological status of the individuals [7] .", [["infection", "DISEASE", 133, 142], ["death", "DISEASE", 146, 151], ["infection", "PROBLEM", 133, 142], ["death", "PROBLEM", 146, 151], ["the disease", "PROBLEM", 239, 250], ["infected", "OBSERVATION", 73, 81], ["infection", "OBSERVATION", 133, 142]]], ["The SEIR model studies the disease transmission.", [["the disease transmission", "PROBLEM", 23, 47], ["disease", "OBSERVATION", 27, 34]]], ["Four compartments are present: Susceptible, Exposed, Infectious, and Recovered.", [["compartments", "ANATOMY", 5, 17], ["Susceptible", "OBSERVATION_MODIFIER", 31, 42], ["Infectious", "OBSERVATION", 53, 63]]], ["The cumulative number of reported symptomatic infectious cases at time t, denoted by CR(t) is computed.", [["symptomatic infectious cases", "PROBLEM", 34, 62], ["symptomatic", "OBSERVATION_MODIFIER", 34, 45], ["infectious", "OBSERVATION", 46, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Data descriptionThe data available in [2] gives the number of COVID-19 positive cases per day, the number of deaths due to COVID-19, and the number of reported recoveries.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 311, 317], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["COVID", "TEST", 264, 269], ["COVID", "TEST", 325, 330], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The data entry was done manually 1 .", [["The data entry", "TEST", 0, 14]]], ["The total number of deaths is 4.", [["deaths", "DISEASE", 20, 26], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["It represents 6.7 \u2030 of total reported cases.", [["6.7 \u2030", "OBSERVATION_MODIFIER", 14, 19]]], ["Patients who die on a given day j were infected much earlier, so the mortality rate denominator should be the total number of patients infected at the same time as those who died [12] .", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 126, 134], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 126, 134], ["infected", "OBSERVATION", 39, 47], ["infected", "OBSERVATION", 135, 143]]], ["The mortality rate is defined byData descriptionwhere M j is the total number of deaths at time j.", [["deaths", "DISEASE", 81, 87]]], ["The median mortality rate during this period is equal to 0.03.", [["The median mortality rate", "TEST", 0, 25], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["The progression of the number of cases reported over the last eighteen days P 18 is known in each country.", [["progression", "OBSERVATION_MODIFIER", 4, 15], ["number", "OBSERVATION_MODIFIER", 23, 29]]], ["It depends on the rate of containment and its effectiveness: Figure 3 shows the progression rate of COVID-19 in Palestine.", [["COVID", "TEST", 100, 105], ["progression", "OBSERVATION_MODIFIER", 80, 91]]], ["The median of P 18 is equal to 3.95Data descriptionand it is used to compute the estimated number of reported and unreported cases [1] .", [["P 18", "DNA", 14, 18]]], ["We estimate the number of cases in Palestine as of April 22 th , 2020 by modulating the estimated mortality rate.Data descriptionIn Figure 4 we take different values of T : from 0.5 to 2%, where P 18 = 3.38 with an account delays of 18 days between the onset of symptoms (or asymptomatic) and death.", [["death", "DISEASE", 293, 298], ["P", "TEST", 195, 196], ["symptoms", "PROBLEM", 262, 270], ["asymptomatic", "PROBLEM", 275, 287], ["death", "PROBLEM", 293, 298]]], ["1 Data is available on https://www.worldometers.info/coronavirus/ and at https://corona.ps/details On the other hand, we scale the number of deaths per 1,000 population due to COVID-19 related to the number of registered infected people per million population.", [["deaths", "DISEASE", 141, 147], ["people", "ORGANISM", 230, 236], ["people", "SPECIES", 230, 236], ["COVID", "TEST", 176, 181]]], ["To measure a death ratio, a delay of 18 days is used between the mortality number and the infected number.", [["death", "DISEASE", 13, 18], ["a death ratio", "TEST", 11, 24], ["infected", "OBSERVATION", 90, 98]]], ["This delay is justified by the days between infection and death, which is about 17 to 19 days [3] .", [["infection", "DISEASE", 44, 53], ["death", "DISEASE", 58, 63], ["infection", "PROBLEM", 44, 53], ["death", "PROBLEM", 58, 63], ["infection", "OBSERVATION", 44, 53]]], ["The relationships between deaths a given day j and the number of cases 18 days before j \u2212 18 is linear for several countries.", [["deaths", "DISEASE", 26, 32]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.MethodsAssume that infected individuals were not infectious during the incubation period [13] .", [["CC", "CHEMICAL", 0, 2], ["individuals", "ORGANISM", 303, 314], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["MethodsAssume", "TREATMENT", 275, 288], ["infected individuals", "PROBLEM", 294, 314], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infected", "OBSERVATION", 294, 302]]], ["Assume population growth rate and death rate are zero.", [["death", "DISEASE", 34, 39], ["growth rate", "TEST", 18, 29], ["death rate", "TEST", 34, 44]]], ["Assume people exhibit consistent behaviors before and during the epidemic [14] .", [["people", "ORGANISM", 7, 13], ["people", "SPECIES", 7, 13]]], ["Assume no quarantine or other mitigation intervention is implemented.MethodsAll these assumptions directly influence the model, which is dependent on several parameters.", [["quarantine", "TREATMENT", 10, 20], ["other mitigation intervention", "TREATMENT", 24, 53], ["Methods", "TREATMENT", 69, 76]]], ["A typical SEIR (susceptible, exposed, infectious, removed) model is done in [4] .", [["A typical SEIR (susceptible", "PROBLEM", 0, 27], ["typical", "OBSERVATION_MODIFIER", 2, 9], ["SEIR", "OBSERVATION", 10, 14], ["susceptible", "OBSERVATION_MODIFIER", 16, 27], ["infectious", "OBSERVATION_MODIFIER", 38, 48]]], ["It can be described as a system of differential equations:Methodswhere, t 0 is the beginning date of the epidemic, t \u2265 t 0 is time in days, S(t) is the number of susceptible at time t, E(t) is the number of exposed at time t, I(t) is the number of infectious at time t, R(t)Methodsis the number of removed, which includes the number of recovered and dead at time t, N (t) is the population at time t and N (t) = S(t) + E(t) + I(t) + R(t).", [["infectious", "OBSERVATION", 248, 258]]], ["Between S and I, the transition rate isMethodswhere \u03b2 is the average number of contacts per person per time, multiplied by the probability 5 .", [["person", "SPECIES", 92, 98]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078279 doi: medRxiv preprint of disease transmission in a contact between a susceptible and an infectious subject, and I/N is the fraction of contact occurrences that involve an infectious individual.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["disease transmission", "PROBLEM", 347, 367], ["an infectious individual", "PROBLEM", 490, 514], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["disease", "OBSERVATION", 347, 354], ["infectious", "OBSERVATION", 410, 420], ["infectious", "OBSERVATION", 493, 503]]], ["The transition rates are \u03b1 and \u03b3.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 25, 26]]], ["We modify the model to estimate the number of unreported infected and asymptomatic cases out of the total number of cases.", [["infected", "OBSERVATION_MODIFIER", 57, 65]]], ["We propose to use a mathematical model, which recovers from data of reported cases, the number of unreported cases for the COVID-19 epidemic in Palestine.", [["a mathematical model", "TREATMENT", 18, 38], ["the COVID", "TEST", 119, 128]]], ["A sophisticated SEIR model is developed in [11] , but we choose to folow the approach of [5] and the model in [6] Figure 5 produces Figure 6 .", [["A sophisticated SEIR model", "TEST", 0, 26]]], ["The model contains a symptom class with both reported and unreported cases.", [["a symptom class", "PROBLEM", 19, 34]]], ["The SEIR is given by the following system of ordinary differential equations:(which was not certified by peer review)Here, S(t) is the number of individuals susceptible to infection at time t, I(t) is the number of asymptomatic infectious individuals at time t, R(t) is the number of reported symptomatic infectious in-6 .", [["infection", "DISEASE", 172, 181], ["SEIR", "DNA", 4, 8], ["infection", "PROBLEM", 172, 181], ["asymptomatic infectious individuals", "PROBLEM", 215, 250], ["symptomatic infectious", "PROBLEM", 293, 315], ["infection", "OBSERVATION", 172, 181], ["asymptomatic", "OBSERVATION_MODIFIER", 215, 227], ["infectious", "OBSERVATION", 228, 238], ["symptomatic", "OBSERVATION_MODIFIER", 293, 304], ["infectious", "OBSERVATION", 305, 315]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078279 doi: medRxiv preprint dividuals (i.e. symptomatic infectious with severe symptoms) at time t, and U (t) is the number of unreported symptomatic infectious individuals (i.e. symptomatic infectious with mild symptoms) at time t.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint dividuals", "TREATMENT", 327, 353], ["severe symptoms", "PROBLEM", 388, 403], ["unreported symptomatic infectious individuals", "PROBLEM", 443, 488], ["symptomatic infectious", "PROBLEM", 495, 517], ["mild symptoms", "PROBLEM", 523, 536], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["symptomatic", "OBSERVATION_MODIFIER", 454, 465], ["infectious", "OBSERVATION", 466, 476]]], ["This system is supplemented by initial data We assume that the removal rate \u03bd is the sum of the removal rate of reported symptomatic infectious individuals, and of the removal rate of unreported symptomatic infectious individuals due to all other causes, such as mild symptom, or other reasons.", [["the removal rate", "TREATMENT", 59, 75], ["the removal rate", "TREATMENT", 92, 108], ["symptomatic infectious individuals", "PROBLEM", 121, 155], ["the removal rate", "TREATMENT", 164, 180], ["unreported symptomatic infectious individuals", "PROBLEM", 184, 229], ["all other causes", "PROBLEM", 237, 253], ["mild symptom", "PROBLEM", 263, 275], ["symptomatic", "OBSERVATION_MODIFIER", 121, 132], ["infectious", "OBSERVATION", 133, 143]]], ["The cumulative number of reported symptomatic infectious cases at time t is denoted by CR(t).", [["symptomatic infectious cases", "PROBLEM", 34, 62], ["symptomatic", "OBSERVATION_MODIFIER", 34, 45], ["infectious", "OBSERVATION", 46, 56]]], ["We assume that CR(t) has the following special form:(which was not certified by peer review)We obtain the model starting time of the epidemic t 0 :(which was not certified by peer review)We fix S 0 to 5 077 760, which corresponds to the total population of Palestine.", [["total", "OBSERVATION_MODIFIER", 237, 242], ["population", "OBSERVATION_MODIFIER", 243, 253]]], ["We assume that the variation in S(t) is small during the period considered, and we fix \u03bd, \u03b7, f .", [["variation", "OBSERVATION_MODIFIER", 19, 28], ["small", "OBSERVATION_MODIFIER", 40, 45]]], ["We obtain I(t) = I 0 exp(\u03c7 2 (t \u2212 t 0 )) and I 0 = \u03c7 2 f \u03bd .", [["\u03bd", "PROTEIN", 57, 58], ["exp", "TEST", 21, 24], ["\u03c7", "TEST", 25, 26], ["I", "TEST", 45, 46]]], ["We must have U (t) = U 0 exp(\u03c7 2 (t \u2212 t 0 )).", [["U 0 exp", "TEST", 21, 28]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078279 doi: medRxiv preprint previous identities, we obtain:(which was not certified by peer review)We fix \u03c4 in such a way that the value \u03c7 2 becomes the dominant eigenvalue of(which was not certified by peer review)and (I 0 , U 0 ) is the positive eigenvector associated with this dominant eigenvalue \u03c7 2 .", [["CC", "CHEMICAL", 0, 2], ["\u03c4", "PROTEIN", 422, 423], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the positive eigenvector", "PROBLEM", 551, 575], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["dominant", "OBSERVATION_MODIFIER", 469, 477], ["eigenvalue", "OBSERVATION", 478, 488]]], ["Moreover, the exponentially growing solution (I(t), U (t)) that we consider (which is starting very close to (0, 0)) follows the direction of the positive eigenvector associated with the dominant eigenvalue \u03c7 2 .", [["the positive eigenvector", "PROBLEM", 142, 166], ["positive eigenvector", "OBSERVATION", 146, 166]]], ["The basic reproductive number becomes:Comparison of models with the dataThe first infected case in Palestine is documented on March 5, 2020.", [["the data", "TEST", 64, 72], ["infected", "OBSERVATION_MODIFIER", 82, 90], ["case", "OBSERVATION", 91, 95]]], ["Fitting Palestinian data from April 15 to April 22 enables to compute CR(t) = \u03c7 1 exp(\u03c7 2 t) \u2212 1.", [["CR", "TEST", 70, 72], ["t", "TEST", 73, 74]]], ["For \u03c7 1 = 30.91, \u03c7 2 = 0.06 and \u03c7 3 = 1, we obtain prediction in Table 3 .", [["\u03c7", "TEST", 17, 18]]], ["Thus, the exponential formula overesti- mates the number of infected cases after 4 months (see Figure 12) .", [["infected", "OBSERVATION_MODIFIER", 60, 68]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org /10.1101 /10. /2020 For N a total population equal to 5 077 760, we suppose that S 0 = N/100 is the susceptible population to be infected by COVID-19.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["https://doi.org", "TEST", 278, 293], ["a total population", "TEST", 320, 338], ["the susceptible population", "PROBLEM", 390, 416], ["COVID", "TEST", 435, 440], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infected", "OBSERVATION", 423, 431]]], ["Figure 7 and Figure 8 show that the range between the most naive model and the slightly more elaborate one is between 113 000 and 11 014 infected cases.", [["Figure", "TEST", 0, 6], ["Figure", "TEST", 13, 19]]], ["The results of this model, if correct, show very good management of the epidemic regarding the number of deaths compared to its neighboring countries.", [["deaths", "DISEASE", 105, 111], ["this model", "TEST", 15, 25]]], ["For these values of parameters, R 0 = 1.54.", [["these values", "TEST", 4, 16], ["parameters", "TEST", 20, 30]]], ["In the literature, the value of R 0 varies from 1.4 to 3.9 [8] .", [["the value", "TEST", 19, 28]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.DiscussionAn epidemic outbreak of a new human coronavirus COVID-19 will occur in Palestine.", [["CC", "CHEMICAL", 0, 2], ["human", "ORGANISM", 315, 320], ["human", "SPECIES", 315, 320], ["coronavirus", "SPECIES", 321, 332], ["human coronavirus COVID-19", "SPECIES", 315, 341], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["a new human coronavirus COVID", "TREATMENT", 309, 338], ["med", "ANATOMY", 105, 108]]], ["We estimate an actual number of infected cases in Palestine based on the 18-day effect from infection to death.", [["infection", "DISEASE", 92, 101], ["death", "DISEASE", 105, 110], ["infection", "PROBLEM", 92, 101], ["death", "PROBLEM", 105, 110], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["cases", "OBSERVATION", 41, 46], ["infection", "OBSERVATION", 92, 101]]], ["To recover these effect of unreported cases, we applied a method developed in [7] to predict the evolution of a COVID-19 epidemic in Palestine, based on reported case data. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org /10.1101 /10. /2020 To estimate the reproductive number R 0 , we initially get the time-dependent function of reported cases CR(t).", [["a method", "TREATMENT", 56, 64], ["a COVID", "TEST", 110, 117], ["The copyright holder", "TREATMENT", 307, 327], ["med", "ANATOMY", 211, 214]]], ["With the SEIR method used, the reproductive number is very sensitive to the data set:(which was not certified by peer review)Formula for CR(t) is descriptive for the reported case data for Palestine, and R 0 is still greater than 1.", [["the SEIR method", "TREATMENT", 5, 20], ["Palestine, and R 0", "TEST", 189, 207]]], ["To reduce R 0 to less than 1, public measures should be taken, such as isolation, quarantine, and public closings.", [["public measures", "TREATMENT", 30, 45], ["quarantine", "TREATMENT", 82, 92], ["public closings", "TREATMENT", 98, 113]]], ["These measures exacerbate the spread of this disease and mitigate the final size of the epidemic [11] .", [["this disease", "PROBLEM", 40, 52], ["spread", "OBSERVATION_MODIFIER", 30, 36], ["size", "OBSERVATION_MODIFIER", 76, 80]]], ["The model used in this paper incorporates social distancing measures through the transmission rate \u03c4 = 4.55 10 \u22126 .", [["the transmission rate", "TEST", 77, 98]]], ["The consequences of late public interventions may have severe consequences for the epidemic outcome.", [["late public interventions", "TREATMENT", 20, 45], ["the epidemic outcome", "PROBLEM", 79, 99]]], ["Changes to this rate (over time) would be advisable when the epidemics will peak.(which was not certified by peer review)In Figure 9 , we graph R 0 as a function of f and 1/\u03bd, to illustrate the importance of these values in the evolution of the epidemic.", [["the epidemics", "PROBLEM", 57, 70], ["the epidemic", "PROBLEM", 241, 253], ["epidemic", "OBSERVATION", 245, 253]]], ["We find that minimum value of R 0 is equal to 1.18 (f = 0.7 and 1/\u03bd = 3), the maximum is equal to 3.3 (f = 0.1 and 1/\u03bd = 8) and the median is equal to 2.24.", [["minimum value", "TEST", 13, 26], ["minimum", "OBSERVATION_MODIFIER", 13, 20], ["maximum", "OBSERVATION_MODIFIER", 78, 85], ["equal", "OBSERVATION_MODIFIER", 89, 94]]], ["Figure 9 : In this figure, we use 1/\u03b7 = 7 days, and we plot the basic reproductive number R 0 as a function of f and 1/\u03bd using \u03c4 = 4.55 10 \u22126 , which corresponds to the data for Palestine in Table 4 Figure 10: Number of infected cases and deaths.", [["deaths", "DISEASE", 239, 245]]], ["The data are divided into different groups.", [["The data", "TEST", 0, 8]]], ["These number are normalized per million for reported infected cases or per miles for death cases i .", [["death", "DISEASE", 85, 90]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078279 doi: medRxiv preprint Figure 13 : Number of deaths at t 0 as a function of the number of cases eighteen days earlier (t 0 -18 days).", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 366, 372], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The data are divided into three groups according to the number of deaths (depending on whether the number of deaths is lower in the country)(which was not certified by peer review)iii .", [["deaths", "DISEASE", 66, 72], ["deaths", "DISEASE", 109, 115]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Table 4 : Data for Palestine -accumulated reported cases, CR(t), and casualties iv .", [["casualties iv", "TREATMENT", 69, 82]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.24.20078279 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv", "TREATMENT", 368, 375], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC6348955": [["Survey methodology ::: IntroductionFor the purpose of this review, we divided the article into sections and disease-specific subsections, focusing on specific diseases, one at a time.", [["sections", "ANATOMY", 95, 103], ["disease", "PROBLEM", 108, 115]]], ["For others, we searched journal specific or government websites (http://www.health.mil), in addition to websites of international organizations such as the World Health Organization (https://www.who.int/tdr/en/) and the Centers for Disease Control (http://www.cdc.gov), to retrieve articles focused on parasitic diseases in specific endemic locations.", [["parasitic diseases", "DISEASE", 302, 320], ["Disease Control", "TREATMENT", 232, 247], ["parasitic diseases", "PROBLEM", 302, 320], ["parasitic diseases", "OBSERVATION", 302, 320], ["endemic", "OBSERVATION_MODIFIER", 333, 340]]], ["Subject directed keywords or terms utilized in our search include armed forces, deployment, malaria, leishmaniasis, epidemiology, military-related autochthonous parasitic diseases, prevention and treatment.", [["malaria", "DISEASE", 92, 99], ["leishmaniasis", "DISEASE", 101, 114], ["parasitic diseases", "DISEASE", 161, 179], ["malaria", "PROBLEM", 92, 99], ["leishmaniasis", "PROBLEM", 101, 114], ["autochthonous parasitic diseases", "PROBLEM", 147, 179], ["treatment", "TREATMENT", 196, 205], ["malaria", "OBSERVATION", 92, 99], ["leishmaniasis", "OBSERVATION", 101, 114], ["autochthonous parasitic diseases", "OBSERVATION", 147, 179]]], ["References include articles directly relating to research data, relevant case reports or clinical presentations in the United States, Canada, or Europe from deployed service men and women.", [["men", "ORGANISM", 174, 177], ["women", "ORGANISM", 182, 187], ["men", "SPECIES", 174, 177], ["women", "SPECIES", 182, 187]]], ["Of additional interest in our search were articles relating to zoonotic (canine) leishmaniasis among military dogs deployed overseas alongside their handlers and potential for disease transmission on return to the United States.Causes ::: Malaria ::: IntroductionHuman malaria is spread via bloodmeals of the female Anopheles mosquito, which picks up gametocytes while feeding on infected individuals, and hosts the developmental stages until full maturation into infective sporozoites, which are then passed on to a new host during another mosquito feeding process (Anderson et al., 2005).", [["gametocytes", "ANATOMY", 351, 362], ["sporozoites", "ANATOMY", 474, 485], ["zoonotic (canine) leishmaniasis", "DISEASE", 63, 94], ["Malaria", "DISEASE", 239, 246], ["malaria", "DISEASE", 269, 276], ["canine", "ORGANISM", 73, 79], ["dogs", "ORGANISM", 110, 114], ["female", "ORGANISM", 309, 315], ["Anopheles mosquito", "ORGANISM", 316, 334], ["sporozoites", "CELL", 474, 485], ["canine", "SPECIES", 73, 79], ["dogs", "SPECIES", 110, 114], ["Anopheles mosquito", "SPECIES", 316, 334], ["canine", "SPECIES", 73, 79], ["Anopheles mosquito", "SPECIES", 316, 334], ["disease transmission", "PROBLEM", 176, 196], ["IntroductionHuman malaria", "PROBLEM", 251, 276], ["infective sporozoites", "PROBLEM", 464, 485], ["malaria", "OBSERVATION", 269, 276]]], ["Clinical malaria is classically due to any of four different Plasmodium (P) species: P. vivax, P. falciparum, P. ovale and P. malariae, though an animal species, P. knowlesi has been confirmed as responsible for significant human infections in parts of southeast Asia (Muller & Schlangehauf, 2014; Millar & Cox-Singh, 2015; Divis et al., 2015).", [["malaria", "DISEASE", 9, 16], ["Plasmodium (P) species", "DISEASE", 61, 83], ["P. vivax", "DISEASE", 85, 93], ["P. falciparum", "DISEASE", 95, 108], ["P. ovale and P. malariae", "DISEASE", 110, 134], ["P. knowlesi", "DISEASE", 162, 173], ["infections", "DISEASE", 230, 240], ["Plasmodium (P) species", "ORGANISM", 61, 83], ["P. vivax", "ORGANISM", 85, 93], ["P. falciparum", "ORGANISM", 95, 108], ["P. ovale", "ORGANISM", 110, 118], ["P. malariae", "ORGANISM", 123, 134], ["P. knowlesi", "ORGANISM", 162, 173], ["human", "ORGANISM", 224, 229], ["P. vivax", "SPECIES", 85, 93], ["P. falciparum", "SPECIES", 95, 108], ["P. ovale", "SPECIES", 110, 118], ["P. malariae", "SPECIES", 123, 134], ["P. knowlesi", "SPECIES", 162, 173], ["human", "SPECIES", 224, 229], ["P. vivax", "SPECIES", 85, 93], ["P. falciparum", "SPECIES", 95, 108], ["P. ovale", "SPECIES", 110, 118], ["P. malariae", "SPECIES", 123, 134], ["P. knowlesi", "SPECIES", 162, 173], ["human", "SPECIES", 224, 229], ["Clinical malaria", "PROBLEM", 0, 16], ["four different Plasmodium (P) species", "PROBLEM", 46, 83], ["vivax", "PROBLEM", 88, 93], ["P. falciparum", "PROBLEM", 95, 108], ["P. ovale", "PROBLEM", 110, 118], ["P. malariae", "PROBLEM", 123, 134], ["an animal species", "PROBLEM", 143, 160], ["significant human infections", "PROBLEM", 212, 240], ["infections", "OBSERVATION", 230, 240]]], ["The dominant species causing infection among the armed forces is P. vivax (Ciminera & Brundage, 2007), although the latest update on malaria in the military shows a shift to increasing infections with P. falciparum, as the causative agent for the most number of cases (Armed Forces Health Surveillance Branch, 2018), likely due to the locations of reporting.", [["infection", "DISEASE", 29, 38], ["P. vivax", "DISEASE", 65, 73], ["malaria", "DISEASE", 133, 140], ["infections", "DISEASE", 185, 195], ["P. falciparum", "DISEASE", 201, 214], ["P. vivax", "ORGANISM", 65, 73], ["P. falciparum", "ORGANISM", 201, 214], ["P. vivax", "SPECIES", 65, 73], ["P. falciparum", "SPECIES", 201, 214], ["P. vivax", "SPECIES", 65, 73], ["P. falciparum", "SPECIES", 201, 214], ["The dominant species", "PROBLEM", 0, 20], ["infection", "PROBLEM", 29, 38], ["vivax", "PROBLEM", 68, 73], ["malaria", "PROBLEM", 133, 140], ["increasing infections", "PROBLEM", 174, 195], ["P. falciparum", "PROBLEM", 201, 214], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["species", "OBSERVATION", 13, 20], ["infection", "OBSERVATION", 29, 38], ["increasing", "OBSERVATION_MODIFIER", 174, 184], ["infections", "OBSERVATION", 185, 195]]], ["P. vivax, found primarily in Asia and Latin America, and in some parts of Africa, differs from other species in that its life cycle includes a dormant liver stage, during which transformed parasites (otherwise called hypnozoites), can remain for months or even years after the initial mosquito bite, becoming symptomatic if the parasites leave the liver to invade healthy red blood cells (Baird et al., 2016), and responsible for relapses.", [["liver", "ANATOMY", 151, 156], ["hypnozoites", "ANATOMY", 217, 228], ["liver", "ANATOMY", 348, 353], ["red blood cells", "ANATOMY", 372, 387], ["P. vivax", "DISEASE", 0, 8], ["mosquito bite", "DISEASE", 285, 298], ["P. vivax", "ORGANISM", 0, 8], ["liver", "ORGAN", 151, 156], ["hypnozoites", "CANCER", 217, 228], ["liver", "ORGAN", 348, 353], ["red blood cells", "CELL", 372, 387], ["healthy red blood cells", "CELL_TYPE", 364, 387], ["P. vivax", "SPECIES", 0, 8], ["P. vivax", "SPECIES", 0, 8], ["vivax", "PROBLEM", 3, 8], ["a dormant liver stage", "PROBLEM", 141, 162], ["the initial mosquito bite", "PROBLEM", 273, 298], ["symptomatic", "PROBLEM", 309, 320], ["the parasites", "PROBLEM", 324, 337], ["red blood cells", "TEST", 372, 387], ["relapses", "PROBLEM", 430, 438], ["liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 348, 353]]], ["It is uniquely dangerous in that infected patients may remain subclinical for years after returning home from military service (Kotwal et al., 2005), serving as agents of future autochthonous infection.", [["autochthonous infection", "DISEASE", 178, 201], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["future autochthonous infection", "PROBLEM", 171, 201], ["dangerous", "OBSERVATION_MODIFIER", 15, 24], ["infected", "OBSERVATION", 33, 41], ["autochthonous", "OBSERVATION_MODIFIER", 178, 191], ["infection", "OBSERVATION", 192, 201]]], ["Furthermore, because malaria is no longer endemic in the United States, healthcare providers may see a patient presenting with symptoms similar to flu symptoms, without suspecting malaria as the potential cause of such clinical symptoms.", [["malaria", "DISEASE", 21, 28], ["flu symptoms", "DISEASE", 147, 159], ["malaria", "DISEASE", 180, 187], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["malaria", "PROBLEM", 21, 28], ["symptoms", "PROBLEM", 127, 135], ["flu symptoms", "PROBLEM", 147, 159], ["malaria", "PROBLEM", 180, 187], ["such clinical symptoms", "PROBLEM", 214, 236], ["no longer", "UNCERTAINTY", 32, 41]]], ["This leads to delays in diagnosis and institution of appropriate treatment.Causes ::: Malaria ::: IntroductionThe symptoms of P. vivax malaria are consistent with all types of malaria: fever, chills, nausea/vomiting, myalgia, fatigue, and general malaise (Yohannes & Ketema, 2016), with infection and lysis of red blood cells during the active erythrocytic cycle leading to jaundice and anemia (Markus, 2011).", [["red blood cells", "ANATOMY", 310, 325], ["erythrocytic", "ANATOMY", 344, 356], ["Malaria", "DISEASE", 86, 93], ["P. vivax malaria", "DISEASE", 126, 142], ["malaria", "DISEASE", 176, 183], ["fever", "DISEASE", 185, 190], ["chills", "DISEASE", 192, 198], ["nausea", "DISEASE", 200, 206], ["vomiting", "DISEASE", 207, 215], ["myalgia", "DISEASE", 217, 224], ["fatigue", "DISEASE", 226, 233], ["infection", "DISEASE", 287, 296], ["jaundice", "DISEASE", 374, 382], ["anemia", "DISEASE", 387, 393], ["P. vivax", "ORGANISM", 126, 134], ["red blood cells", "CELL", 310, 325], ["red blood cells", "CELL_TYPE", 310, 325], ["P. vivax", "SPECIES", 126, 134], ["P. vivax", "SPECIES", 126, 134], ["appropriate treatment", "TREATMENT", 53, 74], ["The symptoms", "PROBLEM", 110, 122], ["P. vivax malaria", "PROBLEM", 126, 142], ["malaria", "PROBLEM", 176, 183], ["fever", "PROBLEM", 185, 190], ["chills", "PROBLEM", 192, 198], ["nausea", "PROBLEM", 200, 206], ["vomiting", "PROBLEM", 207, 215], ["myalgia", "PROBLEM", 217, 224], ["fatigue", "PROBLEM", 226, 233], ["general malaise", "PROBLEM", 239, 254], ["infection", "PROBLEM", 287, 296], ["lysis of red blood cells", "PROBLEM", 301, 325], ["the active erythrocytic cycle", "PROBLEM", 333, 362], ["jaundice", "PROBLEM", 374, 382], ["anemia", "PROBLEM", 387, 393], ["consistent with", "UNCERTAINTY", 147, 162], ["malaria", "OBSERVATION", 176, 183], ["fever", "OBSERVATION", 185, 190], ["myalgia", "OBSERVATION", 217, 224], ["infection", "OBSERVATION", 287, 296], ["erythrocytic cycle", "OBSERVATION", 344, 362], ["jaundice", "OBSERVATION", 374, 382], ["anemia", "OBSERVATION", 387, 393]]], ["The liver hypnozoites do not all have an equal duration of senescence, and patients may experience paroxysmal symptomology, as parasites enter into active erythrocyte infection at different times (Baird et al., 2016).", [["liver hypnozoites", "ANATOMY", 4, 21], ["erythrocyte", "ANATOMY", 155, 166], ["paroxysmal symptomology", "DISEASE", 99, 122], ["erythrocyte infection", "DISEASE", 155, 176], ["liver", "ORGAN", 4, 9], ["patients", "ORGANISM", 75, 83], ["erythrocyte", "CELL", 155, 166], ["patients", "SPECIES", 75, 83], ["paroxysmal symptomology", "PROBLEM", 99, 122], ["parasites", "PROBLEM", 127, 136], ["active erythrocyte infection", "PROBLEM", 148, 176], ["liver", "ANATOMY", 4, 9], ["hypnozoites", "OBSERVATION", 10, 21], ["equal duration", "OBSERVATION_MODIFIER", 41, 55], ["senescence", "OBSERVATION", 59, 69], ["active", "OBSERVATION_MODIFIER", 148, 154], ["erythrocyte infection", "OBSERVATION", 155, 176]]], ["Such a vague presentation with common symptoms of general malaise often leads to misdiagnosis in the United States, where flu and other common ailments are worked up instead (Evans et al., 2014; Goldman-Yassen et al., 2016).Prevention and treatment ::: Malaria ::: IntroductionThe United States military prioritizes prevention over treatment, implementing several protocols to this effect, which theoretically should make it almost impossible for service members to get malaria (Kotwal et al., 2005; Shaha et al., 2013).", [["misdiagnosis", "DISEASE", 81, 93], ["flu", "DISEASE", 122, 125], ["Malaria", "DISEASE", 253, 260], ["malaria", "DISEASE", 470, 477], ["common symptoms", "PROBLEM", 31, 46], ["general malaise", "PROBLEM", 50, 65], ["treatment", "TREATMENT", 332, 341], ["several protocols", "TREATMENT", 356, 373], ["malaria", "PROBLEM", 470, 477], ["vague", "OBSERVATION_MODIFIER", 7, 12]]], ["According to military documentation, there are five major malaria prevention strategies namely: (1) use of factory-treated uniforms; (2) regular application of N,N-diethyl-meta-toluamide (DEET) or picaridin to exposed skin; (3) proper wearing of military uniform; (4) use of permethrin-treated bed net, and (5) continuous chemoprophylaxis during all phases of deployment (Robert, 2001).", [["skin", "ANATOMY", 218, 222], ["malaria", "DISEASE", 58, 65], ["N,N-diethyl-meta-toluamide", "CHEMICAL", 160, 186], ["DEET", "CHEMICAL", 188, 192], ["picaridin", "CHEMICAL", 197, 206], ["permethrin", "CHEMICAL", 275, 285], ["N,N-diethyl-meta-toluamide", "CHEMICAL", 160, 186], ["DEET", "CHEMICAL", 188, 192], ["picaridin", "CHEMICAL", 197, 206], ["permethrin", "CHEMICAL", 275, 285], ["N-diethyl-meta-toluamide", "SIMPLE_CHEMICAL", 162, 186], ["DEET", "SIMPLE_CHEMICAL", 188, 192], ["picaridin", "SIMPLE_CHEMICAL", 197, 206], ["skin", "ORGAN", 218, 222], ["permethrin", "SIMPLE_CHEMICAL", 275, 285], ["regular application of N", "TREATMENT", 137, 161], ["diethyl", "TREATMENT", 164, 171], ["meta-toluamide (DEET)", "TREATMENT", 172, 193], ["picaridin", "TREATMENT", 197, 206], ["permethrin", "TREATMENT", 275, 285], ["continuous chemoprophylaxis", "TREATMENT", 311, 338], ["major", "OBSERVATION_MODIFIER", 52, 57], ["malaria", "OBSERVATION", 58, 65], ["skin", "ANATOMY", 218, 222]]], ["Successful implementation of all five strategies however, is rare, limiting the efficacy of disease prevention.", [["all five strategies", "TREATMENT", 29, 48], ["disease prevention", "TREATMENT", 92, 110], ["disease", "OBSERVATION", 92, 99]]], ["Furthermore, employment of such prophylactic measures, especially with mefloquine, subjects servicemen and women to significant adverse outcomes (Adshead, 2014).Prevention and treatment ::: Malaria ::: IntroductionPermethrin is an insecticide that kills mosquitoes by inducing spasms and paralysis (Isaacs, Lynd & Donnelly, 2017), while DEET, created by the United States Army in 1946, is less insecticidal, masking human scent to prevent mosquito bites (Toynton et al., 2009).", [["mefloquine", "CHEMICAL", 71, 81], ["Malaria", "DISEASE", 190, 197], ["IntroductionPermethrin", "CHEMICAL", 202, 224], ["spasms", "DISEASE", 277, 283], ["paralysis", "DISEASE", 288, 297], ["DEET", "CHEMICAL", 337, 341], ["mosquito bites", "DISEASE", 439, 453], ["mefloquine", "CHEMICAL", 71, 81], ["IntroductionPermethrin", "CHEMICAL", 202, 224], ["mefloquine", "SIMPLE_CHEMICAL", 71, 81], ["women", "ORGANISM", 107, 112], ["IntroductionPermethrin", "SIMPLE_CHEMICAL", 202, 224], ["mosquitoes", "ORGANISM", 254, 264], ["human", "ORGANISM", 416, 421], ["women", "SPECIES", 107, 112], ["human", "SPECIES", 416, 421], ["human", "SPECIES", 416, 421], ["such prophylactic measures", "TREATMENT", 27, 53], ["mefloquine", "TREATMENT", 71, 81], ["IntroductionPermethrin", "TREATMENT", 202, 224], ["inducing spasms", "PROBLEM", 268, 283], ["paralysis", "PROBLEM", 288, 297], ["paralysis", "OBSERVATION", 288, 297]]], ["Despite inclusion in malaria prevention programs, both chemicals have known associated dangers (Diaz, 2016).", [["malaria", "DISEASE", 21, 28], ["malaria prevention programs", "TREATMENT", 21, 48], ["malaria", "OBSERVATION", 21, 28]]], ["DEET is known to have heightened toxicity when applied with sunscreen (Yiin, Tian & Hung, 2015; Rodriguez & Maibach, 2016), a situation likely to arise for military personnel deployed to tropical and subtropical regions of the world.", [["DEET", "CHEMICAL", 0, 4], ["toxicity", "DISEASE", 33, 41], ["DEET", "CHEMICAL", 0, 4], ["DEET", "SIMPLE_CHEMICAL", 0, 4], ["heightened toxicity", "PROBLEM", 22, 41], ["subtropical", "ANATOMY_MODIFIER", 200, 211]]], ["Additionally, synergism has been observed during simultaneous exposure to DEET and permethrin, leading to neuronal degeneration and significant neurobehavioral effects (Abdel-Rahman et al., 2004).Prevention and treatment ::: Malaria ::: IntroductionThe chemoprophylactic drugs (doxycycline or mefloquine) administered by the military, also have known adverse effects, associated with use.", [["neuronal", "ANATOMY", 106, 114], ["DEET", "CHEMICAL", 74, 78], ["permethrin", "CHEMICAL", 83, 93], ["neuronal degeneration", "DISEASE", 106, 127], ["Malaria", "DISEASE", 225, 232], ["doxycycline", "CHEMICAL", 278, 289], ["mefloquine", "CHEMICAL", 293, 303], ["DEET", "CHEMICAL", 74, 78], ["permethrin", "CHEMICAL", 83, 93], ["doxycycline", "CHEMICAL", 278, 289], ["mefloquine", "CHEMICAL", 293, 303], ["DEET", "SIMPLE_CHEMICAL", 74, 78], ["permethrin", "SIMPLE_CHEMICAL", 83, 93], ["neuronal", "CELL", 106, 114], ["doxycycline", "SIMPLE_CHEMICAL", 278, 289], ["mefloquine", "SIMPLE_CHEMICAL", 293, 303], ["synergism", "PROBLEM", 14, 23], ["DEET", "TREATMENT", 74, 78], ["permethrin", "TREATMENT", 83, 93], ["neuronal degeneration", "PROBLEM", 106, 127], ["significant neurobehavioral effects", "PROBLEM", 132, 167], ["The chemoprophylactic drugs", "TREATMENT", 249, 276], ["doxycycline", "TREATMENT", 278, 289], ["mefloquine)", "TREATMENT", 293, 304], ["neuronal", "ANATOMY", 106, 114], ["degeneration", "OBSERVATION", 115, 127], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["neurobehavioral effects", "OBSERVATION", 144, 167]]], ["Historically, mefloquine was developed by the US military (Nevin, 2005), but is now only considered if doxycycline is not tolerated.", [["mefloquine", "CHEMICAL", 14, 24], ["doxycycline", "CHEMICAL", 103, 114], ["mefloquine", "CHEMICAL", 14, 24], ["doxycycline", "CHEMICAL", 103, 114], ["mefloquine", "SIMPLE_CHEMICAL", 14, 24], ["doxycycline", "SIMPLE_CHEMICAL", 103, 114], ["mefloquine", "TREATMENT", 14, 24], ["doxycycline", "TREATMENT", 103, 114]]], ["The side effects can be extreme, including psychiatric symptoms such as anxiety, paranoia, depression, hallucinations, and psychosis (Tan et al., 2011).", [["psychiatric", "DISEASE", 43, 54], ["anxiety", "DISEASE", 72, 79], ["paranoia", "DISEASE", 81, 89], ["depression", "DISEASE", 91, 101], ["hallucinations", "DISEASE", 103, 117], ["psychosis", "DISEASE", 123, 132], ["psychiatric symptoms", "PROBLEM", 43, 63], ["anxiety", "PROBLEM", 72, 79], ["paranoia", "PROBLEM", 81, 89], ["depression", "PROBLEM", 91, 101], ["hallucinations", "PROBLEM", 103, 117], ["psychosis", "PROBLEM", 123, 132]]], ["Sequelae can also mimic post-traumatic stress disorder (PTSD), a condition for which deployed servicemen are at high risk (Eick-Cost et al., 2017).", [["traumatic stress disorder", "DISEASE", 29, 54], ["PTSD", "DISEASE", 56, 60], ["post-traumatic stress disorder", "PROBLEM", 24, 54], ["PTSD", "PROBLEM", 56, 60], ["traumatic", "OBSERVATION_MODIFIER", 29, 38], ["stress disorder", "OBSERVATION", 39, 54]]], ["Doxycycline is by far safer and more reliable; side effects rare, and when present can range from nausea/vomiting and esophagitis to psychiatric symptoms like depression and anxiety (Brisson & Brisson, 2012).Prevention and treatment ::: Malaria ::: IntroductionUntil recently, infection with P. vivax malaria was treated with primaquine for complete pathogen eradication.", [["Doxycycline", "CHEMICAL", 0, 11], ["nausea/vomiting", "DISEASE", 98, 113], ["esophagitis", "DISEASE", 118, 129], ["psychiatric", "DISEASE", 133, 144], ["depression", "DISEASE", 159, 169], ["anxiety", "DISEASE", 174, 181], ["Malaria", "DISEASE", 237, 244], ["infection", "DISEASE", 277, 286], ["P. vivax malaria", "DISEASE", 292, 308], ["primaquine", "CHEMICAL", 326, 336], ["Doxycycline", "CHEMICAL", 0, 11], ["primaquine", "CHEMICAL", 326, 336], ["Doxycycline", "SIMPLE_CHEMICAL", 0, 11], ["P. vivax", "ORGANISM", 292, 300], ["primaquine", "SIMPLE_CHEMICAL", 326, 336], ["P. vivax", "SPECIES", 292, 300], ["P. vivax", "SPECIES", 292, 300], ["Doxycycline", "TREATMENT", 0, 11], ["nausea", "PROBLEM", 98, 104], ["vomiting", "PROBLEM", 105, 113], ["esophagitis to psychiatric symptoms", "PROBLEM", 118, 153], ["depression", "PROBLEM", 159, 169], ["anxiety", "PROBLEM", 174, 181], ["IntroductionUntil", "TREATMENT", 249, 266], ["infection", "PROBLEM", 277, 286], ["P. vivax malaria", "PROBLEM", 292, 308], ["primaquine", "TREATMENT", 326, 336], ["complete pathogen eradication", "TREATMENT", 341, 370], ["esophagitis", "OBSERVATION", 118, 129], ["infection", "OBSERVATION", 277, 286]]], ["It acts by targeting the dormant hypnozoites in the liver, preventing the possibility for recurrence, thereby facilitating complete recovery (Ashley, Recht & White, 2014).", [["hypnozoites", "ANATOMY", 33, 44], ["liver", "ANATOMY", 52, 57], ["hypnozoites", "GENE_OR_GENE_PRODUCT", 33, 44], ["liver", "ORGAN", 52, 57], ["the dormant hypnozoites in the liver", "PROBLEM", 21, 57], ["recurrence", "PROBLEM", 90, 100], ["dormant", "OBSERVATION_MODIFIER", 25, 32], ["hypnozoites", "OBSERVATION", 33, 44], ["liver", "ANATOMY", 52, 57], ["preventing the possibility for", "UNCERTAINTY", 59, 89], ["recurrence", "OBSERVATION", 90, 100]]], ["Adverse effects have been documented in patients with rare preexisting genetic conditions such as glucose-6-phosphate dehydrogenase deficiency (Valencia et al., 2016; Dombrowski et al., 2017; Watson et al., 2018).", [["glucose-6-phosphate", "CHEMICAL", 98, 117], ["glucose-6-phosphate", "CHEMICAL", 98, 117], ["patients", "ORGANISM", 40, 48], ["glucose-6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 98, 131], ["patients", "SPECIES", 40, 48], ["Adverse effects", "PROBLEM", 0, 15], ["rare preexisting genetic conditions", "PROBLEM", 54, 89], ["glucose", "TEST", 98, 105], ["phosphate dehydrogenase deficiency", "PROBLEM", 108, 142]]], ["Otherwise, the side effect profile is mild and comparable to all other anti-malarial drugs: nausea, vomiting, and abdominal cramps (Burgoine, Bancone & Nosten, 2010).", [["abdominal", "ANATOMY", 114, 123], ["nausea", "DISEASE", 92, 98], ["vomiting", "DISEASE", 100, 108], ["abdominal cramps", "DISEASE", 114, 130], ["abdominal", "ORGANISM_SUBDIVISION", 114, 123], ["nausea", "PROBLEM", 92, 98], ["vomiting", "PROBLEM", 100, 108], ["abdominal cramps", "PROBLEM", 114, 130], ["Burgoine", "TREATMENT", 132, 140], ["mild", "OBSERVATION_MODIFIER", 38, 42], ["abdominal", "ANATOMY", 114, 123], ["cramps", "OBSERVATION", 124, 130]]], ["Recently, tafenoquine was approved by the United States Food and Drug Administration for the radical cure of vivax malaria in patients aged 16 years and older (Rajapaske, Rodrigo & Fernando, 2015; Tenoro, Green & Goyal, 2015), though some genetic contraindications still exist.", [["tafenoquine", "CHEMICAL", 10, 21], ["vivax malaria", "DISEASE", 109, 122], ["tafenoquine", "CHEMICAL", 10, 21], ["tafenoquine", "SIMPLE_CHEMICAL", 10, 21], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["tafenoquine", "TREATMENT", 10, 21], ["Drug Administration", "TREATMENT", 65, 84], ["the radical cure", "TREATMENT", 89, 105], ["vivax malaria", "PROBLEM", 109, 122], ["some genetic contraindications", "PROBLEM", 234, 264]]], ["Both primaquine and tafenoquine should be made available for the treatment of United States military servicemen and women deployed overseas (Watson et al., 2018).Causes ::: Leishmaniasis ::: IntroductionThe number of animal species which can serve as Leishmania reservoir hosts is ever increasing, including rodents, canines, and farm animals (Stephens et al., 2016).", [["primaquine", "CHEMICAL", 5, 15], ["tafenoquine", "CHEMICAL", 20, 31], ["Leishmaniasis", "DISEASE", 173, 186], ["primaquine", "CHEMICAL", 5, 15], ["tafenoquine", "CHEMICAL", 20, 31], ["primaquine", "SIMPLE_CHEMICAL", 5, 15], ["tafenoquine", "SIMPLE_CHEMICAL", 20, 31], ["women", "ORGANISM", 116, 121], ["Leishmania reservoir hosts", "ORGANISM", 251, 277], ["canines", "ORGAN", 317, 324], ["women", "SPECIES", 116, 121], ["Both primaquine", "TREATMENT", 0, 15], ["tafenoquine", "TREATMENT", 20, 31], ["Leishmaniasis", "PROBLEM", 173, 186], ["animal species", "PROBLEM", 217, 231], ["Leishmania reservoir hosts", "TREATMENT", 251, 277], ["Leishmaniasis", "OBSERVATION", 173, 186]]], ["Leishmaniasis was not traditionally considered endemic to the United States, although recent epidemiologic findings reveal this status may be changing, secondary to globalization and autochthonous infections leading to persistent endemicity, especially along the southern border and new animal hosts (Wright et al., 2008; Barry et al., 2013; McIlwee, Weis & Hosler, 2018).", [["Leishmaniasis", "DISEASE", 0, 13], ["infections", "DISEASE", 197, 207], ["Leishmaniasis", "PROBLEM", 0, 13], ["autochthonous infections", "PROBLEM", 183, 207], ["persistent endemicity", "PROBLEM", 219, 240], ["autochthonous", "OBSERVATION_MODIFIER", 183, 196], ["infections", "OBSERVATION", 197, 207], ["persistent", "OBSERVATION_MODIFIER", 219, 229], ["endemicity", "OBSERVATION", 230, 240], ["new", "OBSERVATION_MODIFIER", 283, 286]]], ["Incidence and disease burden are higher in societies where people live in close proximity to host animals (De Vries, Reedijk & Schallig, 2015).", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["disease burden", "PROBLEM", 14, 28], ["disease", "OBSERVATION", 14, 21], ["higher", "OBSERVATION_MODIFIER", 33, 39]]], ["Similar to malaria, it is a vector-borne disease, requiring a phlebotomine sand fly to pick up amastigotes during a bloodmeal from an infected (reservoir) host.", [["malaria", "DISEASE", 11, 18], ["malaria", "PROBLEM", 11, 18], ["a vector-borne disease", "PROBLEM", 26, 48], ["a phlebotomine sand fly", "TREATMENT", 60, 83], ["a bloodmeal", "PROBLEM", 114, 125], ["an infected (reservoir) host", "TREATMENT", 131, 159], ["malaria", "OBSERVATION", 11, 18], ["infected", "OBSERVATION", 134, 142]]], ["Amastigotes undergoes development and maturity in the fly, which then inoculates infective promastigotes into a new mammalian host during the next blood meal.", [["blood", "ANATOMY", 147, 152], ["Amastigotes", "CHEMICAL", 0, 11], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["infective promastigotes", "PROBLEM", 81, 104], ["the next blood meal", "TREATMENT", 138, 157], ["maturity", "OBSERVATION_MODIFIER", 38, 46]]], ["Disease manifests as three distinct clinical forms: cutaneous (including diffuse cutaneous form), mucocutaneous, or visceral.", [["cutaneous", "ANATOMY", 52, 61], ["cutaneous", "ANATOMY", 81, 90], ["mucocutaneous", "ANATOMY", 98, 111], ["visceral", "ANATOMY", 116, 124], ["mucocutaneous", "DISEASE", 98, 111], ["visceral", "TISSUE", 116, 124], ["Disease", "PROBLEM", 0, 7], ["cutaneous (including diffuse cutaneous form)", "PROBLEM", 52, 96], ["mucocutaneous, or visceral", "PROBLEM", 98, 124], ["cutaneous", "ANATOMY", 52, 61], ["diffuse", "OBSERVATION_MODIFIER", 73, 80], ["cutaneous", "ANATOMY", 81, 90], ["mucocutaneous", "OBSERVATION", 98, 111], ["visceral", "ANATOMY", 116, 124]]], ["Cutaneous leishmaniasis (CL) has been the most diagnosed of the three among deployed United States servicemen and women (Weil, 2010; Beaumier et al., 2013), with L. major, the most prevalent (Herwaldt, 1999).", [["CL", "ANATOMY", 25, 27], ["Cutaneous leishmaniasis", "DISEASE", 0, 23], ["CL", "DISEASE", 25, 27], ["Cutaneous leishmaniasis", "PATHOLOGICAL_FORMATION", 0, 23], ["CL", "MULTI-TISSUE_STRUCTURE", 25, 27], ["women", "ORGANISM", 114, 119], ["women", "SPECIES", 114, 119], ["L. major", "SPECIES", 162, 170], ["Cutaneous leishmaniasis", "PROBLEM", 0, 23], ["leishmaniasis", "OBSERVATION", 10, 23]]], ["Overall, 90% of global CL cases occur in Afghanistan, Brazil, Iran, Peru, Saudi Arabia, and Syria.", [["CL", "MULTI-TISSUE_STRUCTURE", 23, 25]]], ["With the United States military active involvement and troop deployment to these locations, increased cases of leishmaniasis were recorded, until drawdown when the number of deployed soldiers reduced dramatically (Shirian et al., 2013; De Vries, Reedijk & Schallig, 2015).", [["leishmaniasis", "DISEASE", 111, 124], ["leishmaniasis", "PROBLEM", 111, 124], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["leishmaniasis", "OBSERVATION", 111, 124]]], ["Expectedly, this is not unique to the US military, with cases of L. major infection and multiple reports of cutaneous disease among British, Dutch, and German soldiers as well (Faulde et al., 2008; Bailey et al., 2012).Symptoms ::: Leishmaniasis ::: IntroductionEach disease pattern has its own set of symptoms and thus differs in severity.", [["cutaneous", "ANATOMY", 108, 117], ["L. major infection", "DISEASE", 65, 83], ["cutaneous disease", "DISEASE", 108, 125], ["Leishmaniasis", "DISEASE", 232, 245], ["L. major", "ORGANISM", 65, 73], ["cutaneous", "ORGANISM_SUBDIVISION", 108, 117], ["L. major infection", "PROBLEM", 65, 83], ["cutaneous disease", "PROBLEM", 108, 125], ["Symptoms", "PROBLEM", 219, 227], ["Leishmaniasis", "PROBLEM", 232, 245], ["Each disease pattern", "PROBLEM", 262, 282], ["symptoms", "PROBLEM", 302, 310], ["L.", "OBSERVATION_MODIFIER", 65, 67], ["major", "OBSERVATION_MODIFIER", 68, 73], ["infection", "OBSERVATION", 74, 83], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["cutaneous disease", "OBSERVATION", 108, 125], ["Leishmaniasis", "OBSERVATION", 232, 245]]], ["Lesions can be self-resolving, as is often the case with many instances of CL, with or without resultant subclinical parasitemia (Micallef & Azzopardi, 2014; Rosales-Chilama et al., 2015; Thomaidou et al., 2015).", [["CL", "ANATOMY", 75, 77], ["CL", "DISEASE", 75, 77], ["parasitemia", "DISEASE", 117, 128], ["CL", "MULTI-TISSUE_STRUCTURE", 75, 77], ["Lesions", "PROBLEM", 0, 7], ["resultant subclinical parasitemia", "PROBLEM", 95, 128], ["parasitemia", "OBSERVATION", 117, 128]]], ["The parasite can also disseminate into internal organs, as in visceral leishmaniasis, becoming fatal in the process.", [["organs", "ANATOMY", 48, 54], ["visceral leishmaniasis", "ANATOMY", 62, 84], ["visceral leishmaniasis", "DISEASE", 62, 84], ["organs", "ORGAN", 48, 54], ["visceral leishmaniasis", "PROBLEM", 62, 84], ["parasite", "OBSERVATION", 4, 12], ["internal organs", "ANATOMY", 39, 54], ["visceral", "ANATOMY", 62, 70], ["leishmaniasis", "OBSERVATION", 71, 84], ["fatal", "OBSERVATION_MODIFIER", 95, 100]]], ["IL-12 and CD4+ Th1 cells have especially been implicated in the development of cellular immunity, though the mechanisms and explicit contributions of each are not yet fully understood (Engwerda, Ato & Kaye, 2004; McCall, Zhang & Matlashewski, 2013; Buxbaum, 2015; Portela et al., 2018).", [["CD4+ Th1 cells", "ANATOMY", 10, 24], ["cellular", "ANATOMY", 79, 87], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 10, 13], ["cellular", "CELL", 79, 87], ["CD4", "PROTEIN", 10, 13], ["Th1 cells", "CELL_TYPE", 15, 24], ["IL", "TEST", 0, 2], ["CD4+ Th1 cells", "TREATMENT", 10, 24], ["cellular immunity", "PROBLEM", 79, 96], ["Th1 cells", "OBSERVATION", 15, 24], ["cellular immunity", "OBSERVATION", 79, 96]]], ["Fortunately, CL has been the dominant clinical form in the US military, though many subclinical cases, which do not require medical treatment occur as well (Reithinger et al., 2007).", [["CL", "MULTI-TISSUE_STRUCTURE", 13, 15], ["medical treatment", "TREATMENT", 124, 141], ["dominant", "OBSERVATION_MODIFIER", 29, 37]]], ["The infection first manifests as a simple, non-swollen, red ring around the bite from the sand fly.", [["red ring", "ANATOMY", 56, 64], ["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["a simple, non-swollen, red ring", "PROBLEM", 33, 64], ["infection", "OBSERVATION", 4, 13], ["simple", "OBSERVATION_MODIFIER", 35, 41], ["ring", "OBSERVATION_MODIFIER", 60, 64]]], ["As the host immune system continues to respond locally at the bite site, sores develop on the skin and can further ulcerate, causing discomfort, but generally painless (Reithinger et al., 2007).", [["immune system", "ANATOMY", 12, 25], ["skin", "ANATOMY", 94, 98], ["skin", "ORGAN", 94, 98], ["sores", "PROBLEM", 73, 78], ["discomfort", "PROBLEM", 133, 143], ["sores", "OBSERVATION", 73, 78], ["skin", "ANATOMY", 94, 98]]], ["In severe cases, these sores can develop on mucosal membranes, degrade the tissues of the mouth and tongue, and potentially interfere with swallowing or cause difficulty breathing.", [["mucosal membranes", "ANATOMY", 44, 61], ["tissues", "ANATOMY", 75, 82], ["mouth", "ANATOMY", 90, 95], ["tongue", "ANATOMY", 100, 106], ["sores", "DISEASE", 23, 28], ["mucosal membranes", "MULTI-TISSUE_STRUCTURE", 44, 61], ["tissues", "TISSUE", 75, 82], ["mouth", "ORGANISM_SUBDIVISION", 90, 95], ["tongue", "ORGAN", 100, 106], ["these sores", "PROBLEM", 17, 28], ["mucosal membranes", "TREATMENT", 44, 61], ["difficulty breathing", "PROBLEM", 159, 179], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["cases", "OBSERVATION", 10, 15], ["sores", "OBSERVATION", 23, 28], ["mucosal membranes", "ANATOMY", 44, 61], ["mouth", "ANATOMY", 90, 95], ["tongue", "ANATOMY", 100, 106]]], ["The incubation period for CL can range from 2 weeks to many months and even years, with potential delay between contraction of the disease and onset of symptoms.", [["CL", "MULTI-TISSUE_STRUCTURE", 26, 28], ["the disease", "PROBLEM", 127, 138], ["symptoms", "PROBLEM", 152, 160], ["disease", "OBSERVATION", 131, 138]]], ["Soldiers may travel between countries, or even back to the United States, unwittingly becoming reservoir hosts in the process (Nagarajan & Sloan, 2015; Goodrich et al., 2017), leading to delay in diagnosis and institution of appropriate treatment, if symptoms occur after the patient has returned to a non-endemic area.Prevention and treatment ::: Leishmaniasis ::: IntroductionThe incidence rate of leishmaniasis among the United States Armed Forces was 7.2 cases per 100,000 person-years for the period of 2001\u20132016, with the majority of cases being CL (Stahlman, Williams & Taubman, 2017).", [["Leishmaniasis", "DISEASE", 348, 361], ["leishmaniasis", "DISEASE", 400, 413], ["patient", "ORGANISM", 276, 283], ["patient", "SPECIES", 276, 283], ["appropriate treatment", "TREATMENT", 225, 246], ["symptoms", "PROBLEM", 251, 259]]], ["The reduced incidence rate of recent years has been attributed to better equipment and an emphasis on personal protective measures (Rowland et al., 2015).", [["personal protective measures", "TREATMENT", 102, 130], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["incidence", "OBSERVATION_MODIFIER", 12, 21]]], ["Nevertheless, there is still a cause for concern when troops are newly deployed to endemic regions; supportive resources may not be fully in place, deployed personnel may have limited knowledge, and a culture of preventative measure necessity may not have yet developed (Coleman, Burkett & Putnam, 2006).", [["a culture", "TEST", 199, 208]]], ["The first line of protection from CL is through the use of personal protection techniques.", [["CL", "MULTI-TISSUE_STRUCTURE", 34, 36], ["personal protection techniques", "TREATMENT", 59, 89]]], ["However, there are no effective chemoprophylaxis drugs and no fully developed vaccines, and thus prevention of CL can be extremely difficult (Ghorbani & Farhoudi, 2018).Prevention and treatment ::: Leishmaniasis ::: IntroductionThe preventative techniques that do exist focus on avoiding the bite of infected sandflies.", [["CL", "DISEASE", 111, 113], ["Leishmaniasis", "DISEASE", 198, 211], ["infected sandflies", "DISEASE", 300, 318], ["CL", "MULTI-TISSUE_STRUCTURE", 111, 113], ["effective chemoprophylaxis drugs", "TREATMENT", 22, 54], ["vaccines", "TREATMENT", 78, 86], ["CL", "PROBLEM", 111, 113], ["The preventative techniques", "TREATMENT", 228, 255], ["infected sandflies", "PROBLEM", 300, 318], ["no", "UNCERTAINTY", 19, 21], ["effective", "OBSERVATION_MODIFIER", 22, 31], ["chemoprophylaxis", "OBSERVATION", 32, 48], ["infected", "OBSERVATION", 300, 308]]], ["Uniforms are impregnated with a type of pyrethroid (usually permethrin), insect repellants are recommended, and personnel are given pyrethrin-treated bed nets (Orsborne et al., 2016).", [["pyrethroid", "CHEMICAL", 40, 50], ["permethrin", "CHEMICAL", 60, 70], ["pyrethrin", "CHEMICAL", 132, 141], ["pyrethroid", "CHEMICAL", 40, 50], ["permethrin", "CHEMICAL", 60, 70], ["pyrethrin", "CHEMICAL", 132, 141], ["pyrethroid", "SIMPLE_CHEMICAL", 40, 50], ["permethrin", "SIMPLE_CHEMICAL", 60, 70], ["pyrethrin", "SIMPLE_CHEMICAL", 132, 141], ["pyrethroid (usually permethrin", "TREATMENT", 40, 70], ["pyrethrin", "TREATMENT", 132, 141]]], ["Cyfluthrin, a pyrethroid insecticide, has been used to decimate sand fly populations, and chloropiricin, a wide-spectrum nematicide and insecticide, has been used to reduce the rodent (leishmania reservoir) population (Aronson et al., 1998; Crum, 2005).Prevention and treatment ::: Leishmaniasis ::: IntroductionFortunately, modern medicine has afforded CL cure rates up to 91%.", [["Cyfluthrin", "CHEMICAL", 0, 10], ["pyrethroid insecticide", "CHEMICAL", 14, 36], ["chloropiricin", "CHEMICAL", 90, 103], ["nematicide", "CHEMICAL", 121, 131], ["Leishmaniasis", "DISEASE", 282, 295], ["Cyfluthrin", "CHEMICAL", 0, 10], ["pyrethroid", "CHEMICAL", 14, 24], ["chloropiricin", "CHEMICAL", 90, 103], ["Cyfluthrin", "SIMPLE_CHEMICAL", 0, 10], ["chloropiricin", "SIMPLE_CHEMICAL", 90, 103], ["CL", "MULTI-TISSUE_STRUCTURE", 354, 356], ["rodent", "SPECIES", 177, 183], ["Cyfluthrin", "TREATMENT", 0, 10], ["a pyrethroid insecticide", "TREATMENT", 12, 36], ["sand fly populations", "TREATMENT", 64, 84], ["chloropiricin", "TREATMENT", 90, 103], ["a wide-spectrum nematicide", "TREATMENT", 105, 131], ["insecticide", "TREATMENT", 136, 147], ["Leishmaniasis", "PROBLEM", 282, 295], ["modern medicine", "TREATMENT", 325, 340], ["CL cure rates", "TEST", 354, 367], ["Leishmaniasis", "OBSERVATION", 282, 295]]], ["The most effective treatment is sodium stibogluconate, given intravenously at doses of 20 mg per kilogram of body weight, for 20 days (Mitchell, Silvitz & Black, 2007; Stahlman, Williams & Taubman, 2017), with side effects such as fatigue, arthralgia, myalgia, headaches, and chemical pancreatitis.", [["intravenously", "ANATOMY", 61, 74], ["body", "ANATOMY", 109, 113], ["sodium stibogluconate", "CHEMICAL", 32, 53], ["fatigue", "DISEASE", 231, 238], ["arthralgia", "DISEASE", 240, 250], ["myalgia", "DISEASE", 252, 259], ["headaches", "DISEASE", 261, 270], ["pancreatitis", "DISEASE", 285, 297], ["sodium stibogluconate", "CHEMICAL", 32, 53], ["sodium stibogluconate", "SIMPLE_CHEMICAL", 32, 53], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["body", "ORGANISM_SUBDIVISION", 109, 113], ["sodium stibogluconate", "TREATMENT", 32, 53], ["side effects", "PROBLEM", 210, 222], ["fatigue", "PROBLEM", 231, 238], ["arthralgia", "PROBLEM", 240, 250], ["myalgia", "PROBLEM", 252, 259], ["headaches", "PROBLEM", 261, 270], ["chemical pancreatitis", "PROBLEM", 276, 297], ["most effective", "OBSERVATION_MODIFIER", 4, 18], ["arthralgia", "OBSERVATION", 240, 250], ["myalgia", "OBSERVATION", 252, 259], ["chemical", "OBSERVATION_MODIFIER", 276, 284], ["pancreatitis", "OBSERVATION", 285, 297]]], ["Sodium stibogluconate is efficacious, but development of new drugs is imperative due to these side effect, the threat of drug resistance, and the high cost ($100 per 100 mL) (Aronson et al., 1998).", [["Sodium stibogluconate", "CHEMICAL", 0, 21], ["Sodium stibogluconate", "CHEMICAL", 0, 21], ["Sodium stibogluconate", "SIMPLE_CHEMICAL", 0, 21], ["Sodium stibogluconate", "TREATMENT", 0, 21], ["new drugs", "TREATMENT", 57, 66], ["these side effect", "PROBLEM", 88, 105], ["drug resistance", "TREATMENT", 121, 136], ["new", "OBSERVATION_MODIFIER", 57, 60], ["drugs", "OBSERVATION", 61, 66], ["drug resistance", "OBSERVATION", 121, 136]]], ["The threat posed by recent reports of treatment failures in South and Latin America leishmaniasis cases, including the induction of transmissible skin microbiota that significantly promotes inflammation, should be a concern for all in the infectious disease community, particularly the military (Mans et al., 2016; Obonaga et al., 2014; Gimblet et al., 2017).Other: military zoonotic leishmaniasis ::: IntroductionCanines are one of the main reservoirs for Leishmania species (Burza, Croft & Boelaert, 2018; Quinnell & Courtenay, 2009), with cases often subclinical.", [["skin", "ANATOMY", 146, 150], ["leishmaniasis", "DISEASE", 84, 97], ["inflammation", "DISEASE", 190, 202], ["zoonotic leishmaniasis", "DISEASE", 375, 397], ["skin", "ORGAN", 146, 150], ["Leishmania species", "ORGANISM", 457, 475], ["Burza, Croft & Boelaert, 2018; Quinnell & Courtenay, 2009)", "SPECIES", 477, 535], ["treatment failures", "PROBLEM", 38, 56], ["transmissible skin microbiota", "PROBLEM", 132, 161], ["inflammation", "PROBLEM", 190, 202], ["IntroductionCanines", "TREATMENT", 402, 421], ["Leishmania species", "PROBLEM", 457, 475], ["skin microbiota", "ANATOMY", 146, 161], ["inflammation", "OBSERVATION", 190, 202], ["infectious", "OBSERVATION", 239, 249], ["zoonotic", "OBSERVATION_MODIFIER", 375, 383], ["leishmaniasis", "OBSERVATION", 384, 397], ["Leishmania species", "OBSERVATION", 457, 475]]], ["As the parasite multiplies in an asymptomatic dog, Leishmania is perpetuated locally via phlebotomine vectors (Killian, 2007).", [["dog", "ORGANISM", 46, 49], ["Leishmania", "ORGANISM", 51, 61], ["dog", "SPECIES", 46, 49], ["Leishmania", "PROBLEM", 51, 61], ["parasite", "OBSERVATION_MODIFIER", 7, 15], ["Leishmania", "OBSERVATION", 51, 61]]], ["The usually implicated species, L. infantum, does not typically infect healthy humans, though incidence of associated infection and disease has increased in recent years (Stoeckle et al., 2013; Kroidl et al., 2014; Bennai et al., 2018; Herrera et al., 2018; Risueno et al., 2018; Teimouri et al., 2018), with immunodeficient individuals at a higher risk of disease (Michel et al., 2011).", [["infection", "DISEASE", 118, 127], ["L. infantum", "ORGANISM", 32, 43], ["humans", "ORGANISM", 79, 85], ["immunodeficient", "ORGANISM", 309, 324], ["L. infantum", "SPECIES", 32, 43], ["humans", "SPECIES", 79, 85], ["L. infantum", "SPECIES", 32, 43], ["humans", "SPECIES", 79, 85], ["L. infantum", "PROBLEM", 32, 43], ["associated infection", "PROBLEM", 107, 127], ["disease", "PROBLEM", 132, 139], ["immunodeficient individuals", "PROBLEM", 309, 336], ["disease", "PROBLEM", 357, 364], ["species", "OBSERVATION_MODIFIER", 23, 30], ["L.", "OBSERVATION_MODIFIER", 32, 34], ["infantum", "OBSERVATION", 35, 43], ["infection", "OBSERVATION", 118, 127], ["disease", "OBSERVATION", 132, 139], ["increased", "OBSERVATION_MODIFIER", 144, 153], ["disease", "OBSERVATION", 357, 364]]], ["Zoonotic transmission of L. infantum to humans often results in visceral leishmaniasis infection (Burza, Croft & Boelaert, 2018).", [["visceral", "ANATOMY", 64, 72], ["visceral leishmaniasis infection", "DISEASE", 64, 96], ["L. infantum", "ORGANISM", 25, 36], ["humans", "ORGANISM", 40, 46], ["visceral", "ORGANISM_SUBDIVISION", 64, 72], ["L. infantum", "SPECIES", 25, 36], ["humans", "SPECIES", 40, 46], ["L. infantum", "SPECIES", 25, 36], ["humans", "SPECIES", 40, 46], ["visceral leishmaniasis infection", "PROBLEM", 64, 96], ["visceral", "ANATOMY", 64, 72], ["leishmaniasis", "OBSERVATION", 73, 86]]], ["Though military personnel often have superior baseline health ratings compared to their civilian cohorts upon deployment, the stress of military life can contribute to development of an immunodeficiency state.", [["immunodeficiency", "DISEASE", 186, 202], ["superior baseline health ratings", "PROBLEM", 37, 69], ["an immunodeficiency state", "PROBLEM", 183, 208], ["immunodeficiency", "OBSERVATION", 186, 202]]], ["Additionally, military personnel are at higher risks of smoking/alcohol/substance-abuse initiation and recidivism, frequently spend long periods of time in environments with sub-standard hygiene, may have more erratic sleep schedules, and overall suffer greater declines in mental and physical health (Dau, Oda & Holodniy, 2009; Spelman et al., 2012).", [["smoking", "CHEMICAL", 56, 63], ["alcohol", "CHEMICAL", 64, 71], ["substance-abuse", "DISEASE", 72, 87], ["declines in mental and physical health", "DISEASE", 262, 300], ["alcohol", "CHEMICAL", 64, 71], ["erratic sleep schedules", "TREATMENT", 210, 233]]], ["In particular, personnel who have served in the Middle East since the Persian Gulf War have reported higher levels of psychosomatic/psychological pain in comparison to cohort military personnel that served contemporarily but in other locations (Gray et al., 1996; Dlugosz et al., 1999).", [["psychosomatic/psychological pain", "DISEASE", 118, 150], ["psychosomatic/psychological pain", "PROBLEM", 118, 150]]], ["Thus, troops are at a relatively high risk of zoonotic canine leishmaniasis due to exposure (military dogs becoming infected, local dogs in endemic areas) and high prevalence of immunodeficiency/extreme stress secondary to their service.Other: military zoonotic leishmaniasis ::: IntroductionCanine Leishmaniasis (CanL) is a common veterinary problem worldwide, with recent prevalence estimates as high as 25\u201380% (Michel et al., 2011; Akhtardanesh et al., 2017; Baneth et al., 2017; Guven et al., 2017; Ruh et al., 2017; Al-Bajalan et al., 2018; Monteiro et al., 2018).", [["canine leishmaniasis", "DISEASE", 55, 75], ["immunodeficiency", "DISEASE", 178, 194], ["zoonotic leishmaniasis", "DISEASE", 253, 275], ["IntroductionCanine Leishmaniasis", "DISEASE", 280, 312], ["CanL", "DISEASE", 314, 318], ["canine", "ORGANISM", 55, 61], ["canine", "SPECIES", 55, 61], ["zoonotic canine leishmaniasis", "PROBLEM", 46, 75], ["infected", "PROBLEM", 116, 124], ["immunodeficiency", "PROBLEM", 178, 194], ["extreme stress", "PROBLEM", 195, 209], ["military zoonotic leishmaniasis", "PROBLEM", 244, 275], ["IntroductionCanine Leishmaniasis", "PROBLEM", 280, 312], ["zoonotic canine leishmaniasis", "OBSERVATION", 46, 75], ["high prevalence", "OBSERVATION_MODIFIER", 159, 174], ["zoonotic", "OBSERVATION_MODIFIER", 253, 261], ["leishmaniasis", "OBSERVATION", 262, 275], ["Leishmaniasis", "OBSERVATION", 299, 312]]], ["Brazil is known to be especially affected (Borja et al., 2016; Torres-Guerrero et al., 2017; Da Rocha et al., 2018; Melo et al., 2018), with published reports highlighting increases in diagnoses and advocating for better public health strategies to be focused specifically on dogs (Camargo & Langoni, 2006; Lima et al., 2010).", [["dogs", "ORGANISM", 276, 280], ["dogs", "SPECIES", 276, 280], ["increases", "OBSERVATION_MODIFIER", 172, 181]]], ["The armed forces regularly use military working dogs (MWD) for special operations, including abroad in Leishmania-endemic regions.", [["dogs", "ORGANISM", 48, 52], ["special operations", "TREATMENT", 63, 81], ["Leishmania", "ANATOMY", 103, 113], ["endemic", "OBSERVATION_MODIFIER", 114, 121]]], ["CanL has been found multiple times in military animals (Kawamura, Yoshikawa & Katakura, 2010; Davoust et al., 2013).", [["CanL", "CHEMICAL", 0, 4], ["CanL", "GENE_OR_GENE_PRODUCT", 0, 4], ["CanL", "PROTEIN", 0, 4], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["times", "OBSERVATION_MODIFIER", 29, 34]]], ["Of domestic importance, these dogs who are deemed \u2018adoptable\u2019 are mandated to return to the US, with adoption priority given to their former handlers.", [["dogs", "ORGANISM", 30, 34], ["dogs", "SPECIES", 30, 34]]], ["Approximately 1,000 former-MWDs enter the US annually (Killian, 2007), potentially serving as a reservoir for Leishmania: both symptomatic and asymptomatic canines have been shown to have similar inoculation abilities (Moshfe et al., 2009), and CanL prevalence has been shown to correlate with that of human disease (Bruhn et al., 2018).", [["canines", "ORGAN", 156, 163], ["CanL", "GENE_OR_GENE_PRODUCT", 245, 249], ["human", "ORGANISM", 302, 307], ["CanL", "PROTEIN", 245, 249], ["human", "SPECIES", 302, 307], ["human", "SPECIES", 302, 307], ["Leishmania", "PROBLEM", 110, 120], ["symptomatic", "PROBLEM", 127, 138], ["asymptomatic canines", "PROBLEM", 143, 163], ["similar inoculation abilities", "PROBLEM", 188, 217], ["human disease", "PROBLEM", 302, 315]]], ["CanL was first found in the United States in the 1980s and 1990s infecting foxhounds, (Enserink, 2000; Petersen, 2009), with limited studies carried out since, to estimate current levels.", [["CanL", "GENE_OR_GENE_PRODUCT", 0, 4], ["limited studies", "TEST", 125, 140]]], ["Autochthonous infection has been reported since in North American dogs (Schantz et al., 2005).", [["infection", "DISEASE", 14, 23], ["dogs", "ORGANISM", 66, 70], ["dogs", "SPECIES", 66, 70], ["Autochthonous infection", "PROBLEM", 0, 23], ["infection", "OBSERVATION", 14, 23]]], ["Without better screening for all MWDs, the possibility remains for import of CanL via former-MWDs and thus future augmentation in L. infantum incidence in US civilian and military populations.", [["MWDs", "DISEASE", 33, 37], ["CanL", "GENE_OR_GENE_PRODUCT", 77, 81], ["L. infantum", "ORGANISM", 130, 141], ["L. infantum", "SPECIES", 130, 141], ["L. infantum", "SPECIES", 130, 141]]], ["Canine vaccination, one possible solution to mitigating CanL disease burdens in the United States has shown some success as a human health preventative measure (Palatnik-de Sousa et al., 2009; Rezvan & Moafi, 2015; Ribeiro et al., 2018), though vaccine efficacy remains low (68\u201371%) (Ribeiro et al., 2018), questioning their utility for preventive purposes.Malaria ::: Future implications ::: IntroductionMalaria is endemic to much of the world, and the United States military will likely continue to engage in endemic areas.", [["CanL disease", "DISEASE", 56, 68], ["Malaria", "DISEASE", 357, 364], ["Malaria", "DISEASE", 405, 412], ["Canine", "ORGANISM", 0, 6], ["human", "ORGANISM", 126, 131], ["Canine", "SPECIES", 0, 6], ["human", "SPECIES", 126, 131], ["Canine", "SPECIES", 0, 6], ["human", "SPECIES", 126, 131], ["Canine vaccination", "TREATMENT", 0, 18], ["CanL disease burdens", "PROBLEM", 56, 76], ["Rezvan", "TREATMENT", 193, 199], ["Moafi", "TREATMENT", 202, 207], ["vaccine efficacy", "TEST", 245, 261], ["preventive purposes", "TREATMENT", 337, 356], ["Malaria", "PROBLEM", 357, 364], ["Malaria", "OBSERVATION", 405, 412]]], ["Drug-resistant strains of malaria have been found, indicating the need for further preventative measures (Fukuda et al., 2011; Cui et al., 2015).", [["malaria", "DISEASE", 26, 33], ["malaria", "ORGANISM", 26, 33], ["resistant strains", "PROBLEM", 5, 22], ["malaria", "PROBLEM", 26, 33], ["further preventative measures", "TREATMENT", 75, 104], ["resistant strains", "OBSERVATION", 5, 22], ["malaria", "OBSERVATION", 26, 33]]], ["Most of these species are found in Asia (White et al., 2014).", [["species", "OBSERVATION", 14, 21]]], ["Globalization of the Asian continent as well as potential future military involvement in Asia could result in military exposure to such species, resulting in, at a minimum complicated treatment.", [["such species", "PROBLEM", 131, 143], ["a minimum complicated treatment", "TREATMENT", 162, 193]]], ["For example, P. vivax is endemic to North Korea (Nishiura et al., 2018), and though present rapprochement between both countries and South Korea seems to have downplayed the threat of military engagement, US troops still engage in military runs in neighboring South Korea.", [["P. vivax", "DISEASE", 13, 21], ["P. vivax", "ORGANISM", 13, 21], ["P. vivax", "SPECIES", 13, 21], ["P. vivax", "SPECIES", 13, 21], ["P. vivax", "PROBLEM", 13, 21]]], ["Furthermore, malaria was eradicated in South Korea in the 1970s, but soldiers (and increasingly, civilians as well) have been diagnosed with P. vivax malaria in the North-South demilitarized zone (Lee et al., 2002; Im et al., 2018), including reports of natural hybridization between local mosquito species and changing meteorological factors, to further perpetuate current observation (Choochote et al., 2014; Phasomkusolsil et al., 2014; Chang et al., 2016; Hwang et al., 2016).Leishmaniasis ::: Future implications ::: IntroductionCL is found primarily in the Middle East, and the US military continues to be at risk of infection.", [["malaria", "DISEASE", 13, 20], ["P. vivax malaria", "DISEASE", 141, 157], ["Leishmaniasis", "DISEASE", 480, 493], ["infection", "DISEASE", 623, 632], ["P. vivax", "ORGANISM", 141, 149], ["P. vivax", "SPECIES", 141, 149], ["P. vivax", "SPECIES", 141, 149], ["malaria", "PROBLEM", 13, 20], ["vivax malaria", "PROBLEM", 144, 157], ["natural hybridization", "PROBLEM", 254, 275], ["local mosquito species", "PROBLEM", 284, 306], ["Leishmaniasis", "PROBLEM", 480, 493], ["infection", "PROBLEM", 623, 632], ["malaria", "OBSERVATION", 13, 20], ["Middle", "ANATOMY_MODIFIER", 563, 569], ["infection", "OBSERVATION", 623, 632]]], ["The Leishmania disease burden in the Middle East is estimated at 100,000 cases annually, indicating that exposure risk remains significant (Salam, Al-Shaqha & Azzi, 2014).", [["Leishmania disease", "DISEASE", 4, 22], ["Leishmania disease", "ORGANISM", 4, 22], ["The Leishmania disease burden", "PROBLEM", 0, 29], ["exposure risk", "PROBLEM", 105, 118], ["Leishmania disease", "OBSERVATION", 4, 22], ["Middle", "ANATOMY_MODIFIER", 37, 43], ["significant", "OBSERVATION_MODIFIER", 127, 138]]], ["True infection rates may be greater than reported due to the fact that majority of affected rural communities lack the infrastructure for precise diagnosis and reporting, and the persistent antagonistic attitude to healthcare workers arising from many years of counterintelligence activities and breakdown of trust.", [["infection", "DISEASE", 5, 14], ["True infection rates", "PROBLEM", 0, 20], ["counterintelligence activities", "PROBLEM", 261, 291], ["breakdown of trust", "PROBLEM", 296, 314], ["infection", "OBSERVATION", 5, 14]]], ["Ongoing civil conflicts in Syria compounds the growing and untenable numbers of individuals symptomatic for disease or sub-clinically infected, showing up as refugees and present clinically in North America, Europe and other countries (Koltas et al., 2014; Saroufim et al., 2014; Bradshaw & Litvinov, 2017; Wollina et al., 2018; Mockenhaupt et al., 2016).", [["disease", "PROBLEM", 108, 115], ["clinically infected", "PROBLEM", 123, 142]]], ["This further compounds disease status among deployed servicemen and women returning to the West, igniting the need for expanding infectious disease experts into current healthcare system, as well as revising medical school curriculum to include training on \u2018exotic\u2019 tropical or subtropical diseases.ConclusionsParasitic diseases are common worldwide, and exposure is common in most deployment locations of the United States military.", [["infectious disease", "DISEASE", 129, 147], ["Parasitic diseases", "DISEASE", 310, 328], ["women", "ORGANISM", 68, 73], ["women", "SPECIES", 68, 73], ["This further compounds disease status", "PROBLEM", 0, 37], ["expanding infectious disease", "PROBLEM", 119, 147], ["subtropical diseases", "PROBLEM", 278, 298], ["Parasitic diseases", "PROBLEM", 310, 328], ["infectious", "OBSERVATION", 129, 139], ["tropical", "OBSERVATION_MODIFIER", 266, 274], ["subtropical diseases", "OBSERVATION", 278, 298], ["Parasitic", "OBSERVATION_MODIFIER", 310, 319], ["diseases", "OBSERVATION", 320, 328]]], ["The majority are not yet preventable with vaccines, and the treatments and prophylaxis that are available are accompanied by many side effects.", [["vaccines", "TREATMENT", 42, 50], ["the treatments", "TREATMENT", 56, 70], ["prophylaxis", "TREATMENT", 75, 86]]], ["It is important to continue funding for the treatment and eradication of infectious diseases worldwide for many reasons, including the exposure danger posed to the armed forces.", [["infectious diseases", "DISEASE", 73, 92], ["the treatment", "TREATMENT", 40, 53], ["infectious diseases", "PROBLEM", 73, 92], ["infectious", "OBSERVATION_MODIFIER", 73, 83]]], ["Significantly, the possibility that these pathogens can be imported into the United States by returning service men and women, unknowingly serving as reservoir hosts, should serve as an alarm bell for us to re-evaluate, refocus and strategize how to face the challenges of the 21st century military deployment, protecting them from local pathogenic insults that can potentially lead to epidemics in the homeland.", [["men", "ORGANISM", 112, 115], ["women", "ORGANISM", 120, 125], ["men", "SPECIES", 112, 115], ["women", "SPECIES", 120, 125], ["local pathogenic insults", "PROBLEM", 332, 356]]]], "PMC7407422": [["These actions comprise \u201clock-downs\u201d including not only, for example, universities and schools but also interventions in the personal freedom of people.", [["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150]]], ["At the same time, in many countries, the enforcement of these actions is not so strict that there would be absolutely no decision-making scope which means that to some extent individuals also face situations of voluntary cooperation (Holl\u00e4nder 1990).", [["individuals", "ORGANISM", 175, 186]]], ["The private so-called \u201cCorona parties\u201d may serve as an example of non-cooperative behaviour in the Covid-19 crisis.IntroductionHowever, the apparent compliance of a vast majority of people in Europe may be a worthwhile subject of research.", [["people", "ORGANISM", 182, 188], ["people", "SPECIES", 182, 188], ["non-cooperative behaviour", "PROBLEM", 66, 91], ["the Covid", "TEST", 95, 104]]], ["In this short note, I take a \u201cmanagement control\u201d perspective and\u2014starting with some kind of \u201cthought experiment\u201d \u2014the attempt is made to figure out some lines for future research related to the linkage of micro-level and macro-level perspective on compliance to \u201cunpleasant\u201d actions taken by authorities for crisis management.A thought experiment from a management control perspectiveManagement control could be regarded as a sub-domain in managerial science and is concerned with questions of how to align the behaviour of employees and, in particular, the decisions taken by managers with the overall objectives of an organization (e.g., Merchant and Van der Stede 2017).", [["a \u201cmanagement control", "TREATMENT", 27, 48], ["some lines", "TREATMENT", 149, 159], ["crisis management", "TREATMENT", 309, 326], ["a management control perspectiveManagement control", "TREATMENT", 353, 403]]], ["For this, management control provides a multitude of devices and techniques\u2014so called \u201ccontrols\u201d.", [["this, management control", "TREATMENT", 4, 28], ["a multitude of devices", "TREATMENT", 38, 60]]], ["Following Merchant and Van der Stede (2017), these are results controls (e.g., incentive schemes), action controls (setting behavioural constraints), personnel controls (e.g., selection and placement of employees) and cultural controls (e.g., norms and beliefs).", [["incentive schemes", "TREATMENT", 79, 96], ["action controls (setting behavioural constraints", "TREATMENT", 99, 147], ["placement of employees", "TREATMENT", 190, 212], ["cultural controls", "TEST", 218, 235]]], ["For the prominent framework of Levers of Control (LOC) see Simons (1994); Widener (2007).A thought experiment from a management control perspectiveGiven the long-standing tradition of economics and, in particular, principal-agent theory with the respective analytical approaches in the domain of management control (Guffey and Harp 2017), it is a worthwhile attempt to rely on this perspective for a start.A thought experiment from a management control perspectiveIn the thought experiment, the overall objective related to the spread of the pandemic may come along as \u201cflattening the curve\u201d or (reduction of) the reproduction rate.", [["pandemic", "DISEASE", 542, 550], ["a management control perspective", "TREATMENT", 115, 147], ["management control", "TREATMENT", 296, 314], ["a management control perspective", "TREATMENT", 432, 464], ["the reproduction rate", "TEST", 610, 631], ["prominent", "OBSERVATION_MODIFIER", 8, 17]]], ["For the sake of the argument in the experiment, now I think of an individual A as a young adult person in good shape, i.e., not part of the risk group of Covid-19.", [["person", "SPECIES", 96, 102], ["Covid", "TEST", 154, 159], ["good shape", "OBSERVATION_MODIFIER", 106, 116]]], ["In face of the aforementioned \u201cunpleasant\u201d actions and the level of enforcement taken by the authorities, individual A has to decide (implicitly or explicitly) about the level of compliance to (or cooperation in) the authorities\u2019 unpleasant actions.A thought experiment from a management control perspectiveFrom an economic perspective the next step is to ask for the utility function of individual A and the particular components of individual A\u2019s utility function which may be relevant in that situation.", [["a management control perspective", "TREATMENT", 275, 307]]], ["Reasonably, at least, the following components could be relevant:A\u2019s risk to get infected by the pandemic which decreases with a higher level of compliance; this accounts for A\u2019s expected level of health.A\u2019s level of compliance contributes to the overall objective (\u201cflattening\u201d) and, thus, shortens the expected remaining duration of the unpleasant actions and their expected further consequences on A\u2019s financial wealth, A\u2019s social distancing from family and friends etc.Should A not cooperate, i.e., not comply to the \u201cunpleasant\u201d actions, there is the risk of punishment where the expected level of punishment from the executive authorities is shaped by A\u2019s level of compliance and by the probability that an eventual uncooperative behaviour is uncovered and prosecuted.A\u2019s level of cooperation is also relevant with respect to social or moral norms, i.e., (not) violating norms and (not) getting ashamed accordingly which refers to expected social approval.A thought experiment from a management control perspectiveThese four components are not meant to be complete, they just serve for the thought experiment which continues as follows.", [["the pandemic", "PROBLEM", 93, 105], ["an eventual uncooperative behaviour", "PROBLEM", 710, 745], ["a management control perspective", "TREATMENT", 988, 1020]]], ["According to the behavioural assumptions of traditional schools of economic thought, our individual A is able to assess all the expected values without systematic errors.A thought experiment from a management control perspectiveWith individual A being a young adult in good shape, the aforementioned component 1 would be fairly negligible.", [["systematic errors", "PROBLEM", 152, 169], ["a management control", "TREATMENT", 196, 216], ["good shape", "OBSERVATION_MODIFIER", 269, 279]]], ["Regarding component 2\u2014i.e., A\u2019s individual contribution to the overall objective\u2014one may argue that this depends on the structure of the social network in which A is residing in and A\u2019s position in the network.", [["social network", "MULTI-TISSUE_STRUCTURE", 137, 151]]], ["However, regarding the situation as a public good game, the own contribution to the overall objective (i.e., \u201cflattening the curve\u201d of an entire country) is vague and presumably negligible which, per se, suggests a rather low propensity for cooperation (Holl\u00e4nder 1990; K\u00f6lle 2015).", [["presumably", "UNCERTAINTY", 167, 177], ["negligible", "OBSERVATION_MODIFIER", 178, 188]]], ["In tendency, the higher the punishments the higher the cost of uncooperative behaviour for individual A. The fourth component refers to \u201ccultural controls\u201d and the social approval desired by individual A. This also refers to Holl\u00e4nder (1990) who proposes a model providing an economic understanding of voluntary cooperation as social exchange and relates it to governmental interventions.A thought experiment from a management control perspectiveHence, in how far the aforementioned four components affect our individual A\u2019s decisions regarding compliance (cooperation) is affected by A\u2019s attitude towards risk and further personal traits of A. From the authorities\u2019 perspective, it appears that individual A\u2019s level of cooperation can be affected predominantly by enforcement (action controls) and by social or moral norms (cultural controls).", [["uncooperative behaviour", "PROBLEM", 63, 86], ["governmental interventions", "TREATMENT", 361, 387], ["a management control perspectiveHence", "TREATMENT", 414, 451], ["tendency", "OBSERVATION_MODIFIER", 3, 11], ["higher", "OBSERVATION_MODIFIER", 17, 23], ["higher", "OBSERVATION_MODIFIER", 44, 50]]], ["However, the thought experiment also suggests that the success of these controls is shaped by personal traits of individuals.Broadening the view: Bounded rationality and heterogeneitySome of the assumptions of the above sketched economic perspective could be relaxed in favour of a more realistic view on individuals.", [["shaped", "OBSERVATION_MODIFIER", 84, 90], ["Bounded rationality", "OBSERVATION", 146, 165], ["heterogeneity", "OBSERVATION_MODIFIER", 170, 183]]], ["Second, taking boundedly rational agents into consideration results in heterogeneity of agents since there are numerous forms of departing from rationality or as Axtell (2007, p.", [["boundedly rational agents", "TREATMENT", 15, 40], ["agents", "TREATMENT", 88, 94]]], ["It is needless to say that there is a manifold of attributes in which individuals differ and which may affect the propensity to cooperate in the pandemic management (e.g., social network, state of health, beliefs).Broadening the view: Bounded rationality and heterogeneityFrom the very few bits and pieces of an economically inspired model as outlined above, the relevance of personal traits of individuals regarding the effects of the policy makers\u2019 actions becomes apparent.", [["pandemic", "DISEASE", 145, 153], ["the pandemic management", "TREATMENT", 141, 164], ["Bounded rationality", "OBSERVATION", 235, 254], ["heterogeneity", "OBSERVATION_MODIFIER", 259, 272], ["very", "OBSERVATION_MODIFIER", 281, 285], ["few", "OBSERVATION_MODIFIER", 286, 289]]], ["However, taking heterogeneity of individuals into account makes it more difficult to predict the level of voluntary cooperation of the individuals in the collective in face of a certain set of \u201cunpleasant\u201d actions.Agent-based modelling for studying cultural controls in pandemics managementPredicting the overall effects of actions in crisis management is obviously of particular relevance for policy makers.", [["Agent", "TREATMENT", 214, 219], ["pandemics management", "TREATMENT", 270, 290], ["crisis management", "TREATMENT", 335, 352], ["overall", "OBSERVATION_MODIFIER", 305, 312], ["effects", "OBSERVATION_MODIFIER", 313, 320]]], ["Hence, for understanding the dynamics of a pandemic in a collective and particularly for policy advice an approach is required that allows to deal with the heterogeneity of individuals and to bridge between the individuals\u2019 and the collective\u2019s level.Agent-based modelling for studying cultural controls in pandemics managementIt has been argued that agent-based modelling could be a valuable approach for predicting the effects of actions taken in a crisis situation like the Covid-19 pandemic in conjunction with human behaviour within the crisis (Adam 2020; Saltelli et al. 2020; Squazzoni et al. 2020).", [["human", "ORGANISM", 515, 520], ["human", "SPECIES", 515, 520], ["human", "SPECIES", 515, 520], ["an approach", "TREATMENT", 103, 114], ["the heterogeneity of individuals", "PROBLEM", 152, 184], ["Agent", "TREATMENT", 251, 256], ["pandemics management", "TREATMENT", 307, 327], ["a crisis situation", "PROBLEM", 449, 467], ["the Covid", "TEST", 473, 482]]], ["I agree with this view and want to stress those aspects of agent-based modelling which make it a \u201cnatural\u201d candidate to study the pandemics management and the behavioural effects of \u201cunpleasant\u201d actions at the collective\u2019s level: agent-based modelling allows to capture heterogeneous agents, puts particular emphasis on interactions among agents in a spatially and/or figuratively defined environment and seeks to understand system\u2019s behaviour from the bottom up, i.e., agents\u2019 behaviour (e.g., Epstein 1999).", [["agent", "TREATMENT", 59, 64], ["the pandemics management", "TREATMENT", 126, 150], ["agent", "TREATMENT", 230, 235], ["heterogeneous agents", "TREATMENT", 270, 290]]], ["In this sense, it also allows to explicitly take policy makers as agents and their cognitive and coordinative capabilities into account (Comfort 2007) and to simulate the alternative forms of coordination for crisis management (Christensen et al. 2016).Agent-based modelling for studying cultural controls in pandemics managementAmong the various aspects of the Covid-19 crisis that may be studied by agent-based models a particularly interesting topic could be the effects of what is captured by the term \u201ccultural controls\u201d referring to beliefs, norms, shared values.", [["crisis management", "TREATMENT", 209, 226], ["Agent", "TREATMENT", 253, 258], ["pandemics management", "TREATMENT", 309, 329], ["the Covid", "TEST", 358, 367]]], ["As illustrated in the brief thought experiment above and based on prior research, it appears that the voluntary cooperation of humans to \u201cunpleasant\u201d actions may be particularly shaped by (the desire of) social approval (e.g., Holl\u00e4nder 1990).", [["humans", "ORGANISM", 127, 133], ["humans", "SPECIES", 127, 133], ["humans", "SPECIES", 127, 133]]], ["Social approval refers to social norms which differ across cultures (Rege and Telle 2004; Twenge and Im 2007).", [["cultures", "TEST", 59, 67]]], ["Hence, with social norms as well as attitudes towards risk differing across cultures (Hofstede 2003), agent-based modelling may be a particularly promising approach to study the effects of pandemics management in different cultures.", [["cultures", "TEST", 76, 84], ["agent", "TREATMENT", 102, 107], ["pandemics management", "TREATMENT", 189, 209], ["different cultures", "TEST", 213, 231]]]], "PMC7114154": [["IntroductionCoronaviruses have a wide host range including avian and mammalian.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["avian", "SPECIES", 59, 64]]], ["The known coronavirus species are classified into three groups.", [["coronavirus", "ORGANISM", 10, 21], ["The known coronavirus species", "PROBLEM", 0, 29], ["coronavirus species", "OBSERVATION", 10, 29]]], ["The recently emerging agent for severe acute respiratory syndrome (SARS) has been identified as a new member of coronavirus in group 2.", [["acute respiratory syndrome", "DISEASE", 39, 65], ["SARS", "DISEASE", 67, 71], ["coronavirus", "DISEASE", 112, 123], ["coronavirus", "ORGANISM", 112, 123], ["severe acute respiratory syndrome", "PROBLEM", 32, 65], ["coronavirus", "PROBLEM", 112, 123], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65]]], ["The exact origin of this novel coronavirus is still not clear, but current molecular epidemiological evidence favors an animal origin of the virus (Guan et al., 2003).", [["coronavirus", "DISEASE", 31, 42], ["coronavirus", "ORGANISM", 31, 42], ["this novel coronavirus", "PROBLEM", 20, 42], ["the virus", "PROBLEM", 137, 146], ["coronavirus", "OBSERVATION", 31, 42], ["clear", "OBSERVATION", 56, 61]]], ["So how coronavirus breaks the host species barrier, causes interspecies infection and becomes zoonotic would be interesting questions to be noticed in public.", [["infection", "DISEASE", 72, 81], ["coronavirus", "ORGANISM", 7, 18], ["the host species barrier", "TREATMENT", 26, 50], ["interspecies infection", "PROBLEM", 59, 81], ["zoonotic", "PROBLEM", 94, 102], ["coronavirus breaks", "OBSERVATION", 7, 25], ["host species", "OBSERVATION_MODIFIER", 30, 42], ["infection", "OBSERVATION", 72, 81]]], ["Infectious bronchitis virus (IBV) is the prototype member of coronavirus in group 3, which also consists of turkey coronavirus (TCoV), pheasant coronavirus (PhCoV), goose coronavirus (GCoV), duck coronavirus (DCoV) and pigeon coronavirus (PiCoV).", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["coronavirus", "DISEASE", 61, 72], ["turkey coronavirus", "DISEASE", 108, 126], ["pheasant coronavirus", "DISEASE", 135, 155], ["goose coronavirus", "DISEASE", 165, 182], ["duck coronavirus (DCoV) and pigeon coronavirus", "DISEASE", 191, 237], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["coronavirus", "ORGANISM", 61, 72], ["turkey coronavirus", "ORGANISM", 108, 126], ["TCoV", "ORGANISM", 128, 132], ["pheasant coronavirus", "ORGANISM", 135, 155], ["PhCoV", "ORGANISM", 157, 162], ["goose coronavirus", "ORGANISM", 165, 182], ["GCoV", "ORGANISM", 184, 188], ["duck coronavirus", "ORGANISM", 191, 207], ["DCoV", "ORGANISM", 209, 213], ["pigeon coronavirus", "ORGANISM", 219, 237], ["PiCoV", "CANCER", 239, 244], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["turkey coronavirus", "SPECIES", 108, 126], ["pheasant coronavirus", "SPECIES", 135, 155], ["goose coronavirus", "SPECIES", 165, 182], ["duck coronavirus", "SPECIES", 191, 207], ["pigeon coronavirus", "SPECIES", 219, 237], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["turkey coronavirus", "SPECIES", 108, 126], ["TCoV", "SPECIES", 128, 132], ["pheasant coronavirus", "SPECIES", 135, 155], ["PhCoV", "SPECIES", 157, 162], ["goose coronavirus", "SPECIES", 165, 182], ["GCoV", "SPECIES", 184, 188], ["duck coronavirus", "SPECIES", 191, 207], ["DCoV", "SPECIES", 209, 213], ["pigeon coronavirus", "SPECIES", 219, 237], ["PiCoV", "SPECIES", 239, 244], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["coronavirus", "PROBLEM", 61, 72], ["turkey coronavirus (TCoV)", "PROBLEM", 108, 133], ["pheasant coronavirus (PhCoV", "PROBLEM", 135, 162], ["goose coronavirus", "PROBLEM", 165, 182], ["duck coronavirus", "PROBLEM", 191, 207], ["pigeon coronavirus (PiCoV", "TREATMENT", 219, 244]]], ["Although chickens were believed to be the only natural hosts for IBV, pheasants were also reported to be susceptible to IBV infection (Gough et al., 1996, Spackman and Cameron, 1983).", [["IBV infection", "DISEASE", 120, 133], ["chickens", "ORGANISM", 9, 17], ["IBV", "ORGANISM", 65, 68], ["pheasants", "ORGANISM", 70, 79], ["IBV", "ORGANISM", 120, 123], ["chickens", "SPECIES", 9, 17], ["chickens", "SPECIES", 9, 17], ["IBV", "SPECIES", 65, 68], ["pheasants", "SPECIES", 70, 79], ["IBV", "SPECIES", 120, 123], ["IBV", "PROBLEM", 65, 68], ["pheasants", "TREATMENT", 70, 79], ["IBV infection", "PROBLEM", 120, 133], ["infection", "OBSERVATION", 124, 133]]], ["In addition, it had been described that some galliform birds (guinea fowl, partridge and peafowl) and non-galliform birds (teal) were infected by coronaviruses that were very similar to IBV (Ito et al., 1991, Liu et al., 2005).", [["partridge", "ANATOMY", 75, 84], ["peafowl", "ANATOMY", 89, 96], ["galliform birds", "ORGANISM", 45, 60], ["guinea fowl", "ORGANISM", 62, 73], ["peafowl", "CANCER", 89, 96], ["non-galliform birds", "ORGANISM", 102, 121], ["teal", "ORGANISM_SUBDIVISION", 123, 127], ["coronaviruses", "ORGANISM", 146, 159], ["IBV", "ORGANISM", 186, 189], ["guinea fowl", "SPECIES", 62, 73], ["fowl", "SPECIES", 69, 73], ["IBV", "SPECIES", 186, 189], ["non-galliform birds (teal)", "PROBLEM", 102, 128], ["coronaviruses", "PROBLEM", 146, 159]]], ["Since IBV could infect some birds, there was a high possibility that IBV strains might be transmitted over long distances through the migration.IntroductionIBV is a major pathogen to chicken population, causing an acute and highly contagious disease that mainly affects the respiratory system or sometimes urogenital tracts (King and Cavanagh, 1991).", [["respiratory system", "ANATOMY", 274, 292], ["urogenital tracts", "ANATOMY", 306, 323], ["IntroductionIBV", "CHEMICAL", 144, 159], ["IBV", "ORGANISM", 6, 9], ["birds", "ORGANISM", 28, 33], ["IBV", "ORGANISM", 69, 72], ["chicken", "ORGANISM", 183, 190], ["urogenital tracts", "ORGANISM_SUBDIVISION", 306, 323], ["chicken", "SPECIES", 183, 190], ["IBV", "SPECIES", 6, 9], ["IBV", "SPECIES", 69, 72], ["chicken", "SPECIES", 183, 190], ["IBV", "PROBLEM", 6, 9], ["IBV strains", "PROBLEM", 69, 80], ["a major pathogen", "PROBLEM", 163, 179], ["an acute and highly contagious disease", "PROBLEM", 211, 249], ["IBV", "OBSERVATION", 69, 72], ["migration", "OBSERVATION_MODIFIER", 134, 143], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["highly", "OBSERVATION_MODIFIER", 224, 230], ["contagious", "OBSERVATION_MODIFIER", 231, 241], ["disease", "OBSERVATION", 242, 249], ["respiratory system", "ANATOMY", 274, 292], ["urogenital tracts", "ANATOMY", 306, 323]]], ["Avian infectious bronchitis has caused severe economic losses to the poultry industry all over the world (Estola, 1966, Calnek, 1997).", [["Avian infectious bronchitis", "DISEASE", 0, 27], ["Avian", "ORGANISM", 0, 5], ["Avian", "SPECIES", 0, 5], ["Avian infectious bronchitis", "PROBLEM", 0, 27], ["severe economic losses", "PROBLEM", 39, 61], ["infectious", "OBSERVATION_MODIFIER", 6, 16], ["bronchitis", "OBSERVATION", 17, 27], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["economic", "OBSERVATION_MODIFIER", 46, 54], ["losses", "OBSERVATION", 55, 61]]], ["The genome of IBV is a single-stranded, positive-sense RNA ranging from 27 to 31 kb in size (Cavanagh, 1997).", [["IBV", "ORGANISM", 14, 17], ["IBV", "SPECIES", 14, 17], ["a single-stranded, positive-sense RNA", "PROBLEM", 21, 58], ["IBV", "OBSERVATION", 14, 17], ["sense RNA", "OBSERVATION_MODIFIER", 49, 58], ["27 to 31 kb", "OBSERVATION_MODIFIER", 72, 83], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["Gene 1 encodes many proteins associated with RNA replication and transcription.", [["Gene 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Gene 1", "DNA", 0, 6], ["RNA replication", "TREATMENT", 45, 60]]], ["In addition to four structural protein genes (S, E, M, and N), IBV has two genes encoding four non-structural proteins (3a and 3b, 5a and 5b) (Cavanagh, 2005).IntroductionIn present study, coronavirus infection was investigated in apparently healthy wild peafowls in Guangdong province of China in 2003 during SARS broke out.", [["coronavirus infection", "DISEASE", 189, 210], ["SARS", "DISEASE", 310, 314], ["coronavirus", "ORGANISM", 189, 200], ["structural protein genes", "DNA", 20, 44], ["S", "DNA", 46, 47], ["E", "DNA", 49, 50], ["non-structural proteins", "PROTEIN", 95, 118], ["3a and 3b, 5a and 5b", "PROTEIN", 120, 140], ["coronavirus", "SPECIES", 189, 200], ["IBV", "SPECIES", 63, 66], ["four structural protein genes", "TEST", 15, 44], ["IBV", "PROBLEM", 63, 66], ["5a", "TEST", 131, 133], ["Cavanagh", "TEST", 143, 151], ["IntroductionIn present study", "TEST", 159, 187], ["coronavirus infection", "PROBLEM", 189, 210], ["coronavirus", "OBSERVATION_MODIFIER", 189, 200], ["infection", "OBSERVATION", 201, 210]]], ["Three hundred and fifty-one laryngotracheal swabs and 54 serum samples were collected.", [["laryngotracheal swabs", "ANATOMY", 28, 49], ["serum samples", "ANATOMY", 57, 70], ["laryngotracheal swabs", "CANCER", 28, 49], ["serum samples", "ORGANISM_SUBSTANCE", 57, 70], ["serum samples", "TEST", 57, 70], ["laryngotracheal", "ANATOMY", 28, 43]]], ["A new avian coronavirus strain, Peafowl/GD/KQ6/2003 (KQ6), was isolated and characterized in detail.Sample collection ::: Materials and methodsThree hundred and fifty-one laryngotracheal swabs and 54 serum samples were collected from the apparently healthy wild peafowls of different age in Guangdong province in 2003.", [["laryngotracheal swabs", "ANATOMY", 171, 192], ["serum samples", "ANATOMY", 200, 213], ["avian coronavirus", "DISEASE", 6, 23], ["avian", "ORGANISM", 6, 11], ["coronavirus", "ORGANISM", 12, 23], ["Peafowl/GD/KQ6/2003", "ORGANISM", 32, 51], ["KQ6", "GENE_OR_GENE_PRODUCT", 53, 56], ["laryngotracheal swabs", "CANCER", 171, 192], ["serum samples", "ORGANISM_SUBSTANCE", 200, 213], ["avian coronavirus", "SPECIES", 6, 23], ["Peafowl/GD/KQ6/2003 (KQ6)", "SPECIES", 32, 57], ["A new avian coronavirus strain", "PROBLEM", 0, 30], ["Peafowl/GD/KQ6", "TREATMENT", 32, 46], ["one laryngotracheal swabs", "TEST", 167, 192], ["serum samples", "TEST", 200, 213], ["coronavirus strain", "OBSERVATION", 12, 30], ["laryngotracheal", "ANATOMY", 171, 186]]], ["All peafowls were free of IBV vaccination.", [["peafowls", "ANATOMY", 4, 12], ["peafowls", "CANCER", 4, 12], ["IBV", "ORGANISM", 26, 29], ["IBV", "SPECIES", 26, 29], ["IBV vaccination", "TREATMENT", 26, 41]]], ["These samples were stored at \u221220 \u00b0C.Virus propagation ::: Materials and methodsLaryngotracheal swabs were treated in 0.1% PBS buffer containing antibiotics (penicillin and streptomycin, 2000 IU/ml) for 12 h at 4 \u00b0C. Then 200 \u03bcl of supernatant from the suspension was inoculated into the allantonic cavity of 11-day-old SPF embryonated chicken eggs.", [["samples", "ANATOMY", 6, 13], ["Laryngotracheal swabs", "ANATOMY", 79, 100], ["supernatant", "ANATOMY", 231, 242], ["allantonic cavity", "ANATOMY", 287, 304], ["eggs", "ANATOMY", 343, 347], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 172, 184], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 172, 184], ["Virus", "ORGANISM", 36, 41], ["penicillin", "SIMPLE_CHEMICAL", 157, 167], ["streptomycin", "SIMPLE_CHEMICAL", 172, 184], ["allantonic cavity", "MULTI-TISSUE_STRUCTURE", 287, 304], ["SPF", "ORGANISM", 319, 322], ["chicken", "ORGANISM", 335, 342], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 343, 347], ["chicken", "SPECIES", 335, 342], ["chicken", "SPECIES", 335, 342], ["These samples", "TEST", 0, 13], ["Materials", "TREATMENT", 58, 67], ["methodsLaryngotracheal swabs", "TREATMENT", 72, 100], ["antibiotics", "TREATMENT", 144, 155], ["penicillin", "TREATMENT", 157, 167], ["streptomycin", "TREATMENT", 172, 184], ["the suspension", "TREATMENT", 248, 262], ["Laryngotracheal", "ANATOMY", 79, 94], ["allantonic cavity", "ANATOMY", 287, 304], ["chicken eggs", "OBSERVATION", 335, 347]]], ["Five eggs were used for each sample.", [["Five eggs", "TREATMENT", 0, 9], ["each sample", "TEST", 24, 35]]], ["The inoculated eggs were incubated at 37 \u00b0C and candled daily.", [["eggs", "ANATOMY", 15, 19], ["The inoculated eggs", "TREATMENT", 0, 19]]], ["Eggs died within 24 h of inoculation were discarded.", [["Eggs", "ANATOMY", 0, 4], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["inoculation", "PROBLEM", 25, 36]]], ["At 2\u20133 days after inoculation, surviving eggs were placed at 4 \u00b0C overnight, and the allantoic fluid was collected.", [["eggs", "ANATOMY", 41, 45], ["allantoic fluid", "ANATOMY", 85, 100], ["allantoic fluid", "ORGANISM_SUBSTANCE", 85, 100], ["inoculation", "PROBLEM", 18, 29], ["surviving eggs", "PROBLEM", 31, 45], ["the allantoic fluid", "TEST", 81, 100]]], ["Then three blind serial passages were performed and all the allantoic fluid was harvested for further studies.Detection of coronavirus by RT-PCR ::: Materials and methodsViral RNA was extracted from 200 \u03bcl of infectious allantoic fluid using Trizol reagents (GIBCO-BRL).", [["allantoic fluid", "ANATOMY", 60, 75], ["allantoic fluid", "ANATOMY", 220, 235], ["allantoic fluid", "ORGANISM_SUBSTANCE", 60, 75], ["coronavirus", "ORGANISM", 123, 134], ["Viral", "ORGANISM", 170, 175], ["allantoic fluid", "ORGANISM_SUBSTANCE", 220, 235], ["GIBCO-BRL", "CELL", 259, 268], ["Viral RNA", "RNA", 170, 179], ["blind serial passages", "TEST", 11, 32], ["the allantoic fluid", "TEST", 56, 75], ["further studies", "TEST", 94, 109], ["coronavirus", "PROBLEM", 123, 134], ["methodsViral RNA", "PROBLEM", 163, 179], ["infectious allantoic fluid", "TREATMENT", 209, 235], ["Trizol reagents", "TREATMENT", 242, 257], ["allantoic", "ANATOMY", 60, 69], ["fluid", "OBSERVATION", 70, 75], ["infectious", "OBSERVATION_MODIFIER", 209, 219]]], ["The RNA pellet was resuspended in 10 \u03bcl of DNase-free, RNase-free double-distilled water and was used as the template for RT-PCR.", [["DNase", "GENE_OR_GENE_PRODUCT", 43, 48], ["RNase", "GENE_OR_GENE_PRODUCT", 55, 60], ["DNase", "PROTEIN", 43, 48], ["RNase", "PROTEIN", 55, 60], ["The RNA pellet", "TREATMENT", 0, 14], ["DNase", "TREATMENT", 43, 48], ["RNase", "TREATMENT", 55, 60], ["free double-distilled water", "TREATMENT", 61, 88], ["RT-PCR", "TREATMENT", 122, 128], ["RNA pellet", "OBSERVATION", 4, 14]]], ["Three pairs of primers were designed to detect coronavirus.", [["coronavirus", "ORGANISM", 47, 58], ["primers", "PROBLEM", 15, 22], ["coronavirus", "PROBLEM", 47, 58]]], ["The universal primers for coronavirus were P3 (5\u2032-ACTCARWTRAATYTWAARTAYGC-3\u2032) and P4 (5\u2032-TCACAYTTWGGATARTCCCA-3\u2032) (R = A/G, W = A/T, Y = T/C), the specific primers designed according to the conservative region of SARS virus polymerase 1b were R13 (5\u2032-GCGCAAGTATTAAGTGAGATG-3\u2032) and R14 (5\u2032-GAAGTGCATTTACATTGGCTG-3\u2032), and the primers designed according to the 3\u2032-UTR of IBV were UTR-1 (5\u2032-CTAACTCTATACTAGCCTAT-3\u2032) and UTR-2 (5\u2032-GGAAGATAGGCATGTAGCTT-3\u2032).", [["SARS", "DISEASE", 213, 217], ["coronavirus", "ORGANISM", 26, 37], ["SARS virus polymerase 1b", "GENE_OR_GENE_PRODUCT", 213, 237], ["IBV", "ORGANISM", 368, 371], ["UTR-1", "GENE_OR_GENE_PRODUCT", 377, 382], ["UTR-2", "GENE_OR_GENE_PRODUCT", 416, 421], ["SARS virus polymerase 1b", "PROTEIN", 213, 237], ["3\u2032-UTR", "DNA", 358, 364], ["UTR", "DNA", 377, 380], ["UTR-2", "DNA", 416, 421], ["SARS virus", "SPECIES", 213, 223], ["IBV", "SPECIES", 368, 371], ["The universal primers", "TEST", 0, 21], ["coronavirus", "TEST", 26, 37], ["ACTCARWTRAATYTWAARTAYGC", "TEST", 50, 73], ["P4", "TEST", 82, 84], ["TCACAYTTWGGATARTCCCA", "TEST", 89, 109], ["A/G", "TEST", 119, 122], ["W", "TEST", 124, 125], ["A/T", "TEST", 128, 131], ["Y = T/C", "TEST", 133, 140], ["the specific primers", "PROBLEM", 143, 163], ["SARS virus polymerase", "TEST", 213, 234], ["GCGCAAGTATTAAGTGAGATG", "TEST", 251, 272], ["R14", "TEST", 281, 284], ["GAAGTGCATTTACATTGGCTG", "TEST", 289, 310], ["the primers", "TEST", 320, 331], ["IBV", "TEST", 368, 371], ["UTR", "TEST", 377, 380], ["5\u2032-CTAACTCTATACTAGCCTAT", "TEST", 384, 407], ["UTR", "TEST", 416, 419], ["5\u2032-GGAAGATAGGCATGTAGCTT", "TEST", 423, 446]]], ["The cDNA of all specimens were amplified by PCR using these three pairs of primers, respectively.Hemagglutination assay (HA) ::: Materials and methodsThe positive allantoic fluid was centrifuged at 4000 rpm for 5 min, and treated with equal volume of 1% trypsin for 3 h at 37 \u00b0C before HA test by the commonly used procedures (Estola, 1966, Calnek, 1997).", [["specimens", "ANATOMY", 16, 25], ["allantoic fluid", "ANATOMY", 163, 178], ["allantoic fluid", "ORGANISM_SUBSTANCE", 163, 178], ["trypsin", "GENE_OR_GENE_PRODUCT", 254, 261], ["trypsin", "PROTEIN", 254, 261], ["all specimens", "TEST", 12, 25], ["PCR", "TEST", 44, 47], ["Hemagglutination assay", "TEST", 97, 119], ["The positive allantoic fluid", "PROBLEM", 150, 178], ["1% trypsin", "TREATMENT", 251, 261], ["HA test", "TEST", 286, 293], ["positive", "OBSERVATION_MODIFIER", 154, 162], ["allantoic", "OBSERVATION_MODIFIER", 163, 172], ["fluid", "OBSERVATION", 173, 178]]], ["Trypsin-free allantoic fluid was used as negative control.Embryo infection test ::: Materials and methodsThe positive allantoic fluid was inoculated into the allantoic cavity of 11-day-old SPF embryonated chicken eggs.", [["allantoic fluid", "ANATOMY", 13, 28], ["Embryo", "ANATOMY", 58, 64], ["allantoic fluid", "ANATOMY", 118, 133], ["allantoic cavity", "ANATOMY", 158, 174], ["eggs", "ANATOMY", 213, 217], ["Trypsin", "CHEMICAL", 0, 7], ["Embryo infection", "DISEASE", 58, 74], ["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["allantoic fluid", "ORGANISM_SUBSTANCE", 13, 28], ["allantoic fluid", "ORGANISM_SUBSTANCE", 118, 133], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 158, 174], ["SPF", "ORGANISM", 189, 192], ["chicken", "ORGANISM", 205, 212], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 213, 217], ["chicken", "SPECIES", 205, 212], ["chicken", "SPECIES", 205, 212], ["Trypsin", "TREATMENT", 0, 7], ["free allantoic fluid", "TREATMENT", 8, 28], ["Embryo infection test", "PROBLEM", 58, 79], ["The positive allantoic fluid", "PROBLEM", 105, 133], ["the allantoic cavity", "TEST", 154, 174], ["infection", "OBSERVATION", 65, 74], ["positive", "OBSERVATION_MODIFIER", 109, 117], ["allantoic", "OBSERVATION_MODIFIER", 118, 127], ["fluid", "OBSERVATION", 128, 133], ["allantoic cavity", "ANATOMY", 158, 174], ["chicken eggs", "OBSERVATION", 205, 217]]], ["The inoculated eggs continued to be incubated for 120 h at 37 \u00b0C before evaluating embryo dwarfism.", [["eggs", "ANATOMY", 15, 19], ["embryo", "ANATOMY", 83, 89], ["dwarfism", "DISEASE", 90, 98], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 83, 89], ["The inoculated eggs", "TREATMENT", 0, 19], ["embryo dwarfism", "PROBLEM", 83, 98], ["embryo dwarfism", "OBSERVATION", 83, 98]]], ["Inoculated eggs with an equal volume of PBS served as negative controls.Virus interference test ::: Materials and methodsThe positive allantoic fluid was inoculated (0.1 ml/egg) into the allantoic cavity of 11-day-old SPF embryonated chicken eggs and incubated for 10 h at 37 \u00b0C. The Newcastle disease virus (NDV) B1 strain was diluted to 1:10,000 with PBS and inoculated (0.1 ml/egg) into the same location where the peafowl virus strain was inoculated.", [["eggs", "ANATOMY", 11, 15], ["allantoic fluid", "ANATOMY", 134, 149], ["egg", "ANATOMY", 173, 176], ["allantoic cavity", "ANATOMY", 187, 203], ["eggs", "ANATOMY", 242, 246], ["Newcastle disease", "DISEASE", 284, 301], ["Virus", "ORGANISM", 72, 77], ["allantoic fluid", "ORGANISM_SUBSTANCE", 134, 149], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 187, 203], ["SPF", "ORGANISM", 218, 221], ["chicken", "ORGANISM", 234, 241], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 242, 246], ["Newcastle disease virus", "ORGANISM", 284, 307], ["NDV", "ORGANISM", 309, 312], ["peafowl virus", "ORGANISM", 418, 431], ["chicken", "SPECIES", 234, 241], ["NDV", "SPECIES", 309, 312], ["chicken", "SPECIES", 234, 241], ["Newcastle disease virus", "SPECIES", 284, 307], ["NDV", "SPECIES", 309, 312], ["The positive allantoic fluid", "PROBLEM", 121, 149], ["the allantoic cavity", "TEST", 183, 203], ["SPF embryonated chicken eggs", "TREATMENT", 218, 246], ["The Newcastle disease virus (NDV) B1 strain", "PROBLEM", 280, 323], ["PBS", "TEST", 353, 356], ["the peafowl virus strain", "PROBLEM", 414, 438], ["positive", "OBSERVATION_MODIFIER", 125, 133], ["allantoic", "OBSERVATION_MODIFIER", 134, 143], ["fluid", "OBSERVATION", 144, 149], ["allantoic cavity", "ANATOMY", 187, 203], ["Newcastle", "OBSERVATION_MODIFIER", 284, 293], ["disease", "OBSERVATION", 294, 301]]], ["Eggs were incubated for 48 h at 37 \u00b0C before allantoic fluids were harvested and tested by a standard hemaglutination assay.", [["Eggs", "ANATOMY", 0, 4], ["allantoic fluids", "ANATOMY", 45, 61], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["allantoic fluids", "ORGANISM_SUBSTANCE", 45, 61], ["Eggs", "TEST", 0, 4], ["allantoic fluids", "TREATMENT", 45, 61], ["a standard hemaglutination assay", "TEST", 91, 123]]], ["Inoculated eggs with PBS or NDV B1 served as the negative and positive controls, respectively.Neutralization test ::: Materials and methodsChicken-anti-IBV polyclonal serum (polyclonal antibodies against M41 strain, ELISA titer = 7988) and IBV-antibody-free serum were heat-inactivated for 30 min at 56 \u00b0C before use in neutralization test.", [["eggs", "ANATOMY", 11, 15], ["serum", "ANATOMY", 167, 172], ["serum", "ANATOMY", 258, 263], ["NDV B1", "ORGANISM", 28, 34], ["Chicken", "ORGANISM", 139, 146], ["IBV", "ORGANISM", 152, 155], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["IBV", "ORGANISM", 240, 243], ["serum", "ORGANISM_SUBSTANCE", 258, 263], ["polyclonal antibodies", "PROTEIN", 174, 195], ["NDV", "SPECIES", 28, 31], ["Chicken", "SPECIES", 139, 146], ["IBV", "SPECIES", 152, 155], ["IBV", "SPECIES", 240, 243], ["NDV", "SPECIES", 28, 31], ["Chicken", "SPECIES", 139, 146], ["IBV", "SPECIES", 152, 155], ["IBV", "SPECIES", 240, 243], ["PBS", "TEST", 21, 24], ["NDV B1", "TEST", 28, 34], ["Materials", "TEST", 118, 127], ["methods", "TEST", 132, 139], ["Chicken", "TEST", 139, 146], ["anti-IBV polyclonal serum", "TEST", 147, 172], ["polyclonal antibodies", "TEST", 174, 195], ["M41 strain", "TEST", 204, 214], ["ELISA titer", "TEST", 216, 227], ["IBV", "TEST", 240, 243], ["antibody", "TEST", 244, 252], ["neutralization test", "TEST", 320, 339]]], ["The positive allantoic fluid was 10-fold serially diluted (10\u22121\u201310\u22126) before mixing with an equal volume of chicken-anti-IBV polyclonal serum or IBV-antibody-free serum.", [["allantoic fluid", "ANATOMY", 13, 28], ["serum", "ANATOMY", 136, 141], ["serum", "ANATOMY", 163, 168], ["allantoic fluid", "ORGANISM_SUBSTANCE", 13, 28], ["chicken", "ORGANISM", 108, 115], ["IBV", "ORGANISM", 121, 124], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["IBV", "ORGANISM", 145, 148], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["IBV-antibody", "PROTEIN", 145, 157], ["chicken", "SPECIES", 108, 115], ["chicken", "SPECIES", 108, 115], ["IBV", "SPECIES", 121, 124], ["IBV", "SPECIES", 145, 148], ["The positive allantoic fluid", "TEST", 0, 28], ["chicken", "TEST", 108, 115], ["anti-IBV polyclonal serum", "TEST", 116, 141], ["IBV", "TEST", 145, 148], ["antibody", "TEST", 149, 157], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["allantoic", "OBSERVATION_MODIFIER", 13, 22], ["fluid", "OBSERVATION", 23, 28]]], ["The virus\u2013serum mixtures were placed for 30 min at 25 \u00b0C prior to inoculating embryonated eggs (0.2 ml/egg, seven eggs per group).", [["virus\u2013serum", "ANATOMY", 4, 15], ["eggs", "ANATOMY", 90, 94], ["egg", "ANATOMY", 103, 106], ["eggs", "ANATOMY", 114, 118], ["The virus\u2013serum mixtures", "TREATMENT", 0, 24], ["inoculating embryonated eggs", "TREATMENT", 66, 94]]], ["The chicken-anti-IBV polyclonal serum inoculated group, IBV-antibody-free serum inoculated group and peafowl virus strain inoculated group were designated as the positive serum control, negative serum control, and virus control, respectively.", [["serum", "ANATOMY", 32, 37], ["serum", "ANATOMY", 74, 79], ["serum", "ANATOMY", 171, 176], ["serum", "ANATOMY", 195, 200], ["chicken", "ORGANISM", 4, 11], ["IBV", "ORGANISM", 17, 20], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["IBV-antibody", "ORGANISM", 56, 68], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["peafowl virus", "ORGANISM", 101, 114], ["serum", "ORGANISM_SUBSTANCE", 171, 176], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["chicken", "SPECIES", 4, 11], ["IBV", "SPECIES", 17, 20], ["IBV", "SPECIES", 56, 59], ["chicken", "SPECIES", 4, 11], ["IBV", "SPECIES", 17, 20], ["IBV", "SPECIES", 56, 59], ["peafowl virus", "SPECIES", 101, 114], ["The chicken-anti-IBV polyclonal serum", "TEST", 0, 37], ["IBV", "TEST", 56, 59], ["antibody", "TEST", 60, 68], ["peafowl virus strain", "PROBLEM", 101, 121], ["virus control", "TREATMENT", 214, 227]]], ["After inoculation, eggs were continuously incubated for 7 days at 37 \u00b0C. The EID50 of the chicken-anti-IBV polyclonal serum and IBV-antibody-free serum inoculated groups were determined.", [["eggs", "ANATOMY", 19, 23], ["serum", "ANATOMY", 118, 123], ["serum", "ANATOMY", 146, 151], ["chicken", "ORGANISM", 90, 97], ["IBV", "ORGANISM", 103, 106], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["IBV", "ORGANISM", 128, 131], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["EID50", "PROTEIN", 77, 82], ["chicken", "SPECIES", 90, 97], ["IBV", "SPECIES", 103, 106], ["IBV", "SPECIES", 128, 131], ["chicken", "SPECIES", 90, 97], ["IBV", "SPECIES", 103, 106], ["IBV", "SPECIES", 128, 131], ["inoculation", "TREATMENT", 6, 17], ["eggs", "TREATMENT", 19, 23], ["the chicken", "TEST", 86, 97], ["anti-IBV polyclonal serum", "TEST", 98, 123], ["IBV", "TEST", 128, 131], ["antibody", "TEST", 132, 140], ["free serum inoculated groups", "PROBLEM", 141, 169]]], ["A neutralization index was calculated from the EID50 value as: EID50 of chicken-anti-IBV polyclonal serum inoculated group/EID50 of IBV-antibody-free serum inoculated group.", [["serum", "ANATOMY", 100, 105], ["serum", "ANATOMY", 150, 155], ["chicken", "ORGANISM", 72, 79], ["IBV", "ORGANISM", 85, 88], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["IBV", "ORGANISM", 132, 135], ["serum", "ORGANISM_SUBSTANCE", 150, 155], ["EID50", "PROTEIN", 47, 52], ["EID50", "PROTEIN", 123, 128], ["chicken", "SPECIES", 72, 79], ["chicken", "SPECIES", 72, 79], ["IBV", "SPECIES", 85, 88], ["IBV", "SPECIES", 132, 135], ["A neutralization index", "TEST", 0, 22], ["chicken", "TREATMENT", 72, 79], ["anti-IBV polyclonal serum", "TEST", 80, 105], ["EID50", "TEST", 123, 128], ["IBV", "TEST", 132, 135], ["antibody", "TEST", 136, 144]]], ["A neutralization index greater than 50 was considered as Massachusetts serotype positive.Pathogenicity in chickens and peafowls ::: Materials and methodsThree groups of White Leghorn SPF chickens (n= 10) and three groups of IBV negative peafowls (n= 5) were housed in isolators.", [["peafowls", "ANATOMY", 237, 245], ["chickens", "ORGANISM", 106, 114], ["Leghorn SPF chickens", "ORGANISM", 175, 195], ["IBV", "ORGANISM", 224, 227], ["chickens", "SPECIES", 106, 114], ["Leghorn SPF chickens", "SPECIES", 175, 195], ["chickens", "SPECIES", 106, 114], ["White Leghorn SPF chickens", "SPECIES", 169, 195], ["IBV", "SPECIES", 224, 227], ["A neutralization index", "TEST", 0, 22], ["Massachusetts serotype positive", "PROBLEM", 57, 88], ["White Leghorn SPF chickens", "TREATMENT", 169, 195], ["IBV negative peafowls", "TREATMENT", 224, 245]]], ["At 7 days old, one group of chickens and peafowls were inoculated intranasally with 106 EID50 of the positive allantoic fluid, another group of chickens and peafowls were inoculated intranasally with 106 EID50 of M41 strain, respectively.", [["peafowls", "ANATOMY", 41, 49], ["intranasally", "ANATOMY", 66, 78], ["allantoic fluid", "ANATOMY", 110, 125], ["peafowls", "ANATOMY", 157, 165], ["intranasally", "ANATOMY", 182, 194], ["chickens", "ORGANISM", 28, 36], ["peafowls", "CELL", 41, 49], ["allantoic fluid", "ORGANISM_SUBSTANCE", 110, 125], ["chickens", "ORGANISM", 144, 152], ["chickens", "SPECIES", 28, 36], ["chickens", "SPECIES", 144, 152], ["chickens", "SPECIES", 28, 36], ["chickens", "SPECIES", 144, 152], ["peafowls", "TREATMENT", 41, 49], ["the positive allantoic fluid", "PROBLEM", 97, 125], ["allantoic fluid", "OBSERVATION", 110, 125]]], ["Some chickens and peafowls served as mock-infected controls with 0.1 ml of allantoic fluid from normal SPF eggs.", [["peafowls", "ANATOMY", 18, 26], ["allantoic fluid", "ANATOMY", 75, 90], ["eggs", "ANATOMY", 107, 111], ["chickens", "ORGANISM", 5, 13], ["peafowls", "CELL", 18, 26], ["controls", "ORGANISM", 51, 59], ["allantoic fluid", "ORGANISM_SUBSTANCE", 75, 90], ["chickens", "SPECIES", 5, 13], ["chickens", "SPECIES", 5, 13], ["Some chickens and peafowls", "PROBLEM", 0, 26], ["allantoic fluid", "PROBLEM", 75, 90], ["chickens", "OBSERVATION", 5, 13], ["SPF eggs", "OBSERVATION", 103, 111]]], ["Chickens and peafowls were examined daily for clinical signs for 14 days post-inoculation.", [["peafowls", "ANATOMY", 13, 21], ["Chickens", "ORGANISM", 0, 8], ["peafowls", "CELL", 13, 21], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Chickens and peafowls", "TREATMENT", 0, 21], ["clinical signs", "TEST", 46, 60]]], ["Necropsies were performed immediately after death and the infected birds were sacrificed by intravenous injection with barbiturate for examination of gross lesions.", [["intravenous", "ANATOMY", 92, 103], ["gross lesions", "ANATOMY", 150, 163], ["death", "DISEASE", 44, 49], ["barbiturate", "CHEMICAL", 119, 130], ["birds", "ORGANISM", 67, 72], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 103], ["barbiturate", "SIMPLE_CHEMICAL", 119, 130], ["gross lesions", "CANCER", 150, 163], ["Necropsies", "TEST", 0, 10], ["the infected birds", "TREATMENT", 54, 72], ["barbiturate", "TREATMENT", 119, 130], ["examination", "TEST", 135, 146], ["gross lesions", "PROBLEM", 150, 163], ["gross", "OBSERVATION_MODIFIER", 150, 155], ["lesions", "OBSERVATION", 156, 163]]], ["Lung, trachea, kidney and proventriculus were collected.", [["Lung", "ANATOMY", 0, 4], ["trachea", "ANATOMY", 6, 13], ["kidney", "ANATOMY", 15, 21], ["proventriculus", "ANATOMY", 26, 40], ["Lung", "ORGAN", 0, 4], ["trachea", "MULTI-TISSUE_STRUCTURE", 6, 13], ["kidney", "ORGAN", 15, 21], ["proventriculus", "ORGAN", 26, 40], ["trachea", "ANATOMY", 6, 13], ["kidney", "ANATOMY", 15, 21], ["proventriculus", "ANATOMY", 26, 40]]], ["These tissue samples were fixed with 10% neutral buffered formalin for 7 days.", [["tissue samples", "ANATOMY", 6, 20], ["formalin", "CHEMICAL", 58, 66], ["formalin", "CHEMICAL", 58, 66], ["tissue samples", "CANCER", 6, 20], ["formalin", "SIMPLE_CHEMICAL", 58, 66], ["These tissue samples", "TREATMENT", 0, 20], ["10% neutral buffered formalin", "TREATMENT", 37, 66]]], ["The fixed tissues were then cut into four pieces and immersed in 98% formic acid for 1 h before routine processing and paraffin wax embedding.", [["tissues", "ANATOMY", 10, 17], ["formic acid", "CHEMICAL", 69, 80], ["formic acid", "CHEMICAL", 69, 80], ["paraffin", "CHEMICAL", 119, 127], ["tissues", "TISSUE", 10, 17], ["formic acid", "SIMPLE_CHEMICAL", 69, 80], ["routine processing and paraffin wax embedding", "TREATMENT", 96, 141], ["fixed tissues", "OBSERVATION", 4, 17]]], ["Five-micrometer thick sections were cut and stained with hematoxylin and eosin for routine histopathological examination.Genome sequencing ::: Materials and methodsTwenty-nine pairs of primers (Table 1) were designed for the amplification, cloning, and sequencing of genomic segments of the peafowl coronavirus.", [["sections", "ANATOMY", 22, 30], ["hematoxylin", "CHEMICAL", 57, 68], ["eosin", "CHEMICAL", 73, 78], ["sections", "MULTI-TISSUE_STRUCTURE", 22, 30], ["hematoxylin", "SIMPLE_CHEMICAL", 57, 68], ["eosin", "SIMPLE_CHEMICAL", 73, 78], ["peafowl coronavirus", "ORGANISM", 291, 310], ["coronavirus", "SPECIES", 299, 310], ["peafowl coronavirus", "SPECIES", 291, 310], ["Five-micrometer thick sections", "TREATMENT", 0, 30], ["hematoxylin", "TREATMENT", 57, 68], ["routine histopathological examination", "TEST", 83, 120], ["the amplification", "TEST", 221, 238], ["the peafowl coronavirus", "PROBLEM", 287, 310], ["peafowl coronavirus", "ANATOMY", 291, 310]]], ["Reverse transcription-polymerase chain reaction (RT-PCR) was used to amplify the genomic segments.", [["genomic segments", "DNA", 81, 97], ["Reverse transcription", "TREATMENT", 0, 21], ["polymerase chain reaction", "PROBLEM", 22, 47], ["RT-PCR)", "TREATMENT", 49, 56], ["genomic segments", "OBSERVATION", 81, 97]]], ["Viral RNA was extracted from 200 \u03bcl of infectious allantoic fluid using Trizol reagents (GIBCO-BRL), then reverse transcription, 3\u2032-RACE and 5\u2032-RACE were performed.", [["allantoic fluid", "ANATOMY", 50, 65], ["Viral", "ORGANISM", 0, 5], ["allantoic fluid", "ORGANISM_SUBSTANCE", 50, 65], ["GIBCO-BRL", "CELL", 89, 98], ["Viral RNA", "RNA", 0, 9], ["reverse transcription, 3\u2032-RACE and 5\u2032-RACE", "DNA", 106, 148], ["Viral RNA", "PROBLEM", 0, 9], ["infectious allantoic fluid", "TREATMENT", 39, 65], ["Trizol reagents", "TREATMENT", 72, 87], ["GIBCO", "TEST", 89, 94], ["RNA", "OBSERVATION", 6, 9], ["infectious", "OBSERVATION_MODIFIER", 39, 49], ["allantoic fluid", "OBSERVATION", 50, 65]]], ["PCR products were excised from 1.0% agarose gels, and purified using the gel extraction kit (Omega Bio-tek, USA).", [["PCR products", "TREATMENT", 0, 12], ["1.0% agarose gels", "TREATMENT", 31, 48], ["the gel extraction", "TREATMENT", 69, 87]]], ["The purified PCR products were cloned into the pMD18-T Vector (TaKaRa).", [["pMD18-T Vector", "GENE_OR_GENE_PRODUCT", 47, 61], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 63, 69], ["pMD18", "PROTEIN", 47, 52], ["T Vector", "PROTEIN", 53, 61], ["The purified PCR products", "TREATMENT", 0, 25]]], ["Plasmid DNA for sequencing was prepared with the plasmid mini kit (Omega Bio-tek).", [["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["Plasmid DNA", "DNA", 0, 11], ["Plasmid DNA", "TREATMENT", 0, 11], ["the plasmid mini kit (Omega Bio-tek)", "TREATMENT", 45, 81]]], ["Sequencing of three independent clones of each PCR product was performed in order to eliminate errors resulting from the RT-PCR or cloning steps.", [["each PCR product", "TEST", 42, 58], ["the RT-PCR", "TEST", 117, 127]]], ["Genomic segments were sequenced by Shanghai BioAsia Biological Technology Co., Ltd.Nucleotide sequence accession numbers ::: Materials and methodsThe GenBank accession number of the sequence reported in this paper is AY641576.Sequence analysis ::: Materials and methodsThe sequence lengths of the whole genome, 5\u2032-UTR, 3\u2032-UTR and protein1ab, S, 3a, 3b, E, M, 5a, 5b and N of the peafowl isolate were compared with those of other avian coronavirus isolates available in the GenBank database.", [["AY641576", "CHEMICAL", 217, 225], ["AY641576", "CHEMICAL", 217, 225], ["AY641576", "SIMPLE_CHEMICAL", 217, 225], ["protein1ab", "GENE_OR_GENE_PRODUCT", 330, 340], ["E", "GENE_OR_GENE_PRODUCT", 353, 354], ["5", "ORGANISM", 363, 364], ["b", "GENE_OR_GENE_PRODUCT", 364, 365], ["avian coronavirus", "ORGANISM", 429, 446], ["5\u2032-UTR, 3\u2032-UTR", "DNA", 311, 325], ["protein1ab", "DNA", 330, 340], ["avian coronavirus", "SPECIES", 429, 446], ["avian coronavirus", "SPECIES", 429, 446], ["Sequence analysis", "TEST", 226, 243], ["the whole genome", "TEST", 293, 309], ["UTR", "TEST", 314, 317], ["protein1ab", "TEST", 330, 340], ["the peafowl isolate", "TEST", 375, 394], ["other avian coronavirus isolates", "PROBLEM", 423, 455], ["segments", "ANATOMY_MODIFIER", 8, 16]]], ["These viruses include the partridge IBV strain partridge/GD/S14/2003 (S14, AY646283), the peafowl IBV strain Peafowl/China/LKQ3/2003 (LKQ3, AY702085), and the avian IBV strains M41 (AY851295), Beaudette (NC_001451) and BJ (AY319651).Sequence analysis ::: Materials and methodsThe nucleotide and amino acid sequences of three main structural protein genes S1, M and N of the peafowl IBV were compared with those of LKQ3 and reference avian IBV strains with MegAlign software (DNAStar 5.01).", [["nucleotide", "CHEMICAL", 280, 290], ["amino acid", "CHEMICAL", 295, 305], ["nucleotide", "CHEMICAL", 280, 290], ["amino acid", "CHEMICAL", 295, 305], ["partridge IBV", "ORGANISM", 26, 39], ["peafowl IBV", "ORGANISM", 90, 101], ["avian IBV", "ORGANISM", 159, 168], ["amino acid", "AMINO_ACID", 295, 305], ["peafowl IBV", "ORGANISM", 374, 385], ["LKQ3", "GENE_OR_GENE_PRODUCT", 414, 418], ["IBV", "ORGANISM", 439, 442], ["avian IBV", "SPECIES", 159, 168], ["IBV strain partridge/GD/S14/2003", "SPECIES", 36, 68], ["peafowl IBV strain Peafowl/China/LKQ3/2003", "SPECIES", 90, 132], ["peafowl IBV", "SPECIES", 374, 385], ["IBV", "SPECIES", 439, 442], ["These viruses", "PROBLEM", 0, 13], ["Sequence analysis", "TEST", 233, 250], ["The nucleotide and amino acid sequences", "TEST", 276, 315], ["the peafowl IBV", "TREATMENT", 370, 385], ["LKQ3", "TREATMENT", 414, 418], ["viruses", "OBSERVATION", 6, 13], ["protein genes", "OBSERVATION", 341, 354]]], ["Four types of IBVs (respiratory, respiratory mutant, nephrogenic and proventriculous) were selected for reference strains.", [["IBVs", "ANATOMY", 14, 18], ["respiratory", "ANATOMY", 20, 31], ["respiratory, respiratory mutant, nephrogenic and proventriculous)", "DISEASE", 20, 85], ["IBVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["IBVs", "TREATMENT", 14, 18], ["nephrogenic and proventriculous)", "PROBLEM", 53, 85], ["IBVs", "OBSERVATION", 14, 18], ["respiratory", "ANATOMY", 20, 31]]], ["These reference strains were IBVs isolated from chickens in China and two M41 serotype IBV vaccine strains, M41 and H120, which had been widely used to control avian infectious bronchitis for many years in China.", [["M41", "CHEMICAL", 108, 111], ["H120", "CHEMICAL", 116, 120], ["avian infectious bronchitis", "DISEASE", 160, 187], ["IBVs", "ORGANISM", 29, 33], ["chickens", "ORGANISM", 48, 56], ["M41 serotype IBV", "ORGANISM", 74, 90], ["chickens", "SPECIES", 48, 56], ["M41 serotype IBV", "SPECIES", 74, 90], ["avian", "SPECIES", 160, 165], ["chickens", "SPECIES", 48, 56], ["IBV", "SPECIES", 87, 90], ["IBVs", "PROBLEM", 29, 33], ["two M41 serotype IBV vaccine strains", "TREATMENT", 70, 106], ["H120", "TREATMENT", 116, 120], ["avian infectious bronchitis", "PROBLEM", 160, 187], ["infectious", "OBSERVATION_MODIFIER", 166, 176], ["bronchitis", "OBSERVATION", 177, 187]]], ["The sequences of reference IBV strains were obtained from GenBank.Sequence analysis ::: Materials and methodsTo reveal the relationships between the peafowl isolate and other coronaviruses at the molecular level, the whole genome nucleotide sequences were compared with those of representative animals and human coronaviruses available in the GenBank database, including BCoV (bovine coronavirus, NC_003045), HCoV-229E (human coronavirus 229E, NC_002645), IBV (infectious bronchitis virus M41, AY851295), MHV (murine hepatitis virus strain A59, NC_001846), PEDV (porcine epidemic diarrhea virus, NC_003436), TGEV (transmissible gastroenteritis virus, NC_002306) and SARS-CoV (severe acute respiratory syndrome coronavirus, NC_004718).", [["infectious bronchitis virus", "DISEASE", 461, 488], ["AY851295", "CHEMICAL", 494, 502], ["murine hepatitis virus", "DISEASE", 510, 532], ["NC_001846", "CHEMICAL", 545, 554], ["porcine epidemic diarrhea", "DISEASE", 563, 588], ["NC_003436", "CHEMICAL", 596, 605], ["transmissible gastroenteritis", "DISEASE", 614, 643], ["NC_002306", "CHEMICAL", 651, 660], ["SARS-CoV", "DISEASE", 666, 674], ["acute respiratory syndrome coronavirus", "DISEASE", 683, 721], ["IBV", "ORGANISM", 27, 30], ["human", "ORGANISM", 306, 311], ["BCoV", "GENE_OR_GENE_PRODUCT", 371, 375], ["bovine coronavirus", "ORGANISM", 377, 395], ["NC_003045", "ORGANISM", 397, 406], ["HCoV-229E", "ORGANISM", 409, 418], ["human coronavirus 229E", "ORGANISM", 420, 442], ["NC_002645", "ORGANISM", 444, 453], ["IBV (infectious bronchitis virus M41", "ORGANISM", 456, 492], ["AY851295", "ORGANISM", 494, 502], ["MHV", "ORGANISM", 505, 508], ["murine hepatitis virus strain A59", "ORGANISM", 510, 543], ["NC_001846", "ORGANISM", 545, 554], ["PEDV (", "ORGANISM", 557, 563], ["porcine epidemic diarrhea virus", "ORGANISM", 563, 594], ["NC_003436", "ORGANISM", 596, 605], ["TGEV (transmissible gastroenteritis virus", "ORGANISM", 608, 649], ["NC_002306", "ORGANISM", 651, 660], ["SARS-CoV", "ORGANISM", 666, 674], ["human", "SPECIES", 306, 311], ["bovine", "SPECIES", 377, 383], ["human", "SPECIES", 420, 425], ["coronavirus", "SPECIES", 426, 437], ["IBV", "SPECIES", 456, 459], ["infectious bronchitis virus", "SPECIES", 461, 488], ["MHV", "SPECIES", 505, 508], ["murine", "SPECIES", 510, 516], ["hepatitis virus", "SPECIES", 517, 532], ["porcine epidemic diarrhea virus", "SPECIES", 563, 594], ["TGEV", "SPECIES", 608, 612], ["transmissible gastroenteritis virus", "SPECIES", 614, 649], ["IBV", "SPECIES", 27, 30], ["human coronaviruses", "SPECIES", 306, 325], ["BCoV", "SPECIES", 371, 375], ["bovine coronavirus", "SPECIES", 377, 395], ["HCoV-229E", "SPECIES", 409, 418], ["human coronavirus 229E, NC_002645)", "SPECIES", 420, 454], ["IBV", "SPECIES", 456, 459], ["infectious bronchitis virus M41", "SPECIES", 461, 492], ["MHV", "SPECIES", 505, 508], ["murine hepatitis virus strain A59", "SPECIES", 510, 543], ["PEDV", "SPECIES", 557, 561], ["porcine epidemic diarrhea virus", "SPECIES", 563, 594], ["TGEV", "SPECIES", 608, 612], ["transmissible gastroenteritis virus", "SPECIES", 614, 649], ["SARS-CoV (severe acute respiratory syndrome coronavirus", "SPECIES", 666, 721], ["reference IBV strains", "TEST", 17, 38], ["Sequence analysis", "TEST", 66, 83], ["other coronaviruses", "PROBLEM", 169, 188], ["the whole genome nucleotide sequences", "TEST", 213, 250], ["human coronaviruses", "PROBLEM", 306, 325], ["the GenBank database", "TEST", 339, 359], ["BCoV", "TEST", 371, 375], ["bovine coronavirus", "TEST", 377, 395], ["NC", "TEST", 397, 399], ["HCoV", "TEST", 409, 413], ["human coronavirus", "TEST", 420, 437], ["NC", "TEST", 444, 446], ["IBV (infectious bronchitis virus", "PROBLEM", 456, 488], ["AY", "TEST", 494, 496], ["MHV", "TEST", 505, 508], ["murine hepatitis virus strain", "TEST", 510, 539], ["NC", "TEST", 545, 547], ["PEDV (porcine epidemic diarrhea virus", "PROBLEM", 557, 594], ["NC", "TEST", 596, 598], ["TGEV (transmissible gastroenteritis virus", "PROBLEM", 608, 649], ["NC", "TEST", 651, 653], ["SARS", "PROBLEM", 666, 670], ["CoV (severe acute respiratory syndrome coronavirus", "PROBLEM", 671, 721], ["MHV", "ANATOMY", 505, 508], ["severe", "OBSERVATION_MODIFIER", 676, 682], ["acute", "OBSERVATION_MODIFIER", 683, 688], ["respiratory syndrome", "OBSERVATION", 689, 709]]], ["The radialized phylogenetic tree was drawn with the MEGA 3.1 program by using neighbor-joining analysis.Serological survey ::: Materials and methodsSince IBV was isolated from peafowls, it would be possible that peafowls could carry anti-IBV antibodies.", [["IBV", "ORGANISM", 154, 157], ["peafowls", "CANCER", 212, 220], ["anti-IBV antibodies", "GENE_OR_GENE_PRODUCT", 233, 252], ["anti-IBV antibodies", "PROTEIN", 233, 252], ["IBV", "SPECIES", 154, 157], ["anti-IBV", "SPECIES", 233, 241], ["neighbor-joining analysis", "TEST", 78, 103], ["IBV", "PROBLEM", 154, 157], ["anti-IBV antibodies", "PROBLEM", 233, 252], ["tree", "ANATOMY_MODIFIER", 28, 32]]], ["To investigate into the IBV infections in peafowls, we examined the serum samples collected from the wild peafowls in 2003 for the presence of anti-IBV antibodies using an ELISA kit per manufacturer's instruction (IDEXX, Spain).A novel IBV strain from peafowls was biologically characterized ::: ResultsOnly 1 sample from 351 laryngotracheal swabs was coronavirus positive and confirmed as IBV rather than SARS virus.", [["serum samples", "ANATOMY", 68, 81], ["laryngotracheal swabs", "ANATOMY", 326, 347], ["IBV infections", "DISEASE", 24, 38], ["SARS", "DISEASE", 406, 410], ["IBV", "ORGANISM", 24, 27], ["peafowls", "CANCER", 42, 50], ["serum samples", "ORGANISM_SUBSTANCE", 68, 81], ["IBV", "ORGANISM", 236, 239], ["peafowls", "CANCER", 252, 260], ["laryngotracheal swabs", "ORGAN", 326, 347], ["coronavirus", "ORGANISM", 352, 363], ["IBV", "ORGANISM", 390, 393], ["anti-IBV antibodies", "PROTEIN", 143, 162], ["IBV", "SPECIES", 24, 27], ["anti-IBV", "SPECIES", 143, 151], ["IBV", "SPECIES", 236, 239], ["IBV", "SPECIES", 390, 393], ["SARS virus", "SPECIES", 406, 416], ["the IBV infections in peafowls", "PROBLEM", 20, 50], ["the serum samples", "TEST", 64, 81], ["anti-IBV antibodies", "TREATMENT", 143, 162], ["A novel IBV strain", "PROBLEM", 228, 246], ["laryngotracheal swabs", "TEST", 326, 347], ["coronavirus positive", "PROBLEM", 352, 372], ["IBV", "PROBLEM", 390, 393], ["SARS virus", "PROBLEM", 406, 416], ["infections", "OBSERVATION", 28, 38], ["IBV strain", "OBSERVATION", 236, 246], ["laryngotracheal", "ANATOMY", 326, 341]]], ["No specific PCR products were detected from the rest of examined samples.", [["samples", "ANATOMY", 65, 72], ["PCR products", "DNA", 12, 24], ["specific PCR products", "PROBLEM", 3, 24], ["PCR products", "OBSERVATION", 12, 24]]], ["This isolate from peafowl was named as Peafowl/GD/KQ6/2003 (KQ6).", [["Peafowl/GD/KQ6/2003 (KQ6", "SPECIES", 39, 63]]], ["For further understanding of KQ6 strain, biological characteristics of KQ6 were determined systematically.", [["KQ6", "GENE_OR_GENE_PRODUCT", 29, 32], ["KQ6", "GENE_OR_GENE_PRODUCT", 71, 74], ["KQ6", "DNA", 71, 74], ["KQ6 strain", "PROBLEM", 29, 39], ["KQ6", "TREATMENT", 71, 74]]], ["In the HA test, the HA titer of KQ6 was greater than 64, whereas no detectable HA titer was observed in the non-treated control samples, which indicated that trypsinized virus was able to hemaglutinate chicken red blood cells as observed in many other strains of IBVs.", [["samples", "ANATOMY", 128, 135], ["red blood cells", "ANATOMY", 210, 225], ["IBVs", "ANATOMY", 263, 267], ["IBVs", "DISEASE", 263, 267], ["KQ6", "GENE_OR_GENE_PRODUCT", 32, 35], ["HA", "GENE_OR_GENE_PRODUCT", 79, 81], ["chicken", "ORGANISM", 202, 209], ["red blood cells", "CELL", 210, 225], ["IBVs", "CANCER", 263, 267], ["KQ6", "PROTEIN", 32, 35], ["chicken red blood cells", "CELL_TYPE", 202, 225], ["chicken", "SPECIES", 202, 209], ["chicken", "SPECIES", 202, 209], ["the HA test", "TEST", 3, 14], ["the HA titer of KQ6", "TEST", 16, 35], ["detectable HA titer", "PROBLEM", 68, 87], ["trypsinized virus", "PROBLEM", 158, 175], ["red blood cells", "TEST", 210, 225], ["IBVs", "TREATMENT", 263, 267]]], ["In the embryo infection test, all of the embryos showed dwarfism post-infection with the peafowl isolate, losing at least 2 g of body weight compared with the negative controls.", [["embryo", "ANATOMY", 7, 13], ["embryos", "ANATOMY", 41, 48], ["body", "ANATOMY", 129, 133], ["embryo infection", "DISEASE", 7, 23], ["dwarfism", "DISEASE", 56, 64], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 7, 13], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 41, 48], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["the embryo infection test", "TEST", 3, 28], ["dwarfism post-infection", "PROBLEM", 56, 79], ["the peafowl isolate", "TREATMENT", 85, 104], ["body weight", "TEST", 129, 140], ["infection", "OBSERVATION", 14, 23], ["dwarfism post-infection", "OBSERVATION", 56, 79]]], ["This observation clearly demonstrated that KQ6 was able to inhibit the growth of chicken embryos as many other IBV strains did.", [["embryos", "ANATOMY", 89, 96], ["KQ6", "CHEMICAL", 43, 46], ["KQ6", "GENE_OR_GENE_PRODUCT", 43, 46], ["chicken", "ORGANISM", 81, 88], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 89, 96], ["IBV", "ORGANISM", 111, 114], ["KQ6", "PROTEIN", 43, 46], ["chicken", "SPECIES", 81, 88], ["chicken", "SPECIES", 81, 88], ["IBV", "SPECIES", 111, 114], ["chicken embryos", "TREATMENT", 81, 96], ["many other IBV strains", "PROBLEM", 100, 122]]], ["To further characterize the isolate, the virus interference test was performed.", [["the virus interference test", "TEST", 37, 64]]], ["It was found that the reciprocal HA titers of KQ6 + NDV B1 infected eggs were lower than 20, while those infected with NDV B1 only were greater than 256 and no HA titers in PBS inoculated controls, which clearly demonstrated the interference of the isolate to the growth of NDV.", [["eggs", "ANATOMY", 68, 72], ["HA", "GENE_OR_GENE_PRODUCT", 33, 35], ["KQ6 + NDV B1", "ORGANISM", 46, 58], ["eggs", "ORGANISM", 68, 72], ["NDV B1", "ORGANISM", 119, 125], ["NDV", "ORGANISM", 274, 277], ["KQ6", "PROTEIN", 46, 49], ["NDV", "SPECIES", 52, 55], ["NDV", "SPECIES", 119, 122], ["NDV", "SPECIES", 52, 55], ["NDV", "SPECIES", 119, 122], ["NDV", "SPECIES", 274, 277], ["the reciprocal HA titers", "TEST", 18, 42], ["KQ6", "TEST", 46, 49], ["NDV B1 infected eggs", "PROBLEM", 52, 72], ["NDV B1", "TEST", 119, 125], ["HA titers", "PROBLEM", 160, 169], ["NDV", "PROBLEM", 274, 277], ["infected", "OBSERVATION", 105, 113], ["growth", "OBSERVATION_MODIFIER", 264, 270], ["NDV", "OBSERVATION", 274, 277]]], ["Moreover, we performed the neutralization test for further identification of the isolate.", [["the neutralization test", "TEST", 23, 46]]], ["It was found that the EID50 of chicken-anti-IBV serum-treated group was 10\u22122.7, while the EID50 of IBV-antibody-free serum-treated group was 10\u22124.5, giving out the neutralization index of 63.09.", [["serum", "ANATOMY", 48, 53], ["serum", "ANATOMY", 117, 122], ["chicken", "ORGANISM", 31, 38], ["IBV", "ORGANISM", 44, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["IBV", "ORGANISM", 99, 102], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["EID50", "PROTEIN", 22, 27], ["chicken", "SPECIES", 31, 38], ["chicken", "SPECIES", 31, 38], ["IBV", "SPECIES", 44, 47], ["IBV", "SPECIES", 99, 102], ["chicken", "TEST", 31, 38], ["anti-IBV serum", "TEST", 39, 53], ["the EID50", "TEST", 86, 95], ["IBV", "TEST", 99, 102], ["antibody", "TEST", 103, 111], ["free serum", "TEST", 112, 122], ["the neutralization index", "TEST", 160, 184]]], ["It indicated that the peafowl isolate KQ6 was Massachusetts serotype.", [["the peafowl isolate KQ6", "TREATMENT", 18, 41]]], ["These results showed that no SARS-like coronavirus had been isolated but a novel IBV strain with the typical biological characteristics was identified from peafowls.IBV isolated from peafowl was pathogenic to chickens ::: ResultsClinical signs were observed in all KQ6 and M41 infected chickens 5\u201314 days post-infection.", [["SARS-like coronavirus", "DISEASE", 29, 50], ["SARS-like coronavirus", "ORGANISM", 29, 50], ["IBV", "ORGANISM", 81, 84], ["IBV", "ORGANISM", 165, 168], ["chickens", "ORGANISM", 209, 217], ["chickens", "ORGANISM", 286, 294], ["chickens", "SPECIES", 209, 217], ["chickens", "SPECIES", 286, 294], ["IBV", "SPECIES", 81, 84], ["IBV", "SPECIES", 165, 168], ["chickens", "SPECIES", 209, 217], ["chickens", "SPECIES", 286, 294], ["SARS", "PROBLEM", 29, 33], ["coronavirus", "PROBLEM", 39, 50], ["a novel IBV strain", "PROBLEM", 73, 91], ["IBV", "PROBLEM", 165, 168], ["ResultsClinical signs", "TEST", 222, 243], ["coronavirus", "OBSERVATION", 39, 50]]], ["These clinical signs included listlessness, huddling, dark shrunken combs and ruffled feathers.", [["listlessness", "DISEASE", 30, 42], ["These clinical signs", "TEST", 0, 20], ["listlessness", "PROBLEM", 30, 42], ["huddling", "PROBLEM", 44, 52], ["dark shrunken combs", "PROBLEM", 54, 73], ["ruffled feathers", "PROBLEM", 78, 94], ["dark", "OBSERVATION", 54, 58], ["shrunken combs", "OBSERVATION", 59, 73], ["ruffled feathers", "OBSERVATION", 78, 94]]], ["During the experiment, 3 of 10 chickens in M41 infected group died, however all chickens in KQ6 infected group survived.", [["chickens", "ORGANISM", 31, 39], ["chickens", "ORGANISM", 80, 88], ["chickens", "SPECIES", 31, 39], ["chickens", "SPECIES", 80, 88], ["chickens", "SPECIES", 31, 39], ["chickens", "SPECIES", 80, 88]]], ["Gross lesions in the organs of the dead M41 infected chickens were primarily confined to the lungs with haemorrhagic changes.", [["Gross lesions", "ANATOMY", 0, 13], ["organs", "ANATOMY", 21, 27], ["lungs", "ANATOMY", 93, 98], ["haemorrhagic", "DISEASE", 104, 116], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["organs", "ORGAN", 21, 27], ["chickens", "ORGANISM", 53, 61], ["lungs", "ORGAN", 93, 98], ["chickens", "SPECIES", 53, 61], ["chickens", "SPECIES", 53, 61], ["Gross lesions", "PROBLEM", 0, 13], ["the dead M41 infected chickens", "PROBLEM", 31, 61], ["haemorrhagic changes", "PROBLEM", 104, 124], ["lesions", "OBSERVATION", 6, 13], ["organs", "ANATOMY", 21, 27], ["lungs", "ANATOMY", 93, 98], ["haemorrhagic", "OBSERVATION", 104, 116]]], ["Microscopic examination demonstrated that there were severe haemorrhagic changes, epithelium degeneration and lymphocyte infiltration in the lungs of some M41 infected chickens, while the similar pathological changes were observed in both lungs and kidneys from some KQ6 infected chickens (Fig. 1).", [["epithelium", "ANATOMY", 82, 92], ["lymphocyte", "ANATOMY", 110, 120], ["lungs", "ANATOMY", 141, 146], ["lungs", "ANATOMY", 239, 244], ["kidneys", "ANATOMY", 249, 256], ["epithelium", "TISSUE", 82, 92], ["lymphocyte", "CELL", 110, 120], ["lungs", "ORGAN", 141, 146], ["chickens", "ORGANISM", 168, 176], ["lungs", "ORGAN", 239, 244], ["kidneys", "ORGAN", 249, 256], ["chickens", "ORGANISM", 280, 288], ["chickens", "SPECIES", 168, 176], ["chickens", "SPECIES", 280, 288], ["chickens", "SPECIES", 168, 176], ["chickens", "SPECIES", 280, 288], ["Microscopic examination", "TEST", 0, 23], ["severe haemorrhagic changes", "PROBLEM", 53, 80], ["epithelium degeneration", "PROBLEM", 82, 105], ["lymphocyte infiltration in the lungs", "PROBLEM", 110, 146], ["some M41 infected chickens", "PROBLEM", 150, 176], ["some KQ6 infected chickens", "PROBLEM", 262, 288], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["haemorrhagic", "OBSERVATION", 60, 72], ["epithelium degeneration", "OBSERVATION", 82, 105], ["lymphocyte infiltration", "OBSERVATION", 110, 133], ["lungs", "ANATOMY", 141, 146], ["some", "OBSERVATION_MODIFIER", 150, 154], ["M41", "OBSERVATION_MODIFIER", 155, 158], ["infected", "OBSERVATION_MODIFIER", 159, 167], ["chickens", "OBSERVATION", 168, 176], ["similar", "OBSERVATION_MODIFIER", 188, 195], ["pathological", "OBSERVATION", 196, 208], ["both", "ANATOMY_MODIFIER", 234, 238], ["lungs", "ANATOMY", 239, 244], ["kidneys", "ANATOMY", 249, 256], ["infected", "OBSERVATION_MODIFIER", 271, 279], ["chickens", "OBSERVATION", 280, 288]]], ["In contrast, mock-infected chickens showed no significant changes in the lung, kidney, trachea and proventriculus when examined microscopically.IBV could be carried in peafowls causing no clinical sign ::: ResultsELISA kit (IDEXX) was used to measure the titers of anti-IBV antibodies from the peafowl serum in nature infection.", [["lung", "ANATOMY", 73, 77], ["kidney", "ANATOMY", 79, 85], ["trachea", "ANATOMY", 87, 94], ["proventriculus", "ANATOMY", 99, 113], ["serum", "ANATOMY", 302, 307], ["infection", "DISEASE", 318, 327], ["chickens", "ORGANISM", 27, 35], ["lung", "ORGAN", 73, 77], ["kidney", "ORGAN", 79, 85], ["trachea", "MULTI-TISSUE_STRUCTURE", 87, 94], ["proventriculus", "ORGAN", 99, 113], ["IBV", "ORGANISM", 144, 147], ["anti-IBV antibodies", "GENE_OR_GENE_PRODUCT", 265, 284], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["anti-IBV antibodies", "PROTEIN", 265, 284], ["chickens", "SPECIES", 27, 35], ["chickens", "SPECIES", 27, 35], ["IBV", "SPECIES", 144, 147], ["anti-IBV", "SPECIES", 265, 273], ["significant changes in the lung, kidney, trachea and proventriculus", "PROBLEM", 46, 113], ["IBV", "TREATMENT", 144, 147], ["anti-IBV antibodies", "PROBLEM", 265, 284], ["the peafowl serum in nature infection", "PROBLEM", 290, 327], ["no", "UNCERTAINTY", 43, 45], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["changes", "OBSERVATION", 58, 65], ["lung", "ANATOMY", 73, 77], ["kidney", "ANATOMY", 79, 85], ["trachea", "ANATOMY", 87, 94], ["proventriculus", "ANATOMY", 99, 113], ["infection", "OBSERVATION", 318, 327]]], ["It was found that 17 out of 54 serum samples were anti-IBV positive (ELISA titer \u2265 227), which indicated that about one-third (31.48%) of peafowls carried IBV in Guangdong province.IBV could be carried in peafowls causing no clinical sign ::: ResultsExperimental infection was performed to evaluate the virulence of KQ6 in IBV negative peafowl.", [["serum samples", "ANATOMY", 31, 44], ["infection", "DISEASE", 263, 272], ["KQ6", "CHEMICAL", 316, 319], ["serum samples", "ORGANISM_SUBSTANCE", 31, 44], ["anti-IBV", "GENE_OR_GENE_PRODUCT", 50, 58], ["peafowls", "ORGANISM", 138, 146], ["IBV", "ORGANISM", 155, 158], ["IBV", "ORGANISM", 181, 184], ["KQ6", "GENE_OR_GENE_PRODUCT", 316, 319], ["IBV", "ORGANISM", 323, 326], ["KQ6", "DNA", 316, 319], ["anti-IBV", "SPECIES", 50, 58], ["IBV", "SPECIES", 155, 158], ["IBV", "SPECIES", 181, 184], ["IBV", "SPECIES", 323, 326], ["serum samples", "TEST", 31, 44], ["anti-IBV", "TEST", 50, 58], ["ELISA titer", "TEST", 69, 80], ["IBV", "TREATMENT", 181, 184], ["ResultsExperimental infection", "PROBLEM", 243, 272], ["infection", "OBSERVATION", 263, 272]]], ["Interestingly, no peafowls inoculated with KQ6 or M41 strain displayed clinical signs and lesions, while the specific antibodies could be detected post-infection (data not shown).Genome characterization ::: ResultsThe genome of KQ6 was 27,434 bp in length, including the poly-(A) tail.", [["lesions", "ANATOMY", 90, 97], ["KQ6", "GENE_OR_GENE_PRODUCT", 43, 46], ["lesions", "PATHOLOGICAL_FORMATION", 90, 97], ["KQ6", "GENE_OR_GENE_PRODUCT", 228, 231], ["KQ6", "DNA", 228, 231], ["poly-(A) tail", "DNA", 271, 284], ["peafowls", "PROBLEM", 18, 26], ["KQ6", "TEST", 43, 46], ["M41 strain", "PROBLEM", 50, 60], ["clinical signs", "PROBLEM", 71, 85], ["lesions", "PROBLEM", 90, 97], ["the specific antibodies", "TEST", 105, 128], ["KQ6", "TEST", 228, 231], ["bp in length", "TEST", 243, 255], ["no", "UNCERTAINTY", 15, 17], ["lesions", "OBSERVATION", 90, 97], ["tail", "ANATOMY", 280, 284]]], ["As many IBVs, gene 1 of KQ6 accounted for approximately two-third of the genome.", [["IBVs", "GENE_OR_GENE_PRODUCT", 8, 12], ["KQ6", "GENE_OR_GENE_PRODUCT", 24, 27], ["IBVs", "DNA", 8, 12], ["gene 1", "DNA", 14, 20], ["KQ6", "DNA", 24, 27], ["KQ6", "TREATMENT", 24, 27]]], ["KQ6 also had four structural protein genes (S, E, M, and N) and two genes encoding four non-structural proteins (3a and 3b, 5a and 5b).", [["KQ6", "GENE_OR_GENE_PRODUCT", 0, 3], ["b", "GENE_OR_GENE_PRODUCT", 132, 133], ["KQ6", "DNA", 0, 3], ["structural protein genes", "DNA", 18, 42], ["S", "DNA", 44, 45], ["E", "DNA", 47, 48], ["N", "DNA", 57, 58], ["non-structural proteins", "PROTEIN", 88, 111], ["3a and 3b, 5a and 5b", "PROTEIN", 113, 133], ["four structural protein genes", "PROBLEM", 13, 42], ["non-structural proteins", "TEST", 88, 111], ["protein genes", "OBSERVATION", 29, 42]]], ["Its genome organization was 5\u2032-Gene1-S-3a-3b-E-M-5a-5b-N-3\u2032, which was typical for IBV.", [["5\u2032-Gene1-S-3a-3b-E-M-5a-5b-N-3\u2032", "CHEMICAL", 28, 59], ["IBV", "ORGANISM", 83, 86], ["Gene1", "DNA", 31, 36], ["S", "DNA", 37, 38], ["3a-3b", "DNA", 39, 44], ["E", "DNA", 45, 46], ["5a-5b", "DNA", 49, 54], ["N", "DNA", 55, 56], ["3\u2032", "DNA", 57, 59], ["IBV", "SPECIES", 83, 86], ["Its genome organization", "TEST", 0, 23], ["IBV", "PROBLEM", 83, 86], ["IBV", "OBSERVATION", 83, 86]]], ["As shown in Table 2, there was a great diversity in the genome of different avian coronavirus strains in terms of the genome size (27,434\u201327,733 bp), 5\u2032-UTR size (330\u2013529 bp) and 3\u2032-UTR size (322\u2013521 bp), as well as the amino acid numbers of protein 1ab (6610\u20136641 amino acids), S (1153\u20131169 amino acids), 3b (62\u201364 amino acids), E (108\u2013109 amino acids), M (225\u2013226 amino acids) and 5b (81\u201382 amino acids).", [["amino acid", "CHEMICAL", 220, 230], ["amino acids", "CHEMICAL", 265, 276], ["amino acids", "CHEMICAL", 393, 404], ["amino acid", "CHEMICAL", 220, 230], ["amino acids", "CHEMICAL", 265, 276], ["amino acids", "CHEMICAL", 292, 303], ["amino acids", "CHEMICAL", 316, 327], ["amino acids", "CHEMICAL", 341, 352], ["amino acids", "CHEMICAL", 366, 377], ["amino acids", "CHEMICAL", 393, 404], ["avian coronavirus", "ORGANISM", 76, 93], ["amino acid", "AMINO_ACID", 220, 230], ["1ab", "GENE_OR_GENE_PRODUCT", 250, 253], ["amino acids", "AMINO_ACID", 265, 276], ["amino acids", "AMINO_ACID", 292, 303], ["amino acids", "AMINO_ACID", 316, 327], ["amino acids", "AMINO_ACID", 341, 352], ["amino acids", "AMINO_ACID", 366, 377], ["amino acids", "AMINO_ACID", 393, 404], ["protein 1ab", "PROTEIN", 242, 253], ["E", "PROTEIN", 330, 331], ["avian coronavirus", "SPECIES", 76, 93], ["avian coronavirus", "SPECIES", 76, 93], ["different avian coronavirus strains", "PROBLEM", 66, 101], ["bp", "TEST", 145, 147], ["UTR size", "TEST", 153, 161], ["bp", "TEST", 171, 173], ["3\u2032", "TEST", 179, 181], ["UTR size", "TEST", 182, 190], ["bp", "TEST", 200, 202], ["the amino acid numbers", "TEST", 216, 238], ["protein", "TEST", 242, 249], ["amino acids", "TEST", 265, 276], ["S", "TEST", 279, 280], ["amino acids", "TEST", 292, 303], ["amino acids", "TEST", 316, 327], ["E", "TEST", 330, 331], ["amino acids", "TEST", 341, 352], ["amino acids", "TEST", 366, 377], ["5b", "TEST", 383, 385], ["amino acids", "TEST", 393, 404], ["great", "OBSERVATION_MODIFIER", 33, 38], ["diversity", "OBSERVATION", 39, 48], ["coronavirus strains", "OBSERVATION", 82, 101], ["size", "OBSERVATION_MODIFIER", 125, 129], ["size", "OBSERVATION_MODIFIER", 157, 161], ["size", "OBSERVATION_MODIFIER", 186, 190]]], ["However, the amino acid numbers of protein 3a, 5a and N were invariable.Genome characterization ::: ResultsThe S1 subunit was identified as the major target of neutralizing antibodies and as the determinant gene altering cell tropism (Casais et al., 2003, Cavanagh et al., 1988, Ignjatovic and Galli, 1994).", [["cell", "ANATOMY", 221, 225], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["protein 3a", "GENE_OR_GENE_PRODUCT", 35, 45], ["S1", "GENE_OR_GENE_PRODUCT", 111, 113], ["cell", "CELL", 221, 225], ["protein 3a, 5a and N", "PROTEIN", 35, 55], ["S1 subunit", "PROTEIN", 111, 121], ["neutralizing antibodies", "PROTEIN", 160, 183], ["the amino acid numbers", "TEST", 9, 31], ["protein", "TEST", 35, 42], ["neutralizing antibodies", "PROBLEM", 160, 183], ["neutralizing antibodies", "OBSERVATION", 160, 183], ["cell tropism", "OBSERVATION", 221, 233], ["Galli", "ANATOMY", 294, 299]]], ["The S1 gene of KQ6 strain was 1611 bp in length with a G + C percentage of 35.88%, encoding 537 amino acids that contain 18 potential N-glycosylation sites.", [["amino acids", "CHEMICAL", 96, 107], ["amino acids", "CHEMICAL", 96, 107], ["N", "CHEMICAL", 134, 135], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["KQ6", "GENE_OR_GENE_PRODUCT", 15, 18], ["G + C", "GENE_OR_GENE_PRODUCT", 55, 60], ["amino acids", "AMINO_ACID", 96, 107], ["S1 gene", "DNA", 4, 11], ["KQ6", "DNA", 15, 18], ["N-glycosylation sites", "PROTEIN", 134, 155], ["KQ6 strain", "TEST", 15, 25], ["bp", "TEST", 35, 37], ["length", "TEST", 41, 47], ["a G + C percentage", "TEST", 53, 71], ["amino acids", "TEST", 96, 107], ["glycosylation sites", "TREATMENT", 136, 155]]], ["Hydrophilicity analysis of the deduced S1 amino acid sequence revealed that the first 20 amino acid residues formed a hydrophobic region that was presumed to be the signal sequence of S precursor protein.", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 89, 99], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 89, 99], ["amino acid", "AMINO_ACID", 42, 52], ["amino acid", "AMINO_ACID", 89, 99], ["S1 amino acid sequence", "PROTEIN", 39, 61], ["hydrophobic region", "PROTEIN", 118, 136], ["S precursor protein", "PROTEIN", 184, 203], ["Hydrophilicity analysis", "TEST", 0, 23], ["the deduced S1 amino acid sequence", "TEST", 27, 61], ["the first 20 amino acid residues", "PROBLEM", 76, 108], ["a hydrophobic region", "PROBLEM", 116, 136], ["presumed to be", "UNCERTAINTY", 146, 160]]], ["The amino acid sequences at the cleavage site of S precursor protein were RRFRR.Genome characterization ::: ResultsThe M gene was 678 bp in length, encoding 225 amino acids.", [["amino acid", "CHEMICAL", 4, 14], ["amino acids", "CHEMICAL", 161, 172], ["amino acid", "CHEMICAL", 4, 14], ["amino acids", "CHEMICAL", 161, 172], ["amino acid", "AMINO_ACID", 4, 14], ["amino acids", "AMINO_ACID", 161, 172], ["cleavage site", "PROTEIN", 32, 45], ["S precursor protein", "PROTEIN", 49, 68], ["RRFRR", "PROTEIN", 74, 79], ["M gene", "DNA", 119, 125], ["The amino acid sequences", "TEST", 0, 24], ["RRFRR", "PROBLEM", 74, 79], ["bp", "TEST", 134, 136], ["length", "TEST", 140, 146], ["amino acids", "TEST", 161, 172]]], ["There were two predicted N-glycosylation sites at the N-terminus.", [["N", "CHEMICAL", 25, 26], ["N-glycosylation sites", "PROTEIN", 25, 46], ["N-terminus", "PROTEIN", 54, 64], ["glycosylation sites", "OBSERVATION", 27, 46]]], ["The first 11 amino acid residues were hydrophilic, forming the outer membrane sequence of the M protein.", [["outer membrane", "ANATOMY", 63, 77], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["outer membrane", "CELLULAR_COMPONENT", 63, 77], ["outer membrane sequence", "PROTEIN", 63, 86], ["M protein", "PROTEIN", 94, 103], ["The first 11 amino acid residues", "PROBLEM", 0, 32], ["hydrophilic", "OBSERVATION_MODIFIER", 38, 49]]], ["The subsequent 20\u2013100 amino acids formed three hydrophobic regions which were thought to be three transmembrane structures.Genome characterization ::: ResultsThe N gene was 1230 bp in length and encoded 409 amino acids, with a single predicted N-glycosylation site at the N-terminus.", [["transmembrane structures", "ANATOMY", 98, 122], ["amino acids", "CHEMICAL", 22, 33], ["amino acids", "CHEMICAL", 207, 218], ["amino acids", "CHEMICAL", 22, 33], ["amino acids", "CHEMICAL", 207, 218], ["N", "CHEMICAL", 244, 245], ["amino acids", "AMINO_ACID", 22, 33], ["amino acids", "AMINO_ACID", 207, 218], ["hydrophobic regions", "PROTEIN", 47, 66], ["N gene", "DNA", 162, 168], ["N-glycosylation site", "PROTEIN", 244, 264], ["N-terminus", "PROTEIN", 272, 282], ["The subsequent 20\u2013100 amino acids", "TREATMENT", 0, 33], ["bp in length", "TEST", 178, 190], ["amino acids", "TEST", 207, 218], ["a single predicted N-glycosylation site", "TREATMENT", 225, 264], ["thought to be", "UNCERTAINTY", 78, 91]]], ["The deduced amino acid sequence of the N protein was hydrophilic, which was likely beneficial for the interaction between N protein and genomic RNA.Phylogenetic analysis ::: ResultsThe nucleotide and amino acid sequences of the S1, M and N genes of KQ6 were compared with those of reference avian IBV strains (Table 3).", [["amino acid", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 185, 195], ["amino acid", "CHEMICAL", 200, 210], ["amino acid", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 185, 195], ["amino acid", "CHEMICAL", 200, 210], ["amino acid", "AMINO_ACID", 12, 22], ["amino acid", "AMINO_ACID", 200, 210], ["S1", "GENE_OR_GENE_PRODUCT", 228, 230], ["KQ6", "GENE_OR_GENE_PRODUCT", 249, 252], ["avian IBV", "ORGANISM", 291, 300], ["N protein", "PROTEIN", 39, 48], ["N protein", "PROTEIN", 122, 131], ["genomic RNA", "RNA", 136, 147], ["S1, M and N genes", "DNA", 228, 245], ["KQ6", "DNA", 249, 252], ["avian IBV", "SPECIES", 291, 300], ["The deduced amino acid sequence", "TEST", 0, 31], ["the N protein", "TEST", 35, 48], ["the interaction between N protein and genomic RNA", "PROBLEM", 98, 147], ["Phylogenetic analysis", "TEST", 148, 169], ["The nucleotide and amino acid sequences", "TEST", 181, 220], ["KQ6", "TEST", 249, 252], ["amino acid", "OBSERVATION", 12, 22], ["genomic RNA", "OBSERVATION", 136, 147]]], ["It showed that KQ6 was most closely related to Massachusetts serotype IBV strains, such as M41, GX1-98, LKQ3, H120, and so on.", [["KQ6", "GENE_OR_GENE_PRODUCT", 15, 18], ["Massachusetts serotype IBV", "ORGANISM", 47, 73], ["GX1-98", "GENE_OR_GENE_PRODUCT", 96, 102], ["KQ6", "DNA", 15, 18], ["Massachusetts serotype IBV", "SPECIES", 47, 73], ["Massachusetts serotype IBV strains", "PROBLEM", 47, 81], ["M41", "TEST", 91, 94], ["GX1", "TEST", 96, 99], ["LKQ3", "TEST", 104, 108]]], ["Interestingly, only 0.4% differences at nucleotide level and 1.1% differences at amino acid level were found when compared the S1 genes of KQ6 and M41.Phylogenetic analysis ::: ResultsPhylogenetic analysis based on the whole genome sequence was performed.", [["nucleotide", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 81, 91], ["nucleotide", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 81, 91], ["amino acid", "AMINO_ACID", 81, 91], ["KQ6", "GENE_OR_GENE_PRODUCT", 139, 142], ["M41", "GENE_OR_GENE_PRODUCT", 147, 150], ["S1 genes", "DNA", 127, 135], ["KQ6", "DNA", 139, 142], ["M41", "DNA", 147, 150], ["whole genome sequence", "DNA", 219, 240], ["nucleotide level", "TEST", 40, 56], ["amino acid level", "TEST", 81, 97], ["KQ6", "TEST", 139, 142], ["Phylogenetic analysis", "TEST", 151, 172], ["Phylogenetic analysis", "TEST", 184, 205], ["the whole genome sequence", "TEST", 215, 240]]], ["As shown in Fig. 2, all coronaviruses were clearly divided into three groups.", [["coronaviruses", "ORGANISM", 24, 37], ["all coronaviruses", "PROBLEM", 20, 37], ["Fig", "OBSERVATION", 12, 15], ["coronaviruses", "OBSERVATION", 24, 37]]], ["KQ6 and IBV (M41) were in the same cluster of group 3, and they were distant from SARS coronaviruses in group 2, which further confirmed that KQ6 was a member of IBV.Discussion and conclusionsIBV is not a simple pathogen because of its heterogeneity with respect to its protein sequences, broad tissue tropism and pathogenicity in the wide host range.", [["tissue", "ANATOMY", 295, 301], ["SARS coronaviruses", "DISEASE", 82, 100], ["KQ6", "GENE_OR_GENE_PRODUCT", 0, 3], ["IBV", "ORGANISM", 8, 11], ["KQ6", "GENE_OR_GENE_PRODUCT", 142, 145], ["IBV", "ORGANISM", 162, 165], ["tissue", "TISSUE", 295, 301], ["KQ6", "DNA", 0, 3], ["KQ6", "PROTEIN", 142, 145], ["IBV", "SPECIES", 8, 11], ["SARS coronaviruses", "SPECIES", 82, 100], ["IBV", "SPECIES", 162, 165], ["IBV (M41", "TREATMENT", 8, 16], ["SARS coronaviruses", "PROBLEM", 82, 100], ["IBV", "TREATMENT", 162, 165], ["a simple pathogen", "PROBLEM", 203, 220], ["its heterogeneity", "PROBLEM", 232, 249], ["its protein sequences", "TEST", 266, 287], ["broad tissue tropism", "PROBLEM", 289, 309], ["pathogenicity", "PROBLEM", 314, 327], ["broad tissue", "OBSERVATION_MODIFIER", 289, 301], ["tropism", "OBSERVATION", 302, 309], ["wide host", "OBSERVATION_MODIFIER", 335, 344]]], ["It has been shown that an avian coronavirus from one species can replicate in other species, but no clinical sign is observed in most cases (Lister et al., 1985, Ismail et al., 2003, Guy, 2000).", [["avian coronavirus", "ORGANISM", 26, 43], ["avian coronavirus", "SPECIES", 26, 43], ["avian coronavirus", "SPECIES", 26, 43], ["an avian coronavirus", "PROBLEM", 23, 43], ["avian", "OBSERVATION_MODIFIER", 26, 31], ["coronavirus", "OBSERVATION", 32, 43]]], ["It was not until 2005 that peafowl infected by IBV (LKQ3) was first reported in Guangdong province, Southern China (Liu et al., 2005).", [["peafowl infected", "DISEASE", 27, 43], ["IBV", "ORGANISM", 47, 50], ["IBV", "SPECIES", 47, 50]]], ["LKQ3 shared high degree of identity with the Massachusetts serotype IBV strains H120.", [["LKQ3", "GENE_OR_GENE_PRODUCT", 0, 4], ["Massachusetts serotype IBV", "ORGANISM", 45, 71], ["LKQ3", "PROTEIN", 0, 4], ["Massachusetts serotype IBV", "SPECIES", 45, 71], ["high degree", "OBSERVATION_MODIFIER", 12, 23]]], ["But KQ6 was different from LKQ3 in terms of its high sequence identity with M41 and its pathogenicity to chickens.Discussion and conclusionsIt is well known that IBV has a high error rate during the transcription of its genomes (Lai and Cavanagh, 1997) because its RNA polymerase lacks the 3\u2032\u20135\u2032 exonuclease activity (editing function) of DNA polymerase.", [["KQ6", "GENE_OR_GENE_PRODUCT", 4, 7], ["LKQ3", "GENE_OR_GENE_PRODUCT", 27, 31], ["chickens", "ORGANISM", 105, 113], ["IBV", "ORGANISM", 162, 165], ["3\u2032\u20135\u2032 exonuclease", "GENE_OR_GENE_PRODUCT", 290, 307], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["KQ6", "DNA", 4, 7], ["LKQ3", "PROTEIN", 27, 31], ["RNA polymerase", "PROTEIN", 265, 279], ["3\u2032\u20135\u2032 exonuclease", "PROTEIN", 290, 307], ["DNA polymerase", "PROTEIN", 339, 353], ["chickens", "SPECIES", 105, 113], ["chickens", "SPECIES", 105, 113], ["IBV", "SPECIES", 162, 165], ["KQ6", "TREATMENT", 4, 7], ["IBV", "PROBLEM", 162, 165], ["a high error rate", "PROBLEM", 170, 187], ["its RNA polymerase", "TEST", 261, 279], ["DNA polymerase", "PROBLEM", 339, 353], ["IBV", "OBSERVATION", 162, 165], ["high error", "OBSERVATION", 172, 182]]], ["If point mutations, insertions, deletions or RNA recombinations occur in the antigenic S protein, the characters of antigen will change and a new type of virus might be born (Jia et al., 1995, Wang et al., 1993, Wang et al., 1994).", [["antigenic S protein", "GENE_OR_GENE_PRODUCT", 77, 96], ["antigenic S protein", "PROTEIN", 77, 96], ["point mutations", "PROBLEM", 3, 18], ["insertions, deletions", "TREATMENT", 20, 41], ["RNA recombinations", "TREATMENT", 45, 63], ["the antigenic S protein", "TEST", 73, 96], ["a new type of virus", "PROBLEM", 140, 159]]], ["Interestingly, the S1 gene of KQ6 had extremely high degree of identity with that of the Massachusetts prototype IBV, M41, which has undergone countless number of in vivo and in vitro host passages since 1940s.", [["S1", "GENE_OR_GENE_PRODUCT", 19, 21], ["KQ6", "GENE_OR_GENE_PRODUCT", 30, 33], ["IBV", "ORGANISM", 113, 116], ["S1 gene", "DNA", 19, 26], ["KQ6", "DNA", 30, 33], ["Massachusetts prototype IBV", "SPECIES", 89, 116], ["high degree", "OBSERVATION_MODIFIER", 48, 59], ["countless", "OBSERVATION_MODIFIER", 143, 152], ["number", "OBSERVATION_MODIFIER", 153, 159], ["host passages", "OBSERVATION", 184, 197]]], ["Only 0.4% differences at nucleotide level and 1.1% differences at amino acid level were found in their S1 genes.", [["nucleotide", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 66, 76], ["nucleotide", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 66, 76], ["amino acid", "AMINO_ACID", 66, 76], ["S1", "GENE_OR_GENE_PRODUCT", 103, 105], ["S1 genes", "DNA", 103, 111], ["nucleotide level", "TEST", 25, 41], ["amino acid level", "TEST", 66, 82], ["S1", "ANATOMY", 103, 105]]], ["One was that propensity of frequent mutation was not necessarily intrinsic to all IBV strains, such as the Massachusetts serotype virus.", [["IBV", "ORGANISM", 82, 85], ["Massachusetts serotype virus", "ORGANISM", 107, 135], ["IBV", "SPECIES", 82, 85], ["Massachusetts serotype virus", "SPECIES", 107, 135], ["frequent mutation", "PROBLEM", 27, 44], ["all IBV strains", "PROBLEM", 78, 93], ["the Massachusetts serotype virus", "PROBLEM", 103, 135]]], ["It had been reported that a difference of only 2% in nucleotide sequence and 4% in amino acid sequence was found in the S1 genes of a Massachusetts serotype virus of the 1940s and the present-day Massachusetts prototype M41 strain (Jia et al., 2002).", [["nucleotide", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 83, 93], ["nucleotide", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 83, 93], ["amino acid", "AMINO_ACID", 83, 93], ["Massachusetts serotype virus", "ORGANISM", 134, 162], ["S1 genes", "DNA", 120, 128], ["Massachusetts serotype virus", "SPECIES", 134, 162], ["nucleotide sequence", "TEST", 53, 72], ["amino acid sequence", "TEST", 83, 102], ["a Massachusetts serotype virus", "PROBLEM", 132, 162], ["S1", "ANATOMY", 120, 122]]], ["The other explanation was that IBV in peafowls had not undergone the immune pressure from vaccine like chickens.", [["IBV", "ORGANISM", 31, 34], ["chickens", "ORGANISM", 103, 111], ["chickens", "SPECIES", 103, 111], ["IBV", "SPECIES", 31, 34], ["chickens", "SPECIES", 103, 111], ["IBV in peafowls", "PROBLEM", 31, 46], ["the immune pressure from vaccine", "TREATMENT", 65, 97]]], ["So the point mutations of IBV in peafowls were much less than those in other species.", [["IBV", "ORGANISM", 26, 29], ["IBV", "SPECIES", 26, 29], ["IBV in peafowls", "PROBLEM", 26, 41], ["IBV", "OBSERVATION", 26, 29]]], ["This high degree of sequence identity showed that KQ6 was a Massachusetts prototype like IBV strain which had undergone few genetic changes.Discussion and conclusionsAlthough LKQ3 and KQ6 had high sequence identity and both belonged to Massachusetts serotype IBV strains, the results of their virulence studies in chickens were completely different.", [["KQ6", "GENE_OR_GENE_PRODUCT", 50, 53], ["IBV", "ORGANISM", 89, 92], ["LKQ3", "GENE_OR_GENE_PRODUCT", 175, 179], ["KQ6", "GENE_OR_GENE_PRODUCT", 184, 187], ["Massachusetts serotype IBV", "ORGANISM", 236, 262], ["chickens", "ORGANISM", 314, 322], ["KQ6", "DNA", 50, 53], ["LKQ3", "DNA", 175, 179], ["KQ6", "DNA", 184, 187], ["chickens", "SPECIES", 314, 322], ["IBV", "SPECIES", 89, 92], ["Massachusetts serotype IBV", "SPECIES", 236, 262], ["chickens", "SPECIES", 314, 322], ["IBV strain", "PROBLEM", 89, 99], ["LKQ3", "TEST", 175, 179], ["high sequence identity", "PROBLEM", 192, 214], ["serotype IBV strains", "PROBLEM", 250, 270], ["their virulence studies", "TEST", 287, 310], ["few", "OBSERVATION_MODIFIER", 120, 123]]], ["No overt disease was observed in chickens that had been inoculated with the first reported peafowl IBV strain LKQ3 (Liu et al., 2005).", [["chickens", "ORGANISM", 33, 41], ["IBV", "ORGANISM", 99, 102], ["chickens", "SPECIES", 33, 41], ["chickens", "SPECIES", 33, 41], ["overt disease", "PROBLEM", 3, 16], ["overt", "OBSERVATION_MODIFIER", 3, 8], ["disease", "OBSERVATION", 9, 16]]], ["In contrast, KQ6 strain was able to cause clinical signs and pathogenic changes in chickens.", [["KQ6", "GENE_OR_GENE_PRODUCT", 13, 16], ["chickens", "ORGANISM", 83, 91], ["chickens", "SPECIES", 83, 91], ["chickens", "SPECIES", 83, 91], ["KQ6 strain", "TREATMENT", 13, 23], ["clinical signs", "PROBLEM", 42, 56], ["pathogenic changes in chickens", "PROBLEM", 61, 91]]], ["Severe haemorrhagic lesions, epithelium degeneration and lymphocyte infiltration were observed in both lungs and kidneys of the KQ6 infected chickens.", [["haemorrhagic lesions", "ANATOMY", 7, 27], ["epithelium", "ANATOMY", 29, 39], ["lymphocyte", "ANATOMY", 57, 67], ["lungs", "ANATOMY", 103, 108], ["kidneys", "ANATOMY", 113, 120], ["haemorrhagic lesions", "PATHOLOGICAL_FORMATION", 7, 27], ["epithelium", "TISSUE", 29, 39], ["lymphocyte", "CELL", 57, 67], ["lungs", "ORGAN", 103, 108], ["kidneys", "ORGAN", 113, 120], ["chickens", "ORGANISM", 141, 149], ["chickens", "SPECIES", 141, 149], ["chickens", "SPECIES", 141, 149], ["Severe haemorrhagic lesions", "PROBLEM", 0, 27], ["epithelium degeneration", "PROBLEM", 29, 52], ["lymphocyte infiltration", "PROBLEM", 57, 80], ["haemorrhagic", "OBSERVATION_MODIFIER", 7, 19], ["lesions", "OBSERVATION", 20, 27], ["epithelium degeneration", "OBSERVATION", 29, 52], ["lymphocyte infiltration", "OBSERVATION", 57, 80], ["both", "ANATOMY_MODIFIER", 98, 102], ["lungs", "ANATOMY", 103, 108], ["kidneys", "ANATOMY", 113, 120], ["infected", "OBSERVATION_MODIFIER", 132, 140], ["chickens", "OBSERVATION", 141, 149]]], ["It was possible that the different experiment procedure, different environment and different criterion in the virulence studies might generate different experiment results, but we believed that KQ6 was pathogenic to chickens.", [["KQ6", "CHEMICAL", 194, 197], ["KQ6", "GENE_OR_GENE_PRODUCT", 194, 197], ["chickens", "ORGANISM", 216, 224], ["chickens", "SPECIES", 216, 224], ["chickens", "SPECIES", 216, 224], ["the different experiment procedure", "TREATMENT", 21, 55], ["the virulence studies", "TEST", 106, 127]]], ["Meanwhile, we found that KQ6 was non-pathogenic to peafowls.Discussion and conclusionsWe also found one-third of peafowls were anti-IBV positive in Guangdong province.", [["peafowls", "ANATOMY", 51, 59], ["peafowls", "ANATOMY", 113, 121], ["KQ6", "GENE_OR_GENE_PRODUCT", 25, 28], ["peafowls", "ORGANISM", 113, 121], ["KQ6", "PROTEIN", 25, 28]]], ["It suggested that peafowl was susceptible to IBV infection and IBVs other than those previously reported in chickens and turkeys might be carried in peafowls causing no clinical sign.", [["IBV infection", "DISEASE", 45, 58], ["IBV", "ORGANISM", 45, 48], ["chickens", "ORGANISM", 108, 116], ["turkeys", "ORGANISM", 121, 128], ["chickens", "SPECIES", 108, 116], ["turkeys", "SPECIES", 121, 128], ["IBV", "SPECIES", 45, 48], ["chickens", "SPECIES", 108, 116], ["turkeys", "SPECIES", 121, 128], ["peafowl", "PROBLEM", 18, 25], ["IBV infection", "PROBLEM", 45, 58], ["IBVs", "TREATMENT", 63, 67], ["IBV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 49, 58]]], ["Up to date, there has been no more data about IBV infection in peafowls, so the exact origin of peafowl IBV is still not clear.", [["peafowls", "ANATOMY", 63, 71], ["IBV infection", "DISEASE", 46, 59], ["IBV", "ORGANISM", 46, 49], ["peafowls", "CANCER", 63, 71], ["peafowl IBV", "ORGANISM", 96, 107], ["IBV", "SPECIES", 46, 49], ["peafowl IBV", "SPECIES", 96, 107], ["IBV infection in peafowls", "PROBLEM", 46, 71], ["peafowl IBV", "PROBLEM", 96, 107], ["infection", "OBSERVATION", 50, 59], ["IBV", "OBSERVATION", 104, 107], ["clear", "OBSERVATION", 121, 126]]], ["Liu et al. speculated that LKQ3 might originate from the attenuated vaccine strain IBV H120.", [["LKQ3", "CHEMICAL", 27, 31], ["LKQ3", "GENE_OR_GENE_PRODUCT", 27, 31], ["IBV H120", "ORGANISM", 83, 91], ["LKQ3", "PROTEIN", 27, 31], ["IBV H120", "SPECIES", 83, 91], ["the attenuated vaccine", "TREATMENT", 53, 75]]], ["But peafowls, unlike many other birds on farms, are not immunized with vaccines in China and peafowls in nature are unlikely to be infected by IBV vaccine strain through direct contacting with immunized chickens.", [["birds", "ORGANISM", 32, 37], ["IBV vaccine strain", "ORGANISM", 143, 161], ["chickens", "ORGANISM", 203, 211], ["chickens", "SPECIES", 203, 211], ["IBV", "SPECIES", 143, 146], ["chickens", "SPECIES", 203, 211], ["vaccines", "TREATMENT", 71, 79], ["IBV vaccine strain", "TREATMENT", 143, 161], ["unlikely to be", "UNCERTAINTY", 116, 130], ["infected", "OBSERVATION", 131, 139]]], ["So we believed that peafowl was the natural carrier for IBV.Discussion and conclusionsSince coronavirus can break the host species barrier, causes trans-species infection and becomes zoonotic, it is necessary to pay attention to the coronavirus IBV infection in other species.", [["infection", "DISEASE", 161, 170], ["coronavirus IBV infection", "DISEASE", 233, 258], ["IBV", "ORGANISM", 56, 59], ["coronavirus", "ORGANISM", 92, 103], ["coronavirus IBV", "ORGANISM", 233, 248], ["coronavirus", "SPECIES", 92, 103], ["coronavirus IBV", "SPECIES", 233, 248], ["IBV", "SPECIES", 56, 59], ["coronavirus IBV", "SPECIES", 233, 248], ["IBV", "PROBLEM", 56, 59], ["coronavirus", "PROBLEM", 92, 103], ["species infection", "PROBLEM", 153, 170], ["zoonotic", "PROBLEM", 183, 191], ["the coronavirus IBV infection in other species", "PROBLEM", 229, 275], ["host species", "OBSERVATION", 118, 130], ["species", "OBSERVATION_MODIFIER", 153, 160], ["infection", "OBSERVATION", 161, 170], ["coronavirus IBV", "OBSERVATION", 233, 248], ["infection", "OBSERVATION", 249, 258]]], ["KQ6 was pathogenic to chickens under experimental conditions, so the peafowl IBV had the potential ability to infect chickens in nature.", [["KQ6", "GENE_OR_GENE_PRODUCT", 0, 3], ["chickens", "ORGANISM", 22, 30], ["peafowl IBV", "ORGANISM", 69, 80], ["chickens", "ORGANISM", 117, 125], ["KQ6", "DNA", 0, 3], ["chickens", "SPECIES", 22, 30], ["chickens", "SPECIES", 117, 125], ["chickens", "SPECIES", 22, 30], ["IBV", "SPECIES", 77, 80], ["chickens", "SPECIES", 117, 125], ["pathogenic", "PROBLEM", 8, 18], ["the peafowl IBV", "TREATMENT", 65, 80]]], ["Our investigations in peafowls indicate that KQ6 is a Massachusetts prototype like coronavirus strain which undergoes few genetic changes and peafowl might have acted as a natural reservoir of IBV for very long time.", [["KQ6", "CHEMICAL", 45, 48], ["peafowls", "CANCER", 22, 30], ["KQ6", "GENE_OR_GENE_PRODUCT", 45, 48], ["coronavirus", "ORGANISM", 83, 94], ["IBV", "ORGANISM", 193, 196], ["coronavirus", "SPECIES", 83, 94], ["IBV", "SPECIES", 193, 196], ["Our investigations", "TEST", 0, 18], ["coronavirus strain", "PROBLEM", 83, 101], ["a natural reservoir of IBV", "TREATMENT", 170, 196], ["coronavirus strain", "OBSERVATION", 83, 101], ["few", "OBSERVATION_MODIFIER", 118, 121]]]], "PMC7323420": [], "676cf33bf8a125ac7dd568b7c19262db6f1de589": [["Besides investigating various reasons for non-reproducibility, the study showed that scientists mostly agree upon the importance of the problem that became known as reproducibility crisis during the last years.", [["non-reproducibility", "PROBLEM", 42, 61], ["the study", "TEST", 63, 72], ["reproducibility crisis", "PROBLEM", 165, 187]]], ["Especially in the field of information retrieval (IR), new findings are manifested by empirical studies and experiments.", [["empirical studies", "TEST", 86, 103]]], ["Despite this intuitive but rather naive assumption, achieving reproducibility in the field of IR is a many-faceted problem.", [["a many-faceted problem", "PROBLEM", 100, 122], ["faceted", "OBSERVATION_MODIFIER", 107, 114], ["problem", "OBSERVATION", 115, 122]]], ["Ten years later, Yang et al. [16] report similar results as part of their meta-evaluation.", [["their meta-evaluation", "TEST", 68, 89]]], ["The lacking upwards trend in retrieval performance can be traced back to non-reproducible findings.", [["upwards", "OBSERVATION_MODIFIER", 12, 19]]], ["If baselines of previous results are not or only laboriously reproducible, the community does not use them adequately.MotivationWe see a gap between reproducibility efforts for offline evaluations on the one side and online retrieval experiments trying to include real-world user interactions on the other side.", [["offline evaluations", "TEST", 177, 196], ["online retrieval experiments", "TREATMENT", 217, 245]]], ["While several initiatives are trying to establish reproducible IR research for offline evaluations on standard test collections, there is little research effort concerning the reproducibility of online experiments.", [["offline evaluations", "TEST", 79, 98], ["standard test collections", "TEST", 102, 127]]], ["This dissertation project will be concerned with the reproducibility of online experiments in the field of information retrieval.Related WorkProgress in information retrieval revolves around the evaluation of experimental results.", [["the evaluation", "TEST", 191, 205]]], ["This research project will focus specifically on two aspects of evaluation in IR -reproducible experiments and the living lab paradigm.", [["evaluation", "TEST", 64, 74], ["IR", "TEST", 78, 80]]], ["This section gives a brief overview of the two evaluation branches.Related WorkAs mentioned in the previous section, meta-evaluations of IR systems revealed limited progress over the years [1, 16] .", [["WorkAs", "DNA", 75, 81], ["IR systems", "TEST", 137, 147], ["branches", "OBSERVATION_MODIFIER", 58, 66]]], ["Conceptually, Ferro and Kelly elaborate an implementation for the field of information retrieval [10] of the ACM Artifact and Review Badging 1 .", [["the ACM Artifact", "PROBLEM", 105, 121]]], ["The PRIMAD model [8] offers orientation which components of an IR experiment may affect reproducibility or have to be considered when trying to reproduce the corresponding experiment.", [["an IR experiment", "PROBLEM", 60, 76]]], ["The Evaluation-as-a-Service (EaaS) paradigm [13] reverses the conventional evaluation approach of a shared task like it is applied at the TREC conference.", [["The Evaluation", "TEST", 0, 14], ["the conventional evaluation", "TEST", 58, 85]]], ["Instead of letting participants submit the results (runs) only, the complete retrieval system is submitted in a form such that it can be rerun independently by others to produce the results.", [["participants", "SPECIES", 19, 31], ["the complete retrieval system", "TREATMENT", 64, 93]]], ["For example, the CENTRE workshop [9] challenges participants to reconstruct IR systems and their results, whereas The Open-Source IR Replicability Challenge (OSIRRC) [7] motivated participants to package their retrieval systems and corresponding software dependencies in advance to prepare them for appropriate reuse.Related WorkCompared to offline ad-hoc retrieval, online search experiments are affected by non-deterministic variables including user behavior, updated data collections, modifications of web interfaces, or traffic dependencies [11] .", [["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 180, 192], ["their retrieval systems", "TREATMENT", 204, 227]]], ["The workshop's organizers challenge the participants to reconstruct results of previous submissions to the CLEF, NTCIR, and TREC conferences.", [["participants", "SPECIES", 40, 52]]], ["CENTRE defines replicability and reproducibility by using the same or another test collection of the original setup, respectively.", [["CENTRE", "DNA", 0, 6], ["another test collection", "TEST", 70, 93], ["reproducibility", "OBSERVATION_MODIFIER", 33, 48]]], ["The results of our experimental setups showed that we can replicate the outcomes fairly well, whereas reproduced outcomes are significantly lower.", [["our experimental setups", "TEST", 15, 38]]], ["Having the reimplementation of an ad-hoc retrieval system at hand, we decided to contribute it to the OSIRRC@SIGIR2019 workshop [7] .", [["an ad-hoc retrieval system", "TREATMENT", 31, 57]]], ["All contributions resulted in an image library of Docker images to which we contributed the IRC-CENTRE2019 image [4] .", [["Docker images", "TEST", 50, 63]]], ["Additionally, we introduced STELLA -a new interpretation of the living lab paradigm -at the OSIRRC workshop [6] .", [["STELLA", "PROTEIN", 28, 34]]], ["We propose to transfer the idea of encapsulating retrieval systems with Docker containers to the online search scenario.", [["encapsulating retrieval systems", "TREATMENT", 35, 66], ["Docker containers", "TREATMENT", 72, 89]]], ["In order to underline the feasibility and benefits of this proposal, we aligned components of the STELLA framework to the PRIMAD model.Preliminary Work and Research ProposalBased on this preliminary work, we investigate the reproducibility of retrieval systems with the main focus on online environments.", [["retrieval systems", "TREATMENT", 243, 260]]], ["Since there exist different terminologies, we use the ACM definitions of repeatability, replicability, and reproducibility as a starting point.", [["different", "OBSERVATION_MODIFIER", 18, 27], ["terminologies", "OBSERVATION", 28, 41]]], ["However, it could be extended such that it also considers the actual user of a retrieval system.Methodology and ExperimentsRegarding RQ2, we primarily focus on vertical search experiments.", [["a retrieval system", "TREATMENT", 77, 95]]], ["Beforehand, the reusability of user logs is particularly interesting, since reusable test collections are fundamental to offline retrieval experiments.", [["reusable test collections", "TEST", 76, 101], ["offline retrieval experiments", "TREATMENT", 121, 150]]], ["As a starting point, we propose to repeat this study with the user logs of another search engine.", [["this study", "TEST", 42, 52]]], ["By comparing a diverse set of different session constellations and corresponding outcomes, we identify significant influences.", [["significant influences", "PROBLEM", 103, 125], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["influences", "OBSERVATION", 115, 125]]], ["The retrieval effectiveness of A outperforms that of B, which is denoted as A B and is confirmed to be reproducible.", [["B", "CELL", 53, 54]]], ["Which components affect the reproducibility?Methodology and ExperimentsHaving identified major influences and key components, we address RQ3 by deriving requirements that have to be met by an adequate living lab infrastructure.", [["reproducibility", "OBSERVATION_MODIFIER", 28, 43]]], ["Furthermore, we have to consider general conditions like the ethical and juridical aspects of data logging.", [["general conditions", "TREATMENT", 33, 51]]]]}